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Abstract 
The lymphatic system serves a critical role in fluid homeostasis, lipid metabolism and 
immune surveillance. The growing appreciation of its implication in various diseases 
challenges the conventional view of lymphatics as a passive transport system. 
Traditionally, the lymphatic endothelium has been perceived as a structural scaffold 
with certain immunological functions but no active involvement in immunomodulation.  
In the lymph nodes (LNs), the main sites of immune regulation in the periphery, 
lymphatic endothelial cells (LECs) come to close contact with immune cells, 
suggesting potential interactions. Indeed, LECs have been recently shown to 
suppress dendritic cell maturation and present peripheral tissue and tumor antigen 
for CD8+ T cell deletion. While LECs have only begun to be acknowledged as active 
regulators of immunity, their function and relative contribution in shaping immune 
responses is as yet poorly understood. 
This thesis aimed to elucidate the direct role of LECs in the induction of CD8+ T cell 
immunity and tolerance. First, we demonstrated that murine LECs can actively 
scavenge and cross-present exogenous antigen to cognate CD8+ T cells under non-
inflamed conditions. By utilizing an in vitro coculture system and the model antigen 
ovalbumin, we investigated the antigen-specific interactions between LECs and CD8+ 
T cells. LEC-educated CD8+ T cells proliferated, exhibiting an activated phenotype, 
however, they displayed early-generation apoptosis and failed to produce effector 
cytokines. Our findings establish LECs as antigen-presenting cells and suggest that 
they may assist in the maintenance of peripheral tolerance during homeostasis. 
The particular differentiation state of LEC-educated CD8+ T cells prompted us to 
investigate whether they are terminally tolerized or they could escape the 
dysfunctional state. We demonstrated that LEC-educated CD8+ T cells adopted a 
distinct phenotype with central memory-like characteristics and shared multiple 
functional properties with memory cells. Upon antigen re-encounter, LEC-educated 
CD8+ T cells mounted proliferative responses and generated cytotoxic effector cells. 
vi
More importantly, they participated in anti-infectious immunity while preserving a 
secondary-memory persistent population. Our findings reveal a unique differentiation 
state of antigen-experienced CD8+ T cells, generated under steady-state conditions, 
which remain inactive but can be functionally reactivated upon antigenic 
inflammatory challenge. 
This previously unanticipated feature of LECs triggered questions for their antigen-
presenting function in an inflammatory setting. We asked whether the previously 
observed extensive proliferation of LECs in the LN during inflammation might directly 
influence the induction of immunity. We employed an anti-VEGFR3 blocking antibody 
to inhibit LEC proliferation and thus, reduce the number of LECs following vaccine 
immunization. Alternatively, we generated the Prox1-Cre-DTR mouse model, 
allowing for specific ablation of LECs following administration of diphtheria toxin in 
vivo. Our findings advance our perception of the relative contribution of LECs in the 
establishment of adaptive immunity. 
This thesis elucidates the multifaceted immunological role of LECs and strongly 
suggests the importance of harnessing their immunomodulatory function to enhance 
current vaccines and immunotherapeutic strategies. Looking forward, our work will 
contribute to future advances in the clinic. 
 
 
Keywords: LEC, LN, cross-presentation, exogenous antigen, peripheral tolerance, 
CD8+ T cell, non-terminal differentiation, memory, lymphangiogenesis, 
immunomodulation 
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Résumé 
Le système lymphatique joue un rôle critique dans l'homéostasie des fluides 
tissulaires, le métabolisme des lipides et la surveillance immunitaire. L'augmentation 
croissante de son implication dans diverses maladies remet en question le point de 
vue conventionnel du réseau lymphatique comme étant un système de transport 
passif. 
Généralement, l'endothélium lymphatique est perçu comme un élément structurel 
avec certaines fonctions immunologiques mais sans participation active dans 
l'immunomodulation. Dans les ganglions lymphatiques (GLs), les sites principaux de 
la régulation immunitaire dans la périphérie, les cellules endothéliales lymphatiques 
(CELs) entrent en contact étroit avec les cellules immunitaires, suggérant une 
interaction potentielle entre elles. En effet, il a été récemment montré que les CELs 
sont capables de stopper la maturation des cellules dendritiques et de présenter des 
antigènes provenant de tissus périphériques et tumoraux pour la délétion des 
cellules T CD8+. Alors que les CELs commencent à être reconnues comme des 
acteurs actifs de l'immunité, leurs fonctions et leur importance relative dans 
l'élaboration de réponses immunitaires sont encore mal comprises. 
Cette thèse vise à élucider le rôle direct des CELs dans l'induction de l’immunité 
cellulaire et de la tolérance des lymphocytes T CD8+. Nous avons tout d’abord 
démontré que les CELs murines peuvent activement capter et cross-présenter 
des antigènes exogènes aux cellules T CD8+ dans des conditions non 
inflammatoires. En utilisant un système de co-culture in vitro et l'ovalbumine comme 
l'antigène modèle, nous avons étudié les interactions spécifiques de l'antigène donné 
entre les CELs et les cellules T CD8+. Les cellules T CD8+ éduquées par les CELs 
ont proliféré et présenté un phénotype activé, cependant, elles ont affiché des signes 
d’apoptose précoce. De plus, elles étaient incapables de produire des cytokines 
induites par les cellules T CD8+ effecteurs. Ces résultats établissent les CELs 
comme des cellules présentatrices d'antigènes et suggèrent qu'elles peuvent 
contribuer au maintien de la tolérance périphérique. 
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Cet état de différenciation particulier de cellules T CD8+ éduquées par les CELs nous 
a incités à étudier si elles étaient rendues tolérantes ou si elles pouvaient échapper  
à cet état dysfonctionnel. Nous avons démontré que les cellules T CD8+ éduquées 
par les CELs ont adopté un phénotype distinct, présentant des caractéristiques 
des cellules T de mémoire centrale et partageaient plusieurs propriétés 
fonctionnelles avec elles. Lors d'une nouvelle rencontre avec l’antigène, elles ont 
induit des lymphocytes T CD8+ effecteurs qui pouvaient proliférer et produire des 
molécules cytotoxiques. Elles ont surtout contribué à l'établissement de l'immunité 
anti-infectieuse, tout en préservant une population persistante de mémoire 
secondaire. Ces résultats révèlent un état de différenciation unique de cellules T 
CD8+, qui sont spécifiques à l'antigène qu’elles ont rencontré en premier en 
conditions non inflammatoires et qui restent inactives tout en gardant la capacité 
d’être réactivées en cas d’apparition d’un antigène inflammatoire. 
Cette nouvelle propriété des CELs a posé des questions sur l’importance de leur 
fonction présentatrice dans le cadre de l’inflammation. Nous avons examiné si la 
prolifération excessive des CELs, précédemment observée dans le GL au cours de 
l'inflammation, pourrait influer directement sur l'induction de la réponse immunitaire. 
Nous avons utilisé un anticorps bloquant le récepteur VEGFR3 (anti-VEGFR3) pour 
limiter la prolifération des CELs et ainsi, réduire le nombre de CELs suivant 
l'immunisation. Parallèlement, nous avons généré un modèle de souris transgénique, 
Prox1-Cre-DTR, permettant d’éliminer précisément les CELs suite à l'administration 
de toxine diphtérique in vivo. Les résultats obtenus ont considérablement 
fait progresser notre perception de la contribution relative des CELs à l'établissement 
de l'immunité adaptative. 
Cette thèse a permis de mettre en évidence les différents rôles immunologiques des 
CELs suggérant l’importance d’exploiter leurs fonctions immunomodulatrices afin 
d’améliorer les vaccins actuels et les stratégies immunothérapeutiques. Notre travail 
peut contribuer aux progrès de la recherche clinique future. 
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Chapter 1    
Introduction 
The lymphatic system plays a crucial role in maintaining tissue homeostasis through 
the clearance of excess fluids from peripheral tissues and the absorption of dietary 
lipids from the intestine to return them into systemic circulation (1-3). Lymphatic 
vessels allow the continuous trafficking of immune cells as well as soluble antigen 
from the periphery to secondary lymphoid organs while lymph nodes (LNs) provide a 
place for antigen presentation and immune activation (4-6). Therefore, the lymphatic 
system represents a critical element for immune surveillance and the generation of 
immune responses.  
The diversity in the physiological functions of the lymphatic system explains why they 
are known to contribute to the pathogenesis of various human diseases. These 
involve lymphedema, fat accumulation, inflammatory disorders such as rheumatoid 
arthritis, as well as solid organ transplant rejection (7, 8). Lymphatics are also 
implicated, through the mesenteric LN, in the regulation of local and systemic food 
tolerance, while they have been reported as the primary site of replication and 
dissemination of various pathogenic viruses inducing critical disease (1). Among the 
diseases involved, the vast majority triggers alterations in the lymphatic network with 
respect to lymph flow, lymphatic vessel size and architecture. Lymphangiogenesis, 
the expansion of lymphatic endothelium, is also observed in tumors allowing for 
increased drainage and transport of immune cells (9, 10). Immune cells and tumor 
antigen are transferred from the tumor to the draining lymph node (dLN) through 
lymphatic vessels and therefore, the dLN status reflects the tumor immune status. In 
addition, tumor associated lymphatics function as an escape route for tumor cells 
enabling their dissemination to the immunological network and subsequent 
metastasis (2, 11). More importantly, peritumoral lymphatic density as well as 
expression of the major lymphatic growth factor, vascular endothelial growth factor C 
(VEGF-C), are included among the prognostic indicators in many human cancers 
(12, 13).  
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The growing recognition of the key roles that the lymphatic system plays in health 
and disease challenges the established conventional view of lymphatics; 
Traditionally, the lymphatic network is portrayed as a passive transport system, with 
lymphatic endothelial cells (LECs) solely forming the structural scaffold for cell and 
antigen circulation. However, the anatomic distribution of the lymphatic system 
suggests several sites for close contact with immune cells (14, 15). In turn, this 
intimate physical contact indicates potential active interactions with immune cells and 
thus, introduces the possibility of regulating their function. Interestingly, LN LECs are 
situated in one of the prime anatomical sites for immunological sampling, being the 
first to get exposed to exogenous antigen arriving from the periphery through the 
lymph. The lymph bathes the LN in soluble foreign antigens as well as tissue-specific 
self-antigens mixed with other molecules present in the draining peripheral tissues 
and therefore, reflects their immunological state. During homeostasis, the lymph 
appears to be significantly enriched, compared to plasma, in proteins and peptides 
derived from tissue homeostatic turn-over (16). Human lymph has also been reported 
to display an expanded peptidome with respect to plasma (17). In the course of 
infection or tissue injury, exogenous antigens and self-peptides from damaged cells, 
along with homeostatic byproducts, all travel through the lymph to the local draining 
LN; hence, the lymph “communicates” to the LN the state of the tissue and LECs, 
positioned at the entrance of the LN, are the first to receive this “information”. 
Emerging evidence and thoughtful reexamination of the existing knowledge strongly 
suggest that LECs are not passive observers but may dynamically participate in the 
modulation of immune responses. While the appreciation for the immunological role 
of LECs grows, many exciting questions are raised and the answers are awaited with 
much anticipation. 
1.1 Bridging the transport and immune functions of the 
lymphatic system 
Viewing the elaborate structure of the lymphatic system through the 
lymphatic-driven journey of immune cells from the periphery to the LN 
The lymphatic network displays a tree-like architecture that allows the unidirectional 
flow of the carried lymph from peripheral tissues to the blood circulation at the 
thoracic duct, passing through chains of LNs on its way (18). The anatomical 
distribution of lymphatic vessels, starting with initial lymphatics (lymphatic capillaries) 
in the periphery, leading to pre-collector vessels and collecting vessels that reach the 
LNs suggests diverse functional roles for LECs and different sites of physical contact 
with immune cells (19).  
Following inflammation in the periphery, activated dermal dendritic cells (DCs) 
adhere firmly to the outer surface of initial lymphatics (15) to subsequently enter the 
vessels by passing through the flaps of oak-leaf shaped LECs that are connected by 
specialized discontinuous button-like junctions (Fig. 1.1A). At this level, the basement 
membrane around lymphatic vessels is almost totally missing, enabling them to be 
also highly endocytic and permeable to proteins (4). LECs of the initial lymphatics are 
characterized by the expression of LYVE-1, Prox-1, VEGFR-3, and podoplanin 
(gp38) and they are known to express the chemokine CCL21-Leu (containing a 
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leucine residue at position 65) (19, 20). Lymphatic-derived expression of CCL21-Leu 
in the periphery (Fig. 1.1B) is known to recruit the activated mature CCR7+ DCs 
towards initial lymphatics via the generation of a chemotactic gradient (4). 
Once in the lumen of initial lymphatics, dermal DCs originally move by active 
crawling, guided by sensing the flow. Later on, initial vessels converge into the larger 
collecting lymphatics, surrounded by smooth muscle cells with pumping activity, and 
from there on, lymph flow transfers DCs to the LN (15). The lymphatic vessels that 
actually reach the LN are thought to branch extensively into the so-called afferent 
lymphatics, as they terminate at, and within, the subcapsular sinus (4). The other 
form of CCL21, CCL21-Ser, is expressed in the LNs and terminal lymphatic vessels 
as opposed to lymphatics in the periphery, and is thought to favor CCR7+ DC 
migration in the LN parenchyma (21) (Fig. 1.1C). The CCR7-CCL21 signaling axis is 
also important for the trafficking of naïve, memory and regulatory T cells from the 
periphery to the LN (22).  
 
Figure 1.1 The lymphatic system regulates immune cell trafficking from the periphery to the LN. 
(A) Entry of DCs in initial lymphatic vessels through the loose button-like junctions of LECs. (B) Similar 
to CCR7+ DCs, memory cells can also enter initial lymphatics in the periphery driven by the expression 
of CCL21 (CCL21-Leu). (C) DCs as well as memory T cells enter the LN via afferent lymphatics. Since 
LNs are frequently arranged in chains, naïve T cells derived from an upstream LN (Primary peripheral 
LN) can also arrive via afferent lymph. A CCL21 gradient (CCL21-Ser) also assists the directional 
migration of DCs from the subcapsular sinus (SCS) into the LN parenchyma. (D) Naïve T cells mainly 
arrive in the LN from the blood via specialized high endothelial venules (HEV). The expression of 
CCL19 and CCL21 in the T cell zone drives the intranodal migration and accumulation of T cells in the 
paracortical T cell areas of the LN. Figure adapted from Girard et al. (14). 
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CCL19, another ligand of CCR7, is also expressed by LECs and fibroblastic reticular 
cells (FRCs) and it is known to facilitate naïve T cell recruitment into the deep 
paracortex of the LN (23) (Fig. 1.1D). 
Within the LN, LECs are divided in three different subgroups with respect to their 
anatomic location (24) (Fig. 1.2). Subcapsular sinus (SCS) LECs line the floor and 
the ceiling of the subcapsular region and come to contact with the residing SCS 
macrophages (Fig. 1.2A). Cortical LECs shape the vessels that emanate in between 
the B-cell follicles and into the T-cell zone and can cross the SCS and medullary 
LECs (Fig. 1.2B). Medullary LECs form the medullary sinuses at the LN exit within 
the medulla of the LN (Fig. 1.2C). While podoplanin (gp38) and PECAM-1 (CD31) 
are usually employed to define LECs and separate them from the other major lymph 
node stromal cell (LNSC) subsets by flow cytometry (25, 26), the expression of PD-
L1, ICAM-1, MAdCAM-1 and LTβR allows for further subdivisions in the above 
described subgroups (27). SCS LECs have been recently shown to play a major role  
 
Figure 1.2 The subanatomical organization of the lymph node and the distinct sites of close 
contact between LECs and immune cells. LN LECs can be divided into three subgroups with regard 
to their localization in one of the three main regions of the LN: the cortex, the paracortex and the 
medulla. (A) Subcapsular sinus LECs line the floor and the ceiling of the subcapsular region of the LN. 
(B) Cortical LECs line the lymphatic vessels that branch between the B cell follicles into the T cell area. 
(C) LECs that form the sinuses at the medulla of the LN are called medullary LECs. (D) SCS LECs 
control the transmigration of DCs from the SCS into the LN parenchyma by driving a CCL21 chemokine 
gradient through the expression of CCRL1 scavenger receptor. (E) Naïve and memory T cells that reach 
the LN via the afferent lymph, come to close contact with LECs at the point of entry, in the SCS. (F) T 
cells are then channeled into the cortical and medullary sinuses. T cells can transmigrate from the 
medullary sinuses into the deep paracortex by sensing the expression of CCL21 and CCL19 in the T 
cell zone. (G) Secretion of S1P by LECs mediates the migration of T cells from the T cell areas into the 
sinuses through the S1P receptor (S1PR) on T cells. After their entry, T cells are flow-guided towards 
the medulla of the LN to exit via the efferent lymphatic vessels. Figure adapted from Girard et al. (14). 
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in the entry of activated DCs from the afferent lymphatic vessel into the LNs by 
driving the CCL21 chemokine gradient through the expression of the atypical CCRL1 
scavenger receptor (28) (Fig. 1.2D).  
Once they enter the LN, migrating DCs initially localize to the subcapsular region (15, 
29) where they come to close contact with SCS LECs. In addition to DCs, T cells also 
interact intimately with LECs at distinct locations within the LN. Activated as well as 
naïve T cells encounter LECs in their route of entry in the LN (Fig. 1.2E) when 
migrating in from afferent lymphatic vessels (30, 31). T cells can then be directed into 
cortical and medullary sinuses, interacting with LECs while reaching the LN lumen 
(27) (Fig. 1.2F). Eventually, T cells are guided to exit the lymph node via efferent 
lymphatics. LECs have been also reported to facilitate T cell egress from the LN 
through secretion of sphingosine-1-phosphate (S1P), of which they are the main 
source (32) (Fig. 1.2G).  
Therefore, it becomes apparent that LECs can dynamically regulate immune cell 
transport and thus, potentially modulate their downstream functions.  
The lymphatic system controls antigen availability and regulates the 
kinetics of antigen presentation 
Apart from the recruitment of immune cells, the lymphatic system also regulates the 
transport of soluble antigens carried in the lymph. In addition to cell-associated 
antigen that reaches the LN with a relative delay, free antigens can rapidly arrive to 
the SCS, through afferent lymphatics. Upon arrival, antigens are channeled to 
different compartments of the LN with respect to their size. Low-molecular weight 
antigens are promoted to FRC–lined conduits to subsequently reach the B and T cell 
zones (33, 34), whereas larger antigens and immune complexes can be directly 
taken up by SCS macrophages. The size-dependent antigen distribution is partially 
mediated by sieve-like diaphragms, composed of plasmalemma vesicle-associated 
protein (PLVAP) in the SCS LECs (35). The remaining high-molecular weight 
molecules will reach the next LN by exiting through the medullary sinuses. While 
passing through those LEC-covered structures, they can be sampled by resident 
DCs that extend their protrusions in the medullary sinuses (36). Smaller antigens can 
also be sampled by immature LN-resident DCs in the paracortex (37). 
During homeostasis, lymph flow constantly supplies the LN with a pool of tissue self-
antigens for the deletion of autoreactive T cells. Following infection or tissue injury, 
the lymph flow is vigorously altered in response to peripheral tissue inflammatory 
signaling, to accommodate increased lymph formation and accelerate the initiation of 
the immune response (38, 39). Additionally, the delayed arrival of DC-transported 
antigen, as opposed to the fast drainage of soluble antigen from the periphery and its 
subsequent capture by resident DCs, suggests an early onset of the adaptive 
immune response which is later amplified by migratory DCs (37, 40). Hence, the 
differential kinetics of lymph drainage, along with the spatial compartmentalization of 
the LN, may delicately orchestrate antigen presentation and in turn, powerfully 
influence the initiation and the magnitude of the immune response.  
Evidently, the transport and immune functions of lymphatic vessels, which were 
previously thought to be distinct, are strongly interconnected. Lymphatics directly link 
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peripheral tissues to the central immune system and thus, constitute an important 
component of the body’s immune defense. 
1.2 LECs as direct participants in immune regulation: from 
simple bystanders to major players? 
Modulation of DC-T cell interactions by LECs 
As discussed earlier, LECs come into intimate contact with DCs and T cells, which 
suggests potential direct immunological interactions. Recent studies have shed some 
light on the functional influence that LECs might exert on DCs and T cells, along with 
the mechanisms implicated (41, 42). LECs have been reported to express diverse 
immunosuppressive molecules, such as the transforming growth factor beta (TGFβ), 
nitric oxide and indoleamine 2,3 dioxygenase (IDO) indicating their potential 
regulatory role (43-46) (Fig. 1.3A). Furthermore, LECs have been demonstrated to 
directly modulate DC differentiation status and function, via a cell contact – 
dependent mechanism (47). Inflamed human skin LECs were shown to induce down-
regulation of the maturation marker CD86 on DCs, which subsequently resulted in 
reduced capacity of stimulating T cell proliferation in the absence of pathogen-
derived signals. This immunosuppressive function required adhesive interactions 
between LECs and DCs and was dependent on binding of macrophage-1 antigen 
(MAC-1), on DCs, to intercellular adhesion molecule 1 (ICAM-1), on LECs (Fig. 
1.3B).  Subsequent findings revealed that the supernatant of IFN-γ - activated LECs 
abrogated the capacity of allogeneic DCs to induce T cell proliferation, pointing to 
IDO as the inhibitory mediator (45). Along the same lines, murine LN LECs, together 
with FRCs, were observed to inhibit CD4+ and CD8+ T cell proliferation via regulated 
expression of the nitric oxide synthase 2 (NOS2) enzyme, which catalyzes the 
production of nitric oxide (NO). The authors proposed a mechanism in which 
interferon-γ (IFN-γ), released from activated splenocytes, together with tumor 
necrosis factor (TNF) signaling, induced NO production in LECs which subsequently  
 
Figure 1.3 LECs employ different mechanisms to modulate immune responses. (A) LECs prohibit 
T cell proliferation via the secretion of immunosuppressive molecules. (B) LECs suppress DC 
maturation and thus, abrogate their ability to functionally activate T cells. (C) LECs can express PTAs 
and present them on MHC I to CD8+ T cells to induce deletional tolerance. Image adapted from Card et 
al. (41). 
A B C 
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resulted in down-regulation of T cell proliferation (48) (Fig. 1.3A). The suppressive 
effect also turned out to be cell-contact dependent, suggesting that bi-directional 
signaling is needed to sensitively fine-tune the outcome of T cell responses.  
Taken together, it becomes evident that LECs can employ different mechanisms to 
modulate DC-T cell interactions. 
Direct antigen presentation by LECs 
LECs express various molecules associated with antigen presentation, which 
suggests that they could also themselves act as antigen presenting cells (APCs) and 
prime T cells. In addition, human and murine LECs express multiple functional Toll-
like receptors (TLRs) (30, 49). Furthermore, LECs display several scavenging 
receptors, C-type lectins, and other known cross-presentation – related receptors, 
which implies that they might also be capable of antigen uptake and processing (42). 
The upregulation of many of these proteins under inflammatory conditions (44) 
further underlines the potential dynamic participation of LECs in shaping immune 
responses.  
As all other nucleated cells, LECs express major histocompatibility complex (MHC) 
class I, which suggests that they can interact directly with CD8+ T cells. Interestingly, 
LECs also display low-level expression of MHC class II in the steady state, which is 
further upregulated upon IFN-γ treatment (44, 50). In terms of costimulatory 
machinery components, LECs were shown to express low levels of CD40 and almost 
no CD80 or CD86 at steady state conditions (30). Expression of those molecules 
under inflammatory conditions was only slightly altered, if any. By contrast, LECs 
were demonstrated to express the coinhibitory programmed death ligand 1 (PD-L1), 
which was further enhanced following TLR-3 stimulation. In line with the murine 
model, HLA-A/B/C were reported to be constitutively expressed on human LN LECs, 
while HLA-DR/DQ/DP expression was induced after IFN-γ or PolyI:C treatment (45). 
Human LN LECs were also shown to express CD58 (LFA-I) although its expression 
was not increased upon IFN-γ or TNF-α stimulation or following treatment with 
several TLR ligands. Therefore, LECs seem to bear several activating and inhibitory 
elements of the antigen-presentation machinery. More importantly, LECs can 
dynamically tune the expression of those molecules in response to the 
immunological status of their microenvironment, similar to conventional APCs. 
Strikingly, LECs, as well as other LNSCs, were found to express a wide variety of 
peripheral tissue-restricted antigens (PTAs), which they presented on MHC I 
molecules to primarily activate and subsequently delete CD8+ T cells (51-53) (Fig. 
1.3C). More specifically, distinct PTAs were found to be expressed among the four 
LNSC subsets (30). However, studies have been primarily focused on LECs and 
FRCs, which have been shown to mediate deletional tolerance. Interestingly, LECs 
were the only cell type among all LNSCs to express the melanocyte epitope 
tyrosinase (Tyr369) and delete tyrosinase-specific CD8+ T cells (54). This might have 
important clinical implications if the observed LEC-mediated induction of tolerance is 
confirmed in human melanomas. Thus, LECs might actively contribute to peripheral 
tolerance exerting non-redundant and biologically relevant regulatory functions. 
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LNSC-mediated induction of tolerance is considered to be reminiscent of the central 
tolerance mechanisms in the thymus, driven by medullary thymic epithelial cells 
(mTECs), which eliminate self-reactive T cells (55). The organized action of central 
versus peripheral tolerance is associated with distinct transcriptional regulators. PTA 
expression in mTECs has been reported to be dependent on the autoimmune 
regulator (Aire), (55) whereas it was found to be Aire-independent in LECs (30). 
Another transcriptional regulator, Deaf 1 (56), may be associated with LEC and FRC-
mediated peripheral tolerance. 
LECs, as well as FRCs, are not the only non-hematopoietic cells that have been 
shown to participate in the maintenance of peripheral tolerance (57). Unconventional 
APCs in the liver, skin, parenchymal tissues, and lymph nodes were found to 
efficiently present tissue-specific and exogenous antigens to naïve CD8+ T cells 
participating in the regulation of immunity in the periphery (58). Hepatocytes and 
pancreatic islets have been suggested to directly present liver antigen to CD8+ T 
cells. Liver sinusoidal endothelial cells (LSECs) constitutively display MHC class I 
and II, as well as low levels of co-stimulatory molecules and they can capture antigen 
for presentation to CD4+ and CD8+ T cells (59).  
In addition to regulating tolerance via presentation of self-antigens, LECs also bear 
the required tools for cross-presentation of exogenous antigens. Indeed, our 
laboratory has recently shown that LECs in the tumor dLN can scavenge and cross-
present tumor antigen on MHC I, to induce apoptotic and dysfunctional tumor-
specific CD8+ T cells, in a VEGF-C - overexpressing mouse B16/F10 melanoma 
tumor model (60). This mechanism is clearly distinct from the presentation of self-
antigens by LNSCs, discussed above, and presents similarities with the scavenging 
function of LSECs, which were demonstrated to cross-present antigen to CD8+ T 
cells with the immunological outcome characterized as rather tolerogenic (61-64). It 
is likely that tumors might harness a physiological ability of LECs (cross-presentation) 
to suppress cytotoxic anti-tumor responses and escape host immunity. However, it 
has not yet been verified whether LECs can exert similar function under steady-state 
conditions and what could be the immunological outcome. The specific mechanisms 
by which LECs capture antigens, as well as the trafficking pathways and processing 
mechanisms implicated remain largely unknown. 
An open question that needs to be addressed is the functional outcome of 
interactions between LECs and CD4+ T cells. Although MHC II expression in LECs 
has been reported (44, 65), it is unknown if this leads to proliferative responses in 
CD4+ T cells. Human LN LECs failed to induce allogeneic, naïve or memory, CD4+ T 
cell proliferation in vitro (45). In a different setting, DC-derived peptide:MHC II 
complexes in LECs did not induce T cell proliferation but instead, promoted cell 
death (50). Further studies should be conducted to clarify the contribution of MHC II 
presentation by LECs in CD4+ T cell immune responses. 
Signaling pathways governing direct LEC-CD8+ T cell interactions 
Our knowledge about the signaling mechanisms tipping LEC-CD8+ T cell interactions 
towards the induction of tolerance is still quite limited. The overall picture of how 
LECs control and shape immune responses needs to be fully formulated. The 
outcome of CD8+ T cell activation by professional APCs has been previously 
described to rely on three different signals; recognition of their cognate antigen 
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presented on an MHC-I molecule, costimulatory signaling, and cytokine or other 
inflammatory signaling (66, 67). In the absence of the appropriate costimulation, 
CD8+ T cell activation is traditionally thought to result in anergy or deletion. 
Costimulatory signals are almost totally absent in LECs and are not enhanced 
following TLR stimulation (30); thus, in accordance with this concept, the observed 
tolerogenic outcome is not surprising (65). 
One of the mechanisms that has been previously suggested to be associated with 
CD8+ T cell impairment is the PD-1/PD-L1 pathway (68, 69). Earlier studies have 
highlighted the role of PD-L1 in the induction of CD8+ T cell tolerance by intestinal 
epithelial cells (70). The same pathway has also been demonstrated to mediate 
deletional CD8+ T tolerance by LSECs (64). Until recently, many of the significant 
immune check points (71), associated with dyfunctional CD8+ T cells, such as 
Cytotoxic Lymphocyte Antigen-4 (CTLA-4), ICOS, LAG3 or TIM-3,  have not been 
examined for their potential implication in LEC-mediated tolerance. In fact, Tewalt et 
al. have recently demonstrated, in a model of LEC-mediated tolerance against 
tyrosinase, that lack of costimulation via 4-1BB (CD137) induced up-regulation of 
PD-1 on activated T cells and subsequently resulted in reduced CD8+ T cell survival 
in vivo (65). In the same model, blockade of the PD-1/PD-L1 pathway led to 
autoimmunity. 
Collectively, multiple inhibitory mechanisms and regulatory molecules appear to be 
associated with LECs’ immunomodulatory function. How all these combinatorial 
aspects might synergize or act independently in order to tightly drive LECs’ behavior 
remains unresolved.  
1.3 A place for LECs as APCs in the immune response 
While the role of LECs as active regulators of immunity is gaining appreciation, this is 
still the beginning of the story.   
The newly emerging concept of LECs’ contribution as APCs to immunomodulation is 
primarily inclined towards the suppression of immune responses. Our current 
understanding and accumulating evidence point towards a complementary role in the 
maintenance of peripheral tolerance coupled to a safety mechanism for the 
preservation of the LN structure during immune responses or even the resolution of 
the immune response. Nevertheless, the potential capacity of exogenous antigen 
presentation in LECs introduces another layer of complexity. If LECs can capture, 
process and present exogenous antigens during homeostasis to sustain peripheral 
tolerance, how does this function influence the initiation of immunity following 
pathogenic infection? 
While the contribution of LECs’ exogenous antigen presentation in immunity is as yet 
poorly understood, what is not in question is the impact of the lymphatic endothelium 
in the modulation of immunity. With this picture as a context background basis, we 
set out to unwind the complex emerging role of LECs in the regulation of T cell 
immunity and tolerance. 
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1.4  Outline of the thesis 
This thesis focuses on elucidating the direct role of LECs in the induction of CD8+ T 
cell-mediated immunity and tolerance.  
In Chapter 2, we explore the ability of LN LECs to capture and process exogenous 
antigen. We demonstrate that LECs can constitutively uptake and cross-present 
exogenous antigens on MHC I to CD8+ T cells under steady-state conditions. We 
employed an in vitro coculture system and the model antigen ovalbumin to study 
antigen-specific LEC-CD8+ T cell interactions. LEC-educated CD8+ T cells 
proliferated, displaying an activated phenotype, however, they appeared to be more 
rapidly apoptotic and failed to produce effector cytokines, compared to T cells 
activated by professional antigen-presenting dendritic cells. The dysfunctionally 
activated state of LEC-educated CD8+ T cells suggested that antigen presentation by 
LECs under steady state conditions might promote self-tolerance against draining 
peripheral antigens. Our findings establish LECs as bona fide APCs and reveal their 
contribution in the maintenance of peripheral tolerance. 
Traditionally, the induction of peripheral tolerance has been assigned to immature 
cross-presenting DCs via different mechanisms, including T cell anergy, suppression 
or deletion. The surviving tolerized CD8+ T cells should remain functionally impaired 
in response to any stimuli in order to sustain homeostasis and prevent autoimmunity. 
This prompted us to further investigate the phenotype and function of LEC-educated 
CD8+ T cells to identify whether those cells are terminally tolerized or whether they 
could escape the dysfunctional state. In Chapter 3, we demonstrate that steady-
state LEC-educated CD8+ T cells adopted a unique phenotype with central and stem 
cell memory-like characteristics, accompanied by additional functional memory-like 
properties. Following antigen re-encounter, LEC-educated CD8+ T cells mounted 
proliferative responses and gave rise to effector cells. Most importantly, they 
participated in anti-infectious immunity while preserving a secondary-memory 
persistent population. Our findings reveal a distinct differentiation state of antigen-
experienced CD8+ T cells, generated under steady-state conditions, which survive in 
an inert state but can be functionally reactivated upon antigenic inflammatory 
challenge. This previously unanticipated function of LECs probably serves as a 
supplementary mechanism, which complements and amplifies CD8+ T cell immune 
responses, and further highlights the diverse immunomodulatory features of LECs. 
The generation of an antigen-experienced CD8+ T cell pool by LN LECs during 
homeostasis triggered questions about the role of LECs in an inflammatory setting. 
Lymph nodes (LNs) undergo considerable expansion during inflammation induced by 
pathogen infection or following vaccination. In Chapter 4, we asked whether the 
observed proliferation and dynamic remodeling of lymphatic structures during 
inflammation might directly impact the induction of CD8+ T cell immunity. We 
demonstrate that LN LECs can sense and integrate signals from their 
microenvironment to actively scavenge exogenous antigen under inflammatory 
conditions. We employed two different strategies in order to determine the 
contribution of antigen presentation by LN LECs in the initiation of immune 
responses. We first exploited an anti-VEGFR3 blocking antibody in order to abrogate 
LEC proliferation following immunization with a subunit vaccine. In an alternative 
approach, we developed the Prox1-Cre-DTR mouse model, which allows for specific 
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ablation of LECs in vivo. Our findings improved our perception of the immunological 
significance of LEC expansion following inflammatory antigenic challenge and gave 
us valuable hints for their active contribution in the establishment of adaptive 
immunity. 
This thesis illuminates the multifaceted immunological role of LECs and highlights 
their dynamic involvement in the regulation of immunity and tolerance. As we acquire 
a deeper understanding of the impact of antigen presentation by LECs, a new 
challenge rises. In Chapter 5, we discuss whether and how we could potentially 
exploit LECs’ function to improve protection against pathogens and tumors, or to 
prevent autoimmunity and transplant rejection.  
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Chapter 2    
Steady-state antigen scavenging, 
cross-presentation and CD8+ T cell 
priming: a new role for LECs* 
Until recently, the known roles of lymphatic endothelial cells (LECs) in immune 
modulation were limited to directing immune cell trafficking and passively 
transporting peripheral antigens to lymph nodes. Recent studies have demonstrated 
that LECs can directly suppress dendritic cell maturation and present peripheral 
tissue and tumor antigens for autoreactive T cell deletion. We asked whether LECs 
play a constitutive role in T cell deletion under homeostatic conditions. Here, we 
demonstrate that murine LECs under non-inflamed conditions actively scavenge and 
cross-present foreign exogenous antigens to cognate CD8+ T cells. This cross-
presentation was sensitive to inhibitors of lysosomal acidification and ER-golgi 
transport and was TAP1-dependent. Furthermore, LECs up-regulated MHC I and the 
PD-1 ligand PD-L1, but not the co-stimulatory molecules CD40, CD80, or CD86, 
upon antigen-specific interactions with CD8+ T cells. Finally, antigen-specific CD8+ T 
cells that were activated by LECs underwent proliferation with early-generation 
apoptosis and dysfunctionally-activated phenotypes that could not be reversed by 
exogenous IL-2, indicating that LEC-mediated CD8+ T cell tolerance is not simply T 
cell exhaustion. These findings help establish LECs as antigen-presenting cells, 
capable of scavenging and cross-presenting exogenous antigens, in turn causing 
dysfunctional activation of CD8+ T cells under homeostatic conditions. We suggest 
that steady-state lymphatic drainage may thus contribute to peripheral tolerance not 
only by delivering self-antigens to lymph node-resident leukocytes, but also by 
providing constant exposure of draining peripheral antigens to LECs, which maintain 
tolerogenic cross-presentation of such antigens.  
????????????????????????????????????????????????????????
??adapted from the original manuscript Hirosue, S., E. Vokali, et al., 2014, The Journal of Immunology 
192: 5002–5011.?
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2.1  Introduction 
The lymphatic system transports interstitial fluid, antigens, solutes and immune cells 
from the periphery and returns them to the blood circulation after surveillance 
through lymph nodes (LNs), thereby initiating adaptive immune responses (1-3). In 
addition to effector immune responses, LNs are important sites for the maintenance 
of peripheral tolerance. Lymph node stromal cells, which include lymphatic and blood 
endothelial cells (LECs and BECs) as well as fibroblastic reticular cells (FRCs) in the 
T cell zone, are thought to contribute to tolerance induction of autoreactive T cells 
that escape central memory (4) as well as regulate the contraction of inflammatory 
responses (5). Indeed, the lymphatic endothelium is emerging as an important player 
in shaping immunity and tolerance (1-3, 6-10). For example, LECs have been shown 
to suppress maturation of DCs (1, 4, 11) and their subsequent priming of CD8+ T 
cells in a contact-dependent manner (4, 5, 9). In addition, LECs as well as FRCs can 
directly prime CD8+ T cells (5); they express components of the antigen presentation 
machinery including major histocompatibility complex (MHC) I and II molecules (6-9, 
12) and have been shown to directly contribute to peripheral tolerance by expression 
and presentation of endogenous peripheral tissue-restricted antigens (PTAs), leading 
to compromised CD8+ T cell activation (6-9). They are also sensitive to pathogen-
associated molecular patterns via the expression of various members of the toll-like 
receptor (TLR) family (8, 11). Together, these studies have established LECs as 
contributors to maintaining peripheral tolerance to endogenously expressed self-
antigens.  
However, little is known about whether LECs as antigen-presenting cells (APCs) 
have the ability to capture and process exogenous antigens for CD8+ T cell deletion. 
While so-called professional APCs such as CD8a+ DCs can process exogenous 
antigens for cross-presentation to CD8+ T cells, some non-hematopoietic cell types 
have also been shown to be capable of cross-presentation (13). For example, liver 
sinusoidal endothelial cells (LSECs) are thought to capture and cross-present 
circulating antigen to CD8+ T cells, leading to CD8+ T cell deletion and the 
establishment of a tolerogenic environment (14). This is especially important in the 
liver, where LSECs are amongst the first cells to encounter the large diversity of 
foreign antigens from food as well as TLR agonists from commensal sources (15). 
Similarly, LECs are the first cells to contact extracellular antigens that arise in the 
periphery and drain into lymphatic vessels after e.g., tissue damage, inflammation, or 
infection. We recently showed that a foreign antigen (OVA) expressed by an 
orthotopically implanted tumor could be cross-presented by tumor-associated LECs 
which, when isolated, could drive dysfunctional activation of cognate CD8+ T cells 
and promote tumor progression (16). As tumors utilize physiological mechanisms to 
promote tolerance for their survival (17), we hypothesized that a similar mechanism 
of antigen cross-presentation by LECs may exist under steady-state conditions to 
promote tolerance against self-antigens. 
Here, we demonstrate that under homeostatic conditions, LECs constitutively uptake 
and cross-present exogenous antigens to CD8+ T cells. We further show that LEC-
activated T cells are more rapidly apoptotic, upregulate so-called exhaustion markers 
(PD-1, CTLA-4, and CD80), secrete less IFNγ and IL-2, and express lower levels of 
the activation markers CD25, CD44, and CD69 compared to T cells activated by 
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DCs. Together, these data suggest that LECs help maintain CD8+ T cell tolerance to 
exogenous antigens that are encountered in lymph under steady-state conditions, 
which may be important for preventing autoimmune reactions against self-antigens 
after infection or injury.  
2.2  Materials and Methods 
Reagents  
All chemicals were from Sigma-Aldrich (Buchs, CH) unless otherwise noted. The mature 
MHC I epitope, OVA256-264 (SIINFEKL) peptide, was from GenScript (Piscataway, NJ, US). 
Endotoxin-free OVA was from Hyglos GmbH, (Bernried am Starnberger See, DE). Antibodies 
used in flow cytometry were from eBioscience (Vienna, AT) or BioLegend (Luzern, CH) 
unless otherwise noted. 
Mice 
The following mice strains were used in this study at age 6-12 weeks unless noted otherwise. 
Female C57BL/6 wild-type mice and OT-I transgenic mice, C57BL/6- Tg(TcraTcrb)1100Mjb/J, 
were purchased from Harlan Laboratories (Gannat, FR). TAP1-/- mice (B6.129S2-
Tap1tm1Arp/J), were purchased from Jackson Laboratories (Farmington, CT, US). Animals 
were housed in pathogen-free facilities and all procedures were approved by the Cantonal 
Veterinary Committee of Vaud, Switzerland (Protocol number 2518). 
Cell lines 
Conditionally immortalized dermal LECs (iLECs) from Immortomice were isolated and 
cultured as previously described (18). Cell culture surfaces used in all assays were coated 
with collagen (10µg/ml PureCol, Advanced Biomatrix, San Diego, CA, US) and 10µg/ml 
human fibronectin (Millipore, Billerica, MA, US) prior to seeding. Cells were grown in 40% 
DMEM low glucose, 40% F12, 20% Fetal Bovine Serum (FBS) (all from Invitrogen, Zug, CH), 
supplemented with 10µg/ml native bovine endothelial mitogen (AbD Serotec, Düsseldorf, DE) 
and 56µg/ml heparin sodium salt from porcine intestinal mucosa (Sigma-Aldrich). To induce 
large T antigen expression, IFNγ (R&D, Abingdon, UK) was added to the media at 100U/ml 
and cells were propagated at 33°C. Prior to all experiments, cells were grown for 72h in the 
absence of IFNγ at 37oC and maintained as such. 
Primary cell isolation 
To obtain primary LN LECs, LNs were digested with 0.25mg/ml Liberase DH and 100µg/ml 
DNase (both from Roche, Basel, CH) to obtain a single cell suspension and cultured as 
described (19). Cells were cultured for 5 days until confluent, removed by Accutase 
(Biological Industries, Lucerna-Chem AG, Lucerne CH), and stained with mAbs against gp38 
(clone 8.1.1), CD31 (clone 390), and CD45 (clone 30-F10) and FACS sorted (FACS Aria II, 
BD, Basel, CH) into the following subpopulations: FRCs (gp38+CD31-) LECs (gp38+CD31+), 
BECs (gp38-CD31+), and DN (gp38-CD31-) as described (20).  Bone marrow-derived DCs 
(BMDCs) were harvested from C57Bl/6 mice, differentiated in GM-CSF as described (21) and 
used at day 7 of culture. 
Synthesis of peptide-conjugated nanoparticles (NPs) 
To explore the mechanisms of cross-presentation poly(propylene sulfide)-nanoparticles (NPs) 
with ~30nm diameter were synthesized and characterized as described (22). The long 
peptide containing the mature MHC I epitope SIINFEKL – Cys-OVA250-264 (COVA250-264) was 
synthesized in-house and activated with a 2-pyridylthiol as previously described (22). Core 
sulfhydryls on NPs were reacted with the activated peptide and purified on a Sepharose 
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CL6B column (Sigma-Aldrich). To fluorescently label the NPs, NPs were exposed to Dy-649 
maleimide (Dyomics GmbH, Jena, DE) after dialysis in a 1:60 molar ratio of dye to NP 
sulfydryl groups in phosphate buffered saline (PBS) at RT for 24 h (22). Free dye was 
removed by gel filtration in as above but in endotoxin-free water (B. Braun Medical AG, 
Sempach Switzerland) as eluent. Endotoxin levels of antigens were routinely assessed by a 
colorimetric assay based on the HEK-Blue ™ TLR4 cell line (InvivoGen, San Diego, CA, 
USA) according to the manufacturer’s protocol using a standard curve generated from the E-
Toxate ™ endotoxin standard (Sigma). 
In vivo antigen drainage 
To determine whether LN LECs can actively capture antigens in vivo, we injected 
fluorescently labeled OVA protein into the limbs of mice and determined its distribution within 
various cells in the LN after 90 min. Endotoxin-free OVA was labeled with AlexaFluor 647 
NHS (Dyomics GmbH, Jena, DE) (OVA AF-647) and purified by size exclusion 
chromatography using a Sephadex G-25 column with PBS as eluent. C57BL/6 mice were 
injected intradermally (i.d.) with 15 μg OVA AF-647 in the limbs. After 90 min, mice were 
transcardially perfused with a heparinized saline solution containing 1g/L glucose and 20mM 
HEPES, pH 7.2.  For immunostaining, brachial LNs were removed and fixed overnight in 2% 
PFA in PBS pH 7.4. After three washes in PBS, LNs were embedded in a block of 2% 
agarose, and sectioned (150µm) using a using a vibratome (Leica, Wetzlar DE). Sections 
were blocked in 0.5% of casein, and further labeled using antibodies against CD3e (BD 
Pharmingen, clone 500A2) and LYVE-1 (Reliatech, San Pablo, CA US). Images were 
acquired on a Leica SP5 confocal microscope using 20x or 60x objectives, and processed 
using Imaris software (Bitplane, Zürich, CH). For flow cytometric analysis, brachial LNs from 
individual mice were pooled and digested with 1mg/ml Collagenase D and 200 kunitz/ml 
DNase I (Sigma Aldrich). After LNs were fully digested as described (19) the single cell 
preparations were enriched for non-hematopoietic stromal cells by CD45 cell depletion using 
CD45 microbeads (Miltenyi Biotec, Bergisch Gladbach, DE). Enriched stroma and the CD45+ 
fraction were then counted, stained with (gp38, CD31, CD45, LYVE-1) and (CD45, CD11c, 
CD11b, MHC II), respectively, and analyzed by flow cytometry.  
Intracellular localization studies  
To determine the intracellular pathways of antigen trafficking, we incubated iLECs with 
fluorescently labeled OVA and stained for different cellular components. Cells were seeded 
on glass coverslips (15mm round, Karl Hecht KG, DE) coated as above at 2×105 cells/well in 
12-well plates. NP-Dy649 or OVA-AF647 at final concentrations of no more than 5 mg/ml, 
10µg /ml, respectively, were added to the cells for 1 hour on ice in buffered (25mM Hepes) 
reduced serum (2% FBS) culture media, then transferred to 37o C for 15 or 90 min. Cells were 
fixed in 4% paraformaldehyde in PBS, permeabilized in permeabilization buffer (3% bovine 
serum albumin and 0.1% saponin) in PBS overnight at 4o C.  Primary antibody incubations 
were 1h followed by species-matched secondary antibodies for 30min at room temperature. 
The 15min time point was stained for clathrin, while the 90min time point was stained for 
LAMP-1. All antibody dilutions were made in permeabilization buffer. Coverslips were 
mounted with Citifluor (Citifluor Ltd., UK), imaged with a 63x oil immersion lens on a LSM 700 
or 710 inverted, or upright confocal microscope (Carl Zeiss, Feldbach, CH) respectively. After 
deconvolution (Huygens Deconvolution software, Scientific Volume Imaging, NL), Fiji 
software (NIH, Bethesda, MD US) applying the Image 5D plugin was used to generate the 
figures. To quantify fluorescent NP or OVA colocalization within clathrin-positive vesicles, 
single z-planes from deconvolved images were analyzed using a script that determines the 
statistical significance of object-based colocalization by comparison of the colocalization 
occurences on actual images as compared to colocalization by chance (23). To determine 
whether NP+ or OVA+ spots were within or outside of LAMP-1+ surfaces, the ImarisXT matlab 
plugin “split spots onto surface objects” was used. Spots were defined as ≤0.2µm in diameter, 
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and LAMP-1+ surfaces were drawn within a resolution of 0.1µm from the immunofluorescence 
signal. Intravesicular spots were defined as spots within this surface.  
In vitro antigen cross-presentation  
To determine whether LECs can cross-present antigen in vitro, cells were plated at 5x104 
cells per well in 24 well plates and stimulated with either 2.5µM OVA257-264 (SIINFEKL), 2.5µM 
NP-ss-COVA250-264, or equivalent concentrations of unconjugated NP for 18h in medium 
buffered with 25mM HEPES (pH7.4) at 4° or 37°C. Cell surface H2-Kb –OVA257–264 complexes 
were detected by the antibody 25d1.16 by flow cytometry. To characterize the kinetics of OVA 
accumulation in LECs, cells were stimulated with 1μΜ OVA-AF647 for up to 90min, washed, 
and analyzed for OVA uptake by flow cytometry. To demonstrate CD8+ T cell priming, APCs 
were seeded at 104 cells per well in 96 well round-bottom (BMDCs) or flat-bottom (LECs) 
plates. 
In vitro T cell co-culture assays 
To determine the outcome of CD8+ T cell interaction with cross-presenting LECs, we 
performed coculture assays. CD8α+ T-cells were purified from the spleen of an OT-I mouse 
by negative selection (CD8α Kit II, Miltenyi Biotec, Bergisch Gladbach, DE). For LEC-T cell or 
DC-T cell coculture studies, 104 LECs or DCs were cocultured  with naïve CD8+ T-cells from 
OT-I mice in 96-well plates for 72h at a ratio of 1:10 APC:T cells in 200 μl of coculture media 
(IMDM with 10% FBS and 1% penicillin/streptomycin). To inhibit antigen uptake and 
processing, cells were pre-treated with either dynasore, LY294002, or lactacystin (inhibitors of 
dynamin, phosphoinositide 3-kinase, and proteasome activity, respectively) 1h prior to 
addition of antigen (SIINFEKL or NP-ss-COVA250-264, 1nM peptide concentration) in APC-
specific media. For drugs that inhibit intracellular antigen trafficking, we applied the antigen 
for 1h prior to addition of brefeldin A (BFA) and chloroquine, which inhibit protein transport 
from the endoplasmic reticulum (ER) to the golgi apparatus and endosome acidification, 
respectively. After 24h incubation at 37oC, cells were washed and fixed with 2% 
paraformaldehyde in PBS (pH7.4) for 10min on ice. After washing, CFSE-labeled CD8+ OT-I 
T cells were added as above. Supernatants were harvested and frozen for cytokine analysis 
by ELISA (R&D Systems, Minneapolis, MN, US). Cells were then processed and stained for 
immunological markers to be analyzed flow cytometry. Cellular proliferation was monitored by 
CFSE dilution and apoptosis was determined by Annexin V staining (BioVision, Milpitas, CA, 
US). OT-I T cell proliferation was determined by assessing CFSE intensity using the 
automated tool in FlowJo 9.4.11 and reported as a division index (i.e., the average number of 
divisions that a cell has undergone; division index = proliferation index (average number of 
divisions) × percent dividing cells). Intracellular IFNγ was determined after 2h of 
PMA/Ionomycin and 2h of BFA treatment. In some experiments, to determine the effect of 
exogenous IL-2 on LEC-T cell interactions, cocultures were supplemented with 50U/ml IL-2 
(Roche, Mannheim, DE) in the co-culture media.  
Flow cytometry 
Cells were washed and stained with a cocktail of surface antibodies in staining buffer, 
containing HBSS (Life Technologies) supplemented with 0.5 % bovine serum albumin. Cell 
viability was determined by propidium iodide incorporation in staining buffer after surface 
antibody staining or with live/dead fixable cell viability reagent (Life Technologies) in PBS 
before surface antibody staining. Apoptosis was determined by annexin V staining (BioVision, 
Milpitas, CA). Finally, cells were resuspended in staining buffer and analyzed by flow 
cytometry (CyAn ADP Flow Cytometer, DAKO). Data analysis was performed using FlowJo 
(v9.4, Tree Star Inc., Ashland, OR, USA).   
20 
Statistical analysis 
Statistical analysis was performed using one-way analysis of variance (ANOVA) followed by 
Bonferroni post-test with Prism software (Graphpad, San Diego, CA, US) unless otherwise 
stated. Results are shown as mean ± standard deviation with significance indicated as 
*p≤0.05, **p≤0.01, and ***p≤0.001.??
2.3  Results 
Lymphatic endothelial cells scavenge exogenous antigen in vivo and 
in vitro 
While LECs transport antigens from the periphery to the lymph, we asked whether 
LECs could also scavenge and process antigens as well. To this end, we injected 
intradermally (i.d.) fluorescently labeled OVA protein (OVA-AF647) in the forearm 
and after 90 min observed its distribution in the brachial draining LN. The use of a 
foreign protein allowed us to determine specifically the immune response against an 
exogenous versus self-expressed PTA. Using confocal microscopy of thick sections 
of the brachial LN, we observed OVA in the lymphatic-rich, LYVE-1+ sinuses of the 
LN (Fig. 2.1A). Upon magnification of the LYVE-1+ regions, we observed that much 
of the OVA was contained within LYVE-1+ cells, suggesting intracellular accumulation 
in LECs (Fig. 2.1B, C). Flow cytometric analysis validated the observed scavenger 
activity and demonstrated that LN LECs (CD45-gp38+CD31+LYVE-1+ cells), as well 
as professional APCs contained soluble OVA (Fig. 2.1D, E and Fig. 2.6). Among the 
CD45- stromal cells, LECs took up the most OVA (50±8%). When considered as a 
percentage of each cell population that took up OVA, LECs were on par with DCs for 
their scavenging ability (30±20% vs. 30±5%, respectively).  
In vitro, we could follow the accumulation of fluorescent OVA by immortalized murine 
LECs (iLECs) (18). The degree of OVA-AF647 accumulation by iLECs was similar to 
that of bone marrow-derived dendritic cells (DCs) over 90 minutes at 37oC, reaching 
a plateau within 40 min, as observed by flow cytometry (Fig. 2.1F, G and Fig. 2.6C). 
This exogenous antigen uptake was an active or energy-dependent process, since 
OVA uptake at 4oC by iLECs was minimal compared to that at 37oC (Fig. 2.1G and 
Fig. 2.6D). These results confirm that exogenous proteins are actively scavenged by 
LECs, both in vivo and in vitro. 
Lymphatic endothelial cells process and route antigen for cross-
presentation on MHC I in a TAP1-dependent manner 
Accumulation of exogenous proteins inside LECs allows for the possibility of antigen 
processing and cross-presentation on MHC I by these cells. We asked if under 
controlled in vitro conditions, hallmarks of cross-presentation could be observed in 
LECs.  
First, we determined whether uptake of exogenous antigens could lead to peptide 
loading onto MHC I molecules and presentation on the cell surface by 
immunostaining cells with the monoclonal antibody 25d1.16, which specifically binds 
the MHC I-bound CD8+ dominant epitope of OVA, SIINFEKL (OVA257-264). In order to 
avoid SIINFEKL peptide binding directly to surface MHC I and thus bypass the need 
for intracellular processing and cross-presentation, we used a N-terminally elongated  
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Figure 2.1 LECs scavenge exogenous protein, in vivo and in vitro. (A-E) After intradermal injection 
into the footpads, lymphatic endothelial cells (LECs) in the draining lymph node (LN) take up ovalbumin 
rapidly. (A) Brachial lymph node section showing LEC (Lyve-1, green) associated distribution of 
AlexaFluor 647 (AF-647)-labeled ovalbumin (OVA, red) after 90min; T cells (CD3e, blue) are shown for 
orientation. Bar, 150µm. (B) Close-up image from region indicated by white box in (A) shows 
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colocalization of OVA with LYVE-1+ LECs. Bar, 75μm.  (C) Further zoom into a LYVE-1+ lymphatic 
vessel shows OVA+ vesicles within the LECs; bar, 10µm. (D) Cellular distribution of OVA in the draining 
LN after 90 min i.d. injection, as analyzed by flow cytometry. Of all OVA+ cells, 6% and 4% were 
dendritic cells (DCs, CD11b-/+CD11c+) and macrophages (MΦ, CD11b+CD11c-), respectively, while 1% 
of OVA+ cells in the LN were stromal cells (CD45-). Amongst these (inset), LECs (gp38+CD31+) 
scavenged the most compared to fibroblastic reticular cells (FRCs, gp38+CD31-), blood endothelial cells 
(BECs, gp38-CD31+), and double negative cells (DN, gp38-CD31-). (E) Shown as percentages of each 
LN cell population positive for OVA, LECs were similar to CD11b-CD11c+MHC IImid+ DCs in their 
scavenging capabilities and these two cell populations represented the highest %OVA+ amongst all LN 
cell types. Data are from 2 independent experiments (n=4). (F-G) To demonstrate in vitro OVA 
accumulation, immortalized dermal LECs (iLECs) and bone marrow-derived dendritic cells (DCs) were 
incubated over 90min at 4 or 37oC with 1μM OVA AF-647. Cells were washed and analyzed for OVA 
uptake by flow cytometric analysis. (F) Percent of OVA-AF-647+ cells plotted for gp38+CD31+ gated 
iLECs and CD11c+ gated DCs at 37oC over time. (G) Geometric mean of OVA fluorescence is plotted 
for iLECs at 4oC versus 37oC. The data are representative from 2 independent experiments (n=3).  
SIINFEKL-peptide conjugated onto synthetic poly(propylene sulfide) 30nm 
nanoparticles (NPs), a tool that we recently developed in our laboratory for more 
efficient SIINFEKL/ MHC I cross-presentation by 25d1.16 as compared to OVA (22). 
While SIINFEKL peptide can bind to MHC I without cell internalization and 
processing, this 16aa peptide on the NPs (NP-ss-COVA250-264) minimally binds to 
surface MHC I, and instead requires uptake and intracellular processing for MHC I 
loading in BMDCs (22). Exogenously applied NP-ss-COVA250-264 resulted in the 
detection of MHC I peptide complexes in an energy-dependent manner in both iLECs 
and ex-vivo cultured primary LN LECs (Fig. 2.2A, B). By conducting this study at both 
4oC and 37oC, we confirmed that the cross-presentation of NP-ss-COVA250-264 by 
LECs requires active processing, as only cells that received SIINFEKL and not NP-
bound peptide antigen showed elevated 25d1.16 staining at 4oC (Fig. 2.2A, B).  
We then applied inhibitors of antigen uptake and intracellular trafficking to elucidate 
the relevant steps in LEC cross-presentation. We co-cultured inhibitor-treated, 
antigen-loaded LECs with OT-I CD8+ T cells and measured T cell proliferation by 
CFSE dilution as a measure of MHC I/SIINFEKL presentation on the LEC surface. To 
confirm that LEC-induced T cell stimulation was dependent on intracellular uptake of 
NP-ss-COVA250-264, we pre-treated iLECs with dynasore, an inhibitor of dynamin that 
affects both clathrin and caveolin mediated uptake (24), or LY294002, a PI-3K 
inhibitor that affects macropinocytosis (25). Both inhibitors led to reduced OT-I T cell 
proliferation in a concentration-dependent manner when LECs were treated with NP-
conjugated antigen, but not free SIINFEKL peptide (Fig. 2.2C), confirming active 
uptake mechanisms contributing to MHC I presentation. 
We next asked whether intracellular transport processes were important in LEC 
cross-presentation.  To this end, we treated iLECs with BFA, which inhibits antigen 
transport from the endoplasmic reticulum (ER) to golgi (26), or chloroquine, which 
inhibits acidification and vesicle fusion to late endosomes/lysosomes (27). LECs 
pretreated with either of these agents also resulted in concentration-dependent 
inhibition of T cell proliferation (Fig. 2.2C). 
Since ER-golgi transport as well as endosome acidification were observed to be 
important in cross-presentation by LECs, we next asked whether exogenous antigen 
processing in LECs depends on the canonical TAP1 pathway, where cytoplasmic 
peptide fragments are loaded onto MHC I in the ER after translocation by TAP1 (28).  
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Figure 2.2 LECs process and cross-present exogenous antigen, resulting in priming naïve CD8+ 
T cells. (A) Detection of the MHC I-SIINFEKL complex using the antibody 25d1.16 on ex-vivo expanded 
lymph node lymphatic endothelial cells (LN LEC; CD45- CD31+ gp38+) after exposure to N-term 
elongated OVA MHC I peptide conjugated to synthetic poly(propylene sulfide) 30 nm particles 
(NPssCOVA250-264). Unlike the free peptide OVA257-264  (SIINFEKL), the NPssCOVA250-264 cannot bind 
extracellularly to MHC I; rather, the antigen must be processed intracellularly as seen by the lack of 
presentation at 4°C. (B) Expression of OVA peptide (SIINFEKL)-MHC I complex by LN LECs and 
cultured immortalized LECs (iLECs) after 18h incubation with NPssCOVA250-264 or SIINFEKL at 2.5µM 
for 18h at 4 or 37oC. Pooled data from 2 independent experiments (n=3 each). (C) Proliferation of 
CFSE-labeled OT-I CD8+ T cells after 3 days of co-culture with iLECs is impaired in the presence of 
dynasore and LY294002, which block antigen uptake pathways, as well as with Brefeldin A and 
chloroquine, which block ER-golgi membrane trafficking and endosome acidification, respectively. 1nM 
SIINFEKL peptide or NPssCOVA250-264 was used as antigen; the data shown are representative of 2 
experiments (n=3). (D) The ability of LECs to cross-prime OT-I CD8+ T cells after OVA uptake depends 
on TAP1, which is required for intra-ER loading of peptides onto MHC I molecules. Percentages of 
proliferation of CFSE-labeled OT-I CD8+ T cells after 3 days of co-culture with LN LECs or DCs derived 
from WT or TAP1-/- mice in the presence of OVA or SIINFEKL. Representative data from one out of 3 
independent experiments (n=3). **p< 0.01 using two-way ANOVA followed by Bonferroni post-test. 
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Using LN LECs and DCs isolated from TAP1-null mice exposed to whole OVA 
protein, we found substantial reduction in OT-I T cell proliferation after coculture 
compared to those exposed to LECs or DCs isolated from WT mice (Fig. 2.2D). As 
expected, T cell proliferation was not significantly altered between WT and TAP1-/- 
with SIINFEKL stimulation, which binds externally to MHC I, suggesting that the 
density of SIINFEKL/MHC I complexes on LECs derived from both strains were 
comparable (Fig. 2.2D and Fig. 2.7). Together, these data suggest that cross-
presentation pathways are active in LECs.   
Collectively, these in vitro studies establish that exogenous antigens such as OVA 
and NPs can be internalized and trafficked to intracellular compartments. 
Subsequently, LECs efficiently process antigens for cross-presentation through 
TAP1 dependent cytoplasmic-ER import of peptides. Both ER-golgi transport of 
peptide loaded MHC I, or endosome acidification dependent MHC I trafficking are 
important for LEC cross-presentation. This suggests that some internalized antigen 
traffics and is loaded onto MHC I through acidified vesicles, while others reach the 
cytosol to be imported by TAP1 for loading onto MHC I (29). 
Direct antigen-specific CD8+ T cell interactions drive upregulation of 
MHC I and PD-L1 on lymphatic endothelial cells 
Having demonstrated the scavenger activity of LECs and efficient processing and 
cross-presentation of exogenous antigens, we next explored the costimulatory 
functions of steady-state LECs in the presence of naïve CD8+ T cells. We compared 
LEC expression of antigen-presentation molecules and costimulatory molecules with 
those of professional antigen presenting cells (DC). As expected, DCs clearly 
demonstrated constitutive expression of CD40, CD86, CD80, and MHC I that were 
further upregulated upon addition of the mature epitope peptide SIINFEKL and OT-I 
CD8+ T cells (Fig. 2.3A bottom panel, OT-I and OT-I + SIINFEKL peptide, 
respectively). The increase in the expression levels of costimulatory molecules and 
receptors on DC surface upon antigen-specific interactions with OT-I CD8+ T cells 
might appear surprising in the absence of TLR stimulation; however, there exist TLR-
independent pathways that can drive maturation, and it has been reported that 
cognate interactions between DC and CD8+ T cells can alone induce an upregulation 
of CD80 and CD86 expression on DCs (30).Furthermore, the transport of peptide-
loaded MHC I to the cell surface has been suggested to be accompanied by an 
increased expression of costimulatory molecules (31).Thus, peptide loading of MHC I 
and subsequent engagement of TCR and T cell activation can indirectly upregulate 
costimulatory molecules on DCs. Since our peptide was not contaminated with 
endotoxin and the observed changes in maturation markers were not induced when 
DCs were incubated with the cognate peptide in the absence of CD8+ T cells (Fig. 
2.3A, bottom panel, SIINFEKL), our data suggest that it is the antigen presentation 
by the APC and subsequent recognition by T cell that leads to the altered 
expression. In contrast to expression by DCs, ex-vivo cultured primary LN LECs 
expressed low levels of CD40 and CD80 and undetectable levels of CD86 in either 
the presence or absence of antigen-specific interactions with CD8+ T cells (Fig. 2.3A 
top panel). Similarly, constitutive expression of costimulatory molecules in human 
LECs was lower than that of human blood-derived DCs (data not shown). However,  
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Figure 2.3 Antigen-specific interactions with naïve CD8+ T cells result in upregulation of MHC I 
and PD-L1 expression on LECs. (A-B) In the presence of antigen-specific CD8+ T cells in vitro, the 
lymphatic endothelial cell (LEC) phenotype suggests coinhibitory signaling. Naïve OVA-specific OT-I 
CD8+ T cells were co-cultured with ex-vivo expanded lymph node LECs (LN LECs) or bone marrow-
derived dendritic cells (DCs) from C57/Bl6 mice in the presence (OT-I +SIINFEKL peptide) or absence 
(OT-I) of 1nM SIINFEKL, the immunodominant MHC I peptide of OVA, or 1nM AMQMLKETI peptide 
(OT-I + mismatched peptide). As an additional control, DCs or LN LECs were also incubated with 1nM 
SIINFEKL in the absence of CD8+ T cells (SIINFEKL). After 24h of T cell/LEC or T cell/DC co-culture, 
the relative expression levels of costimulatory molecules CD40, CD86 (B7-2), CD80 (B7-1), MHC I and 
Programmed Death Ligand 1 (PD-L1 or B7-H1) were determined by flow cytometric analysis. (A) 
Representative histograms for each marker are shown on gp38+CD31+ gated LN LECs or CD11c+ gated 
DCs incubated with, from filled black to light gray, OT-I+SIINFEKL, OT-I+mismatched peptide, 
SIINFEKL only, OT-I only, and isotype control. (B) Percentages of CD40, CD86, CD80, MHC I and PD-
L1+ cells in gp38+CD31+ gated LN LECs in each case; shades of gray are assigned as in (A). 
Representative data from one of 2 independent experiments (n=3). **p< 0.01 using two-way ANOVA 
followed by Bonferroni post-test. 
LECs significantly upregulated MHC I (**p<0.01) in a manner that was dependent on 
antigen-specific CD8+ T cell interactions (Fig. 2.3A, B).  
Consistent with previous reports (32, 33) both LECs and DCs constitutively 
expressed the inhibitory ligand programmed cell death ligand-1 (PD-L1 or B7.H-1, 
Fig. 2.3A), which has been reported to attenuate T cell proliferation and abrogate 
effector T cell differentiation (34). Furthermore, both LECs and DCs expressed higher 
levels of cell surface PD-L1 upon cognate interactions with CD8+ T cells (Fig. 2.3A, 
OT-I + SIINFEKL peptide). Although DCs expressed higher baseline levels of PD-L1 
compared to LECs, the upregulation of PD-L1 upon cognate antigen-specific CD8+ T 
cell interaction was much more pronounced in LECs than in DCs (Fig. 2.3A, B and 
Fig. 2.8). More importantly, this change was not accompanied by increased 
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costimulatory molecule expression in LECs, as it clearly did in DCs. The same trends 
were also observed in cultured iLECs (data not shown), Collectively, these data 
demonstrate an evidently different balance between costimulatory and coinhibitory 
ligand expression in LECs versus DCs, and further suggest that antigen-specific 
interactions between LECs and CD8+ T cells result in dynamic regulation of LEC 
phenotype to favor coinhibitory signaling.   
Cross-presentation of exogenous antigen by lymphatic endothelial 
cells leads to impaired activation of naïve CD8+ T cells in an antigen-
specific manner. 
Having shown that antigen-presenting LECs can upregulate PD-L1 in the presence 
of antigen-specific CD8+ T cells in vitro, we next asked whether cross-presentation by 
LECs and engagement of antigen-specific T cell receptors could lead to a tolerized 
phenotype of CD8+ T cells under steady-state conditions. To this end, we 
investigated the functional capacity of CD8+ T cells after cross-priming by LECs 
compared to cross-priming by DCs in vitro. Upon incubation with iLECs in the 
presence of 1nM NP-ss-COVA250-264, OT-I CD8+ T cells proliferated strongly (Fig. 
2.4A), but these iLEC-primed CD8+ T cells displayed a dysfunctionally activated 
phenotype characterized by high levels of the apoptotic marker Annexin V in early 
generations of proliferating T cells compared to DC-stimulated T cells (Fig 2.4A).  
The upregulation of PD-L1 on LECs upon antigen-specific interactions with CD8+ T 
cells (Fig. 2.3) led us to analyze the expression of PD-L1 binding partners PD-1 and 
CD80 on co-cultured CD8+ T cells. PD-1 is a member of the B7/CD28 superfamily 
and plays a central role in the regulation of T cell immunity; its activation results in 
decreased proliferation, reduced IFNγ and IL-2 production, and increased apoptosis 
(34). We observed that PD-1 expression was consistently high on iLEC-stimulated 
CD8+ T cells from the early proliferative generations, while only later generations of 
DC-stimulated CD8+ T cells expressed elevated levels of PD-1 (Fig. 2.4A). In addition 
to PD-1, recent studies have shown that PD-L1 also binds CD80 at a distinct site (35) 
to deliver inhibitory signals to T cells (36, 36); in those studies, CD80 expression was 
observed on anergic T cells and was further upregulated after re-exposure to the 
antigen. In contrast to DC-stimulated CD8+ T cells, we detected a high percentage of 
CD80 expression on proliferating iLEC-primed CD8+ T cells (Fig. 2.4A). In addition to 
PD-1, CTLA-4 was also substantially upregulated in early generations of CD8+ T cells 
stimulated by LECs vs. DCs (Fig. 2.4A). CTLA-4 is another member of the CD28/B7 
superfamily implicated in tolerogenic responses with a distinct, non-redundant 
regulatory role (34, 37), which competes with CD28 for binding to CD80 and CD86 
on APCs to impede costimulatory signaling and increase CD86 degradation, 
resulting in impaired T cell activation (38). CTLA-4 also disrupts positive signaling 
through recruitment of phosphatases to the immunological synapse and subsequent 
dephosphorylation of key signaling molecules without direct engagement to CD80 
and 86 (38). In addition to CTLA-4 upregulation, we found reduced expression of the 
surface activation markers CD25, CD44 and CD69 in iLEC-primed T cells compared 
to DC-primed T cells (Fig. 2.4B). Finally, OT-I CD8+ T cells primed with iLECs in the 
presence of NP-ss-COVA250-264 produced significantly less IFNγ and IL-2 compared 
to T cells primed with DCs (Fig. 2.4C).  
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Figure 2.4 Cross-presentation by LECs induces impaired CD8+ T cell proliferation. Naïve CFSE-
labeled OVA-specific OT-I CD8+ T cells were co-cultured with immortalized skin lymphatic endothelial 
cells (iLECs) or bone marrow-derived dendritic cells (DCs) from C57/Bl6 mice in the presence of N-term 
elongated OVA MHC I peptide disulfide conjugated to NPs (NPssCOVA250-264) at 1nM and analyzed 
after 3 days. (A) Phenotypes of OT-I CD8+ T cells after priming by cross-presenting DCs or iLECs as 
analyzed by flow cytometric evaluation of Annexin V, Programmed Death 1 (PD-1), CD80 (B7-1), and 
Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) surface marker expression. Left, representative dot plots 
from live-gated cells; right, percentages of positive cells per generation from one representative out of 3-
5 independent experiments (n=3-4). (B) Representative flow cytometry histograms showing activation 
marker expression on OT-I CD8+ cells after 3 days cross-priming by iLECs (black line) or DCs (gray 
line); filled gray area shows naïve (non-educated) OT-I CD8+ T cells. (C) Cytokine secretion by iLEC- or 
DC-educated OT-I CD8+ T cells as assessed by ELISA; Representative data from one of 4 experiments 
(n=4).  *p< 0.05 using two-way ANOVA followed by Bonferroni post-test. 
Taken together, these data indicate that iLECs can efficiently cross-present antigen 
and directly interact with CD8+ T cells to induce antigen-specific proliferating T cells 
with a tolerized phenotype in vitro. The functional outcome of T cell priming differs 
significantly from that of T cells primed by conventional APCs, suggesting a tolerizing 
role for LECs under steady-state conditions. 
IL-2 does not rescue the dysfunctional phenotype of CD8+ T cells 
activated by lymphatic endothelial cells 
Since we observed diminished levels of IL-2 by LEC- vs. DC-stimulated T cells (Fig. 
2.4C), and since IL-2 is essential for CD8+ T cell expansion, we asked whether the T 
cell phenotype could be rescued by exogenous IL-2, as has been shown for 
exhausted T cells in chronic viral infection (39). Interestingly, supplementation of the 
iLEC-T cell co-cultures with IL-2 (50U/ml) resulted in increased expression of the 
activation markers CD25, CD44, and CD69 on CD8+ T cells (Fig. 2.5A). However, no  
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Figure 2.5 The LEC-educated T cell phenotype is only partially reversed by IL- 2. Naïve CFSE-
labeled OVA-specific OT-I CD8+ T cells were co-cultured with immortalized lymphatic endothelial cells 
(iLECs) for 3 days in the presence of antigen (1nM NPssCOVA250-264) and supplemented with 50U/ml IL-
2. (A) Representative flow cytometry histograms showing OT-I surface expression of activation markers 
after 3 days of priming by iLECs in the absence or presence of IL-2 (solid line vs. filled histograms, 
respectively). Representative data from one of 3 independent experiments (n=4). (B) Division index of 
proliferating OT-I CD8+ T cells (left) and IFN-γ release (right) were only slightly affected by IL-2. 
Representative data from one of 4 independent experiments (n=4). (C) Percentage of Annexin V+ and 
PD-1+ OT-I CD8+ T cells per generation after 3 days of co-culture with iLECs is unaffected by IL-2. 
Pooled data from two independent experiments (n=7). 
effect was seen on T cell proliferation or IFNγ production (Fig. 2.5B), nor did IL-2 
significantly decrease the percentages of Annexin V+ or PD-1+ cells per generation 
(Fig. 2.5C). These trends were similar when LN LECs treated with NP-ss-COVA250-264 
and when iLECs were stimulated with 1μM OVA protein instead of NP-ss-COVA250-264 
(data not shown). Together, these data suggest that the phenotype of T cells cross-
primed by LECs were not merely exhausted, as they could not be rescued by IL-2. 
2.4  Discussion 
In addition to carrying antigens to the LN for uptake by immature DCs for immune 
surveillance, this study highlights an important role of lymphatic drainage for 
maintaining peripheral tolerance: the constant exposure of LECs to lymph-borne 
peripheral antigens, which they scavenge and cross-present for tolerance induction 
under steady-state conditions. Antigen cross-presentation was dependent on ER-
golgi trafficking, endosome acidification, and TAP1. We observed that antigen-
specific interactions with CD8+ T cells resulted in upregulation of MHC I and PD-L1 
on LECs and dysfunctional activation of CD8+ T cells, which displayed early 
apoptosis and diminished cytokine production. Thus, in addition to the previously-
described role of LECs in presenting endogenous peripheral tissue antigens for 
autoreactive CD8+ T cell deletion (6-8), the present study demonstrates that LECs 
can efficiently scavenge and cross-present foreign antigen draining from the 
periphery, and thus play an immunoprotective role against a broader range of 
peripheral antigens.  
Until recently, the cross-presentation mechanism in the induction of peripheral 
tolerance to exogenous antigens by non-hematopoietic stromal cells has been nearly 
exclusively attributed to LSECs, which line the hepatic sinusoidal wall and come into 
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close contact with foreign antigens and leukocytes passing through the liver (40). 
Similarly, LECs are positioned in a strategic anatomical site where crucial 
interactions determining the fate of an immune response take place. Here, we have 
demonstrated that antigen scavenging by LECs occurs under non-inflammatory 
steady-state conditions, adding to our previous observation that tumor-associated 
LECs cross-present OVA expressed by B16-F10 tumors (16). Murine LECs in the 
skin-draining LN actively took up peripherally administered OVA protein under 
steady-state conditions (Fig. 2.1A, B, C), consistent with an earlier study (41), and 
could be mediated through LEC expression of the mannose receptor (42, 43). This 
was further supported by our data showing that LN LECs were as effective as DCs in 
taking up OVA (Fig. 2.1D and Fig. 2.6). This is consistent with continual scavenging 
of inflammatory CC-chemokines (44) by D6 on afferent and subcapsular LECs, which 
results in intracellular degradation and reduction of inflammatory chemokines 
entering the LN under homeostatic conditions (45). Together with the data presented 
here, we conclude that LECs constitutively scavenge molecules to sample the 
peripheral lymph entering the LN.  
We turned to in vitro studies to characterize the details of exogenous antigen cross-
presenting mechanisms in LECs and found strong dependencies on temperature, 
dynamin-mediated uptake, intracellular antigen transporters, and TAP1 (Fig. 2.2), 
implicating similar cross-presentation pathways as those seen in DCs. Specifically, 
inhibitor sensitivity data suggested both dynamin (clathrin/ caveolin) and PI3K 
(phagocytosis/ macropinocytosis) pathways contribute to cross-presentation and T 
cell priming by LECs (Fig. 2.2C). This is in agreement with confocal microscopy 
studies (Fig. 2.9) showing OVA colocalization with clathrin heavy chain in LECs at 
early times after exposure. Similar observations have been made with LSECs (14), 
and are consistent with early endosome colocalization observed in BMDCs (46). At 
later time points, OVA was found in LAMP-1+ vesicles, supporting the data showing 
chloroquine inhibition of antigen cross-presentation (Fig. 2.9).  
A hallmark of cross-presentation of exogenous antigens by professional APCs is the 
dependence on TAP1 (47). As described for other murine stromal cells, such as 
LSECs (14, 48), aortic endothelial cells (49), and thymic stromal cells (50), we found 
that the TAP1-dependent transport of cytoplasmic peptides into the ER (Fig. 2.2D) 
and ER-golgi trafficking (Fig. 2.2C) was important in antigen specific CD8+ T cell 
proliferation upon LEC cross-presentation. Furthermore, our data indicate that TAP1-
independent pathways may be also active in LECs (Fig. 2.2D). In APCs, more than 
one pathway for loading of mature peptide epitopes on MHC I have been described, 
including loading in phagolysosomes or recycling endosomes (29, 51, 52). Intra-
phagosome or lysosome release and MHC I loading of peptides in LAMP-1+ MHC I+ 
compartments have been described for DCs (53), which would be consistent with 
chloroquine sensitivity observed (Fig. 2.2C) and antigen presence in LAMP-1+ 
vesicles in LECs (Fig. 2.9).  
Although LECs displayed several similarities to LSECs with regard to Ag processing 
and cross-presenting capacity, LECs exhibited some phenotypic differences to 
LSECs. For example, under steady-state conditions, while LSECs were shown to 
express the costimulatory molecules CD40, CD80, and CD86 (30), LECs lack an 
immunostimulatory phenotype with remarkably low expression of costimulatory 
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molecules (Fig. 2.3). As the endotoxin levels found in portal blood under 
physiological conditions are presumably higher than in peripheral lymph, it is not 
surprising that the steady-state set point of co-stimulatory molecules in LSECs are 
higher than those of LECs. The inability of LECs to upregulate the costimulation 
machinery, together with PD-L1 upregulation upon antigen-specific T cell interactions 
(Fig. 2.3 and Fig. 2.8), indicated to us that LEC cross-presentation may be non-
activating, since lack of costimulation is one mechanism of a dysfunctional CD8+ T 
cell response that is reminiscent of the classical mechanism of peripheral tolerance 
induction by immature DCs under non-inflammatory conditions by T cell anergy and 
deletion (54). 
The functional discrepancy and fate of LEC-educated vs. DC-educated CD8+ T cells 
(Fig. 2.4C) was coupled with the reciprocal upregulation of inhibitory molecular 
partners on CD8+ T cells: the PD-L1 partners PD-1 and CD80, as well as CTLA-4 
(Fig. 2.4A). In accordance with our observations, Tewalt et al. recently demonstrated 
a key role for the PD-L1/PD-1 signaling pathway in the absence of costimulation in 
LEC-induced peripheral tolerance of endogenously expressed PTAs, where blocking 
PD-1 in LEC-educated, tyrosinase-specific CD8+ T cells resulted in autoimmune 
vitiligo (6). While in LSEC-T cell co-cultures, exogenous IL-2 compensated for PD-
L1-mediated coinhibitory signalling in the absence of costimulatory molecules (55), 
supplementation of LEC-T cell cocultures with IL-2 did not alter the phenotype of 
LEC-primed CD8+ T cells (Fig. 2.5). Our data suggest that other regulatory pathways 
might be involved, such as the engagement of PD-1 by CD80 or signaling through 
CTLA-4, or additional ligands reported to be expressed on LEC surface, including the 
B and T lymphocyte attenuator (BTLA) molecule or the lymphocyte activation gene 3 
(LAG-3) (6). Interestingly, there may be more than one differentiation state of CD8+ T 
cells; apparently tolerized LSEC cross-primed CD8+ T cells (30), upon inflammatory 
recall, were capable of becoming effector cells, reminiscent of central memory T cell 
activity (56). This may also apply in steady-state LEC cross-primed CD8+ T cells. 
Further detailed mechanistic studies must be conducted on the coordination (57) of 
antigen processing, presentation and co-stimulatory/coinhibitory molecule pathways 
to shape the fate of these cells.  
Because LECs are situated in one of the prime anatomical sites for immunological 
sampling, our findings support the idea that organ-draining LECs are the first to 
sample and present the exogenous peptides (3, 58), proteins and particulates 
present in lymph. Thus LECs may play an important role in the context of 
immunomodulation. Several findings from the literature support this concept that flow 
from the periphery, and the presence of lymphatics is important in shaping the 
adaptive immune responses in the LN. For example, Friedlaender and Baer showed 
in 1972 that alymphatic skin was more readily sensitized to dansyl chloride than 
intact skin (59), suggesting that presence of lymphatics in intact skin is contributing to 
a dampened delayed-type hypersensitivity response. Using the K14-VEGFR-3-Ig 
mice model, we have previously shown how impaired lymph drainage and absence 
of dermal LECs resulted in impaired acquired tolerance to contact hypersensitivity 
although these mice could mount a systemic T cell response (60). In the 
experimental autoimmune encephalomyelitis model, impaired lymphatic contraction 
and fluid drainage was reported to result in an autoimmune response (61). Together, 
this suggests that impaired lymphatic drainage translates to an inappropriately 
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activated immune response. Reciprocally, steady-state drainage of antigen to LN 
seems to favor tolerogenic responses. For example, the clinical success of allergen-
specific immune therapy is based on a regimen of long-term s.c. low-dose allergen 
injection (62). We have shown that VEGF-C expanded tumor draining LN LECs 
impede a robust antigen-specific CD8+ T cell response, which promotes tumor 
growth (16). In keeping with the idea that peripheral tolerance requires persistent 
antigen (63), continuous access to draining peripheral antigens newly establishes 
LECs as an active player in the maintenance of a tolerogenic LN environment.  It 
implies that after injury or infection, where self-antigens drain to the LN together with 
TLRs and other danger signals, the steady-state tolerization by LECs can act as a 
dampening mechanism to prevent later potential autoimmune reactions. In other 
words, LEC cross-presentation of draining antigens helps amplify the signal-to-noise 
ratio between dangerous antigens and those that have been encountered under 
steady-state conditions.  
This work demonstrates that priming by LEC via direct cross-presentation of 
scavenged exogenous antigens has a tolerizing effect on CD8+ T cells. In addition to 
T cell tolerization against LEC expressed PTA (6-8), and contact-dependent 
immunosuppression of APCs (11), we establish LECs as a bona-fide APC, capable 
of sampling the peripheral antigen repertoire, by active internalization and cross-
presentation of antigens in the MHC I context. This steady-state cross-presentation 
of scavenged peripheral antigens by LECs highlights the importance of lymphatic 
drainage and the role of LECs in immunomodulation, which may contribute an 
additional layer of control against self-reactive T cells in the context of maintaining 
self-tolerance against draining peripheral antigens during homeostasis or tissue 
injury. These findings help to explain why tumor-associated lymphatics promote 
tumor progression and metastasis to distant sites, and why dysfunctional lymphatic 
drainage is correlated with autoimmunity.  
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2.6 Appendix  
 
Figure 2.6 Gating strategy and representative flow cytometry plots for assessing OVA uptake by 
cells in the lymph node and for showing intracellular accumulation of fluorescent OVA in 
cultured cells. 90 min after i.d. injection of OVA AF-647, brachial LNs were digested and the single cell 
preparation was first magnetically separated using anti-CD45 microbeads before analyzing each fraction 
by flow cytometry for data shown in Fig. 1D-E. (A) Using CD45 staining, any remaining CD45+ cells in 
the magnetically sorted CD45- fraction were excluded from analysis before the OVA+ subsets were 
determined for the different populations, with the use of a naive non-injected control. The CD45-OVA+ 
populations were further subdivided in the 4 stromal subsets using gp38, CD31. The CD45+OVA+ 
population was further subdivided in various APC subsets using the CD11b, CD11c and MHC II surface 
markers. To determine the percentage of each cell population out of all OVA+ cells, the counts of OVA+ 
gp38+CD31+ gated LECs, gp38+CD31- gated fibroblastic reticular cells (FRCs), gp38-CD31+ gated blood 
endothelial cells (BECs), gp38-CD31- gated double negative cells (DNs) in the CD45- fraction and OVA+ 
APCs in the CD45+ fraction were separately calculated and subsequently, divided to the overall (added) 
counts of OVA+ cells in both fractions. Here, the gating for the resident CD11b-CD11c+MHC IImid DCs is 
shown. (B) The CD45- stroma was divided in the four LNSC subpopulations using the gp38, CD31 
antibodies and OVA fluorescence was determined in LEC (gp38+CD31+). LECs from a naive non-
injected mouse (no OVA) were used as eference for the OVA gating. The CD45+ fraction was divided in 
CD11b- and CD11b+ cells and the CD11b- subpopulation was further separated with the use of MHC II 
and CD11c surface markers in the MHC IImid/hiCD11c+ DC subpopulations. The fluorescence of OVA 
was determined for the resident CD11b-CD11c+MHC IImid DC subpopulation. The same DC subset from 
a naive non-injected mouse (no OVA) was used as a reference for the OVA gating. Representative flow 
cytometry plots showing intracellular accumulation of fluorescent ovalbumin (OVA) in cultured cells. (C) 
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Representative dot plots of immortalized lymphatic endothelial cells (iLEC) or bone marrow-derived 
dendritic cells (DC) after incubation with 1μM OVA AF-647 for the data shown in Fig. 1F-G. Shown on 
the far right is the no-antigen control (No Ag) used to determine the positive OVA gating. (D) 
Representative histograms for the OVA fluorescence are shown for iLECs (top) and DCs (bottom) at 
4oC versus 37oC showing different time points as indicated. Data shown are representative of 2 
independent experiments, n=3 each. 
 
 
 
 
 
Figure 2.7 TAP1-/- LECs can equally trigger OT-I proliferation at 1 and 5μM SIINFEKL compared to 
WT LECs despite lower MHCI levels. (A) MHC I levels by flow cytometry analysis, with isotype control 
(filled histogram). Lymph node lymphatic endothelial cells (LN LEC) and bone marrow derived dendritic 
cells (DC) from wild type C57Bl/6 (WT) or TAP1-/- mice. Representative histograms of n=3 mice. (B) 
CFSE labeled OT-I CD8 T cells were co-cultured with LN LECs or DCs derived from WT or TAP1-/- mice, 
pulsed with no peptide to 0.001, 0.01, 0.1, 1, and 5μM SIINFEKL peptide. Histogram of CFSE dilution 
after 3 days shows LEC and OT-I T cell co-cultures, with gray filled histogram representing no peptide, 
and the respective concentrations from light to dark gray. (C) Percent OT-I proliferation, n=3 in 2 
independent experiments. 
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Figure 2.8 MHC I and PD-L1 expression levels in the presence versus absence of antigen are 
higher in LN LEC compared to DC. Naïve OVA-specific OT-I CD8+ T cells were co-cultured with ex-
vivo expanded lymph node lymphatic endothelial cells (LN LEC) or bone marrow derived DCs (DC) from 
C57/Bl6 mice in the presence (+ SIINFEKL) or absence (no SIINFEKL) of 1nM immunodominant MHC I 
peptide of OVA (SIINFEKL). After 24h or 72h of T cell/LEC, or after 24h of T cell/DC co-culture, the 
expression levels of costimulatory molecules CD40, CD86 (B7-2), CD80 (B7-1), major histocompatibility 
complex class I (MHC I) and Programmed Death Ligand 1 (PD-L1 or B7-H1) were determined by flow 
cytometric analysis. The Mean Fluorescent Intensity (MFI) was determined for CD40, CD86, CD80, 
MHC I and PD-L1 in the respective positive populations in LN LECs and DCs. Normalized MFI was 
calculated as follows: (MFI + SIINFEKL) / (MFI no SIINFEKL). Values depict mean ± SD from two 
representative experiment (n=3-4). ** p<0.01 and * p<0.05, two-way ANOVA followed by Bonferroni 
post-test. 
 
Figure 2.9 Ovalbumin colocalization analysis shows clathrin colocalization is not by chance, and 
that OVA can be found within the LAMP1 vesicles. (A, C) Cells were exposed to AF647-labeled OVA 
for 15 min or 90 min and stained for clathrin heavy chain or Lysosomal-Associated Membrane Protein 1 
(LAMP-1), respectively. Images were acquired by confocal microscopy. Arrowheads indicate co-
localizing pixels. The regions of interest shown to the right are indicated as white squares on the cell. 
The scale bar corresponds to 4 and 2μm, respectively. (B) Object-based colocalization method of 
Fletcher et al. (2010) was used to determine that those OVA+ vesicles, which are also clathrin+ occur 
more than by chance by comparison to a randomly generated spots. % relative frequency is plotted 
against %OVA+ vesicles. 14 images were analyzed. (D) A typical Imaris analysis for quantifying LAMP-1 
enclosed OVA. Spots (red) were assigned to OVA fluorescence maxima, and the white surfaces were 
drawn around LAMP-1 fluorescence structures. The ImarisXT plugin “split spots into surface objects” 
was used to determine the % OVA inside LAMP-1+ surfaces. Scale bar = 3μm. (E) The result of such 
analysis for 5 images shows that approximately 30% of OVA can be found within LAMP-1+ vesicles. 
???? ???? ???? ????? ?????
?
?
??
??
??
??
??
???
??
???
??
???
???
???
???
???
??
???
??
??
?
??????????
??????????
??????
??
?
????????
??
?
? ? ?? ?? ?? ?? ?? ?? ?? ?? ??
?
??
??
??
??
????????
?? ????????????????????
????? ??????????????
??
???
???
??
????
??
??
??
??
??????
??
?
? ?
?????????
??????????????
?
??
??
??
??
???
??
???
???
???
??
???
??
???
???
?
???

39 
 
 
 
 
Chapter 3    
Phenotype and function of CD8+ T 
cells activated by pMHCI-bearing 
LECs: The multifaceted 
immunomodulatory role of LECs 
Over the last decade, there has been accumulating evidence on the dynamic 
contribution of the lymphatic endothelium to the regulation of immune responses. In 
addition to expressing self-antigens and presenting them for autoreactive T cell 
deletion, we established lymphatic endothelial cells (LECs) as bona fide antigen 
presenting cells (APCs), which are capable of scavenging and cross-presentation of 
foreign exogenous antigens. We previously reported that antigen-specific interactions 
led to naïve CD8+ T cell proliferation albeit with a dysfunctionally activated 
phenotype. Here, we examined the function of LEC-educated CD8+ T cells and 
asked whether they could escape the dysfunctional state. We demonstrated that 
steady-state LEC-educated CD8+ T cells adopted a unique phenotype with central 
memory-like characteristics, distinct from naïve or dendritic cell (DC)-activated 
effector cells. The phenotypic diversification was coupled with functional properties 
and allowed them to preferentially home to the lymph node (LN) and survive long-
term in the absence of the antigen. Once they re-encountered the antigen, LEC-
educated CD8+ T cells mounted proliferative responses and gave rise to effector 
cells, producing cytokines (IFN-γ, TNF-α) and displaying killing activity. In the setting 
of Listeria monocytogenes-expressing-OVA infection, LEC-educated cells not only 
participated in anti-infectious immunity but also preserved a persistent secondary-
memory population. Our findings suggest a previously unanticipated role for LECs in 
immunomodulation: the generation of antigen-experienced CD8+ T cells which 
survive in an inactive state but can be functionally reactivated upon antigenic 
inflammatory challenge, likely acting as a supplementary mechanism that 
complements and enhances immune responses.  
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3.1  Introduction 
Recently, rising evidence has revealed that the lymphatic endothelium is more 
actively involved in the modulation of immunity, shaping T cell responses, both 
directly and indirectly (1-6). Lymphatic endothelial cells (LECs) were shown to 
endogenously express and present peripheral tissue-restricted antigens (PTAs) on 
MHC class I molecules to tolerize CD8+ T cells and thus, participate in the induction 
of peripheral tolerance against self-antigens (7-9). In addition to endogenous antigen 
presentation, we previously showed that LECs can actively scavenge and cross-
present foreign exogenous antigens, both in the context of a tumor (10) as well as 
under homeostatic conditions [Chapter 2 and (11)], to compromise CD8+ T cell 
activation. The interactions of LECs with CD8+ T cells were accompanied by low-
level costimulatory signaling together with increased levels of the inhibitory ligand 
PD-L1 on LECs, and resulted in activated CD8+ T cells displaying early-generation 
apoptosis and dysfunctionally activated phenotypes. LECs have, therefore, been 
established as APCs that can sample the peripheral antigen repertoire inducing 
dysfunctional activation of CD8+ T cells under homeostatic conditions.  
The induction of peripheral tolerance is primarily assigned to professional antigen-
presenting cells (12). Immature DCs obtain self-antigens from peripheral tissues and 
cross-present them in the absence of costimulation (13) to induce T cell anergy, 
suppression or deletion (14). Ensuring that the immune system is restrained from 
attacking self-antigens is critical for the maintenance of homeostasis. Rescued CD8+ 
T cells, which were tolerized against a self-antigen under steady state conditions, 
remained functionally impaired even in response to pathogenic challenge, shielding 
the host from autoimmune reactions (15). By contrast, in the iFABP-tOVA PTA 
model, in which OVA is endogenously expressed under control of the intestinal fatty 
acid binding promoter (iFABP), tolerized CD8+ T cells, which were primed by non-
hematopoietic intestinal epithelial cells, were reactivated upon viral challenge (16). 
Tissue destruction, triggered by the reactivated cells, was dependent on antigen 
density and the presence of inflammatory molecules. Additionally, CD8+ T cells 
tolerized by liver sinusoidal endothelial cells (LSEC) were recently demonstrated to 
exit the non-responsive state once reactivated under inflammatory conditions (17). 
Originally, LSECs were shown to cross-present exogenous antigens on MHC I and 
induce tolerogenic CD8+ T cells (18, 19). Similar to antigen presentation by LECs, 
LSEC-mediated induction of CD8+ T cell tolerance was governed by the PD-L1 – PD-
1 inhibitory signaling. Considering the similarities between LSECs and LECs, the 
question arises whether LEC-educated CD8+ T cells might exhibit similar functional 
properties to LSEC-educated T cells. In other words, whether they can recover from 
the dysfunctional non-responsive state in response to inflammatory challenge. 
The differentiation state of CD8+ T cells following cognate APC-T cell interaction is 
tightly governed by the integration of various signals, including the antigen load, 
costimulation, cytokines and other inflammatory mediators (20-22). The relative 
balance among such signals strongly influences the differentiation fate, leading to the 
generation of different effector and/or memory T cell subsets. An emerging concept 
suggests that T cells educated under conditions of increased inflammation and high 
antigen load are more prone to differentiate into terminal effectors rather than 
memory cells (23, 24). Alternatively, reduced exposure to antigenic and inflammatory 
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signals might favor the generation of memory cells. Among the different inflammatory 
signals that crucially impact T cell responses are various cytokines. IL-12 has been 
shown to suppress memory formation (25, 26) whereas high levels of IL-2 have been 
associated with the generation of short-lived effectors (27, 28). This new 
understanding raises important considerations with regard to CD8+ T cell priming by 
non-hematopoietic cells. Education by LECs and LSECs, orchestrated by decreased 
costimulation and very low levels of pro-inflammatory cytokines, would rather mirror 
the setting of reduced, short-lived inflammation and therefore, disfavor the generation 
of terminally differentiated cells. Indeed, LSEC-educated T cells displayed an 
antigen-experienced phenotype with central memory-like characteristics and homed 
to secondary lymphoid organs (17). However, it is still unknown whether LEC-
education may also promote CD8+ T cells with memory-like phenotypes, as well as 
functional, properties. Furthermore, it remains an open question whether LEC-
education may lead to more than one T cell differentiation state or how plastic that 
fate might be. 
Here, we describe a new role for LECs in the induction of immune responses and the 
development of immunological memory. First, we demonstrate that surviving antigen-
specific CD8+ T cells educated by LECs under steady state conditions are 
phenotypically distinct from naïve or mDC-educated cells and display central-
memory like features. Following in vivo transfer, LEC-educated CD8+ T cells primarily 
homed to the LN, while mDC-educated T cells migrated to the periphery, and 
survived for long periods of time in the absence of the antigen. Upon antigen 
reencounter, LEC-educated CD8+ T cells responded quickly and underwent 
extensive proliferation generating cytotoxic effector cells. Recapitulating a hallmark of 
memory cells, LEC-educated T cells participated in anti-infectious pathogenic 
immunity, not only by controlling bacterial load but also by retaining a secondary 
memory-persistent population. Our findings suggest that cross-priming of peripheral 
antigens to CD8+ T cells by LECs under homeostatic conditions promotes a 
temporarily inert state while allowing them to respond in case of subsequent 
inflammatory challenge. Thus, while being employed for the maintenance of 
peripheral tolerance, they might also function as a reserve of antigen-experienced T 
cells, enhancing immune responses when needed. 
3.2  Materials and Methods 
Reagents  
All chemicals were from Sigma-Aldrich (Buchs, CH) unless otherwise noted. The mature 
MHC I epitope, OVA256-264 (SIINFEKL) peptide, was from GenScript (Piscataway, NJ, US) and 
the gp10025–33 peptide was from Anaspec (Fremont, CA, US). The Endotoxin-free OVA was 
from Hyglos GmbH, (Bernried am Starnberger See, DE). Ultra-pure lipopolysaccharide (LPS, 
01:11 B4) was from Invivogen (InvivoGen, San Diego, CA, USA). Recombinant murine GM-
CSF and IL-15 were purchased from Peprotech (Oak Park, CA, USA), IL-10 from eBioscience 
(Vienna, AT), IL-12, IFN-α and recombinant human TGF-β1 from R&D systems (Minneapolis, 
MN, USA). Antibodies used in flow cytometry were from eBioscience or BioLegend (Luzern, 
CH) unless otherwise noted. 
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Mice 
The following mice strains were used in this study at age 6-12 weeks unless noted otherwise. 
Female C57BL/6 (CD45.2 or CD45.1 Ly5) wild-type mice and OT-I CD45.2 transgenic mice, 
C57BL/6-Tg(TcraTcrb)1100Mjb/J, were purchased from Harlan Laboratories (Gannat, FR). 
Female transgenic OT-I CD45.1.2 mice were acquired from the group of Dietmar Zehn. Pmel 
transgenic mice, B6.Cg-Thy1a/Cy Tg(TcraTcrb)8Rest/J, were  obtained  from  the  group  of  
Pedro  Romero. β2m-/- mice (lacking MHC class I) were obtained from H.R. MacDonald. 
Animals were housed in pathogen-free facilities and all procedures were approved by the 
Cantonal Veterinary Committee of Vaud, Switzerland (Protocol number 2518 and 2992). 
Primary cell isolation 
To obtain primary LN LECs and LN FRCs, LNs were digested with 0.25mg/ml Liberase DH 
and 100µg/ml DNase (both from Roche, Basel, CH) to obtain a single cell suspension and 
cultured as described (29). Cells were cultured for 5 days until confluent, removed by 
Accutase (Biological Industries, Lucerna-Chem AG, Lucerne CH), and stained with mAbs 
against gp38 (clone 8.1.1), CD31 (clone 390), and CD45 (clone 30-F10) and FACS sorted 
(FACS Aria II, BD, Basel, CH) into the following subpopulations: FRCs (gp38+CD31-) LECs 
(gp38+CD31+), BECs (gp38-CD31+), and DN (gp38-CD31-) as described (30).  Bone marrow-
derived DCs (BMDCs) were harvested from C57Bl/6 mice, differentiated in GM-CSF as 
described (31) and used at day 7 of culture. When indicated, BMDCs were matured (mDCs) 
by being cultured in the presence of LPS (10 ng/ml) for another 12h. 
Synthesis of peptide-conjugated nanoparticles (NPs)  
To explore the mechanisms of cross-presentation poly(propylene sulfide)-nanoparticles (NPs) 
with ~30nm diameter were synthesized and characterized as described (32). The long 
peptide containing the mature MHC I epitope SIINFEKL – Cys-OVA250-264 (COVA250-264) was 
synthesized in-house and activated with a 2-pyridylthiol as previously described (32). Core 
sulfhydryls on NPs were reacted with the activated peptide and purified on a Sepharose 
CL6B column (Sigma-Aldrich). To fluorescently label the NPs, NPs were exposed to Dy-649 
maleimide (Dyomics GmbH, Jena, DE) after dialysis in a 1:60 molar ratio of dye to NP 
sulfydryl groups in phosphate buffered saline (PBS) at RT for 24 h (32). Free dye was 
removed by gel filtration as above but in endotoxin-free water (B. Braun Medical AG, 
Sempach Switzerland) as eluent. Endotoxin levels of antigens were routinely assessed by a 
colorimetric assay based on the HEK-Blue ™ TLR4 cell line (InvivoGen, San Diego, CA, 
USA) according to the manufacturer’s protocol using a standard curve generated from the E-
Toxate ™ endotoxin standard (Sigma). 
Generation of bone marrow chimeras 
Bone marrow (BM) was recovered from tibia and femurs by flushing with PBS-EDTA and 
dissociated by repeated passages through a 20-gauge needle. To generate bone marrow 
chimeras, recipient mice (C57BL/6 wild-type or β2m-/- mice) were gamma-irradiated twice with 
450 rad (4h apart) and reconstituted by tail vein injection with 8x106 bone marrow cells from 
wild-type or β2m-/- donor mice. Reconstitution was assessed by analyzing blood cells by flow 
cytometry and used after 8 weeks.  
CD8+ T cell purification 
Splenic CD8+ T cells from OT-I mice or pmel mice were isolated by immunomagnetic CD8 
negative selection using the EasySep Mouse CD8+ T Cell Isolation Kit from Stemcell 
Technologies (Vancouver, BC, Canada).  
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Generation of ex vivo LN LEC/mDC-educated CD8+ T cells  
Naïve CD8α+ T-cells from OT-I or pmel mice were purified and directly cocultured with LN 
LECs or mDCs in the presence of 1nM NPssCOVA250-264 or 1nM SIINFEKL peptide or 1μM of 
gp100 peptide. More specifically, 104 LECs or DCs were cocultured with naïve CD8+ T cells in 
96-well plates for 72h for OT-I and for 6 days for pmel CD8+ T cells at a ratio of 1:10 APC:T 
cells in 200 μl of co-culture media (IMDM with 10% FBS and 1% penicillin/streptomycin - all 
from Life Technologies, Carlsbad, CA, USA). Supernatants were harvested and frozen for 
cytokine analysis. Cells were then processed and stained for immunological markers to be 
analyzed by flow cytometry. Cellular proliferation was monitored by CFSE dilution and 
apoptosis was determined by Annexin V staining (BioVision, Milpitas, CA, US). OT-I T cell 
proliferation was determined by assessing CFSE intensity using the automated tool in FlowJo 
9.4.11.  
In vitro reactivation 
LEC/mDC-educated OT-I CD8+ T cells were harvested on day 3 of coculture, washed at least 
twice with basal medium and counted. 105 LEC-educated or mDC-educated CD8+ T cells 
were subsequently cocultured with 104 mDCs loaded, or not, with the SIINFEKL peptide (1 
nM) for 24h in 200 μl of co-culture media (mDC-recall). Supernatants were harvested and 
frozen for cytokine analysis. Cells were then processed and stained for immunological 
markers to be analyzed by flow cytometry. The levels of intracellular cytokines were 
determined after 3h reactivation and 2h of Brefeldin A (BFA) treatment. In some cases, only 
when indicated, LEC-educated or mDC-educated CD8+ T cells were reactivated by non-LPS-
treated DCs (immature DCs, iDCs) loaded, or not, with the SIINFEKL peptide (1nM) for 24h in 
the presence or absence of the following cytokines: rmIL-12 (5ng/ml), rmIFN-α (2kU/ml), 
rmIL-10 (20ng/ml), rhTGF-β1 (20ng/ml). In some experiments, reactivation of LEC-educated 
or mDC-educated CD8+ T cells was also conducted with plate-bound anti-CD3 antibody 
(145.2C11) at 5μg/ml and/or soluble anti-CD28 (37.51) at 2μg/ml (aCD3/CD28, eBioscience). 
The same procedures, described above, were performed to analyze the phenotype and 
function of the reactivated cells. 
In vitro homeostatic proliferation 
To determine whether LEC-educated CD8+ T cells can respond to homeostatic signals and 
proliferate, we exposed them to IL-15 for different time periods. LEC/mDC-educated CD8+ T 
cells were harvested on day 3 of coculture, washed at least twice with basal medium and 
counted. 105 LEC-educated or mDC-educated CD8+ T cells were subsequently cultured in the 
presence, or absence, of IL-15 (100ng/ml). 24-72h later, the cells were harvested and stained 
for immunological markers to be analyzed by flow cytometry. 
Adoptive CD8+ T cell transfer 
Following CD8+ T cell purification, for the naïve groups, or following 3-day in vitro LEC/mDC – 
CD8+ T cell coculture, cells were collected, washed in basal medium (IMDM, Life 
Technologies, Carlsbad, CA, USA) and resuspended in 100μl volume prior to tail vein 
injection. To assess proliferation of LNSC-educated cells in vivo, 106 naïve OT-I CD8+ T cells 
(CD45.1.2) were adoptively transferred in chimeric mice (CD45.2). To determine the homing 
potential of LN LEC/mDC-educated CD8+ T cells, 106 cells (CD45.1) were adoptively 
transferred in naïve host mice (CD45.2). For the in vivo antigen reencounter experiments, 106 
LEC/mDC-educated cells (CD45.2) were adoptively transferred in naïve host mice (CD45.1). 
For the studies including challenge with bacterial pathogen, 5x104 LN LEC/mDC-educated 
CD8+ T cells (CD45.1 or CD45.1.2) were adoptively transferred in naïve host mice (CD45.2). 
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Antigenic challenge  
In order to determine whether exogenous antigen uptake by LNSCs can drive CD8+ T cell 
proliferation in vivo, we intradermally (i.d.) administered 50μg of endotoxin-free OVA in all four 
limbs at a volume of 10μl/limb, or saline as a control. To test the capacity of LN LEC/mDC-
educated T cells to respond to secondary antigen encounter in vivo, we subcutaneously 
administered 50μg of endotoxin-free OVA plus 100μg of ultrapure LPS.  
Infection with Listeria monocytogenes – expressing OVA (L.m.-OVA) 
In order to assess the functional potential of LN LEC/mDC-educated CD8+ T cell upon 
pathogenic challenge, mice were infected i.v. with L.m.-OVA (33) (103 colony forming units, 
cfu) acquired from log phase of growth in brain heart infusion (BHI) (Sigma-Aldrich) medium. 
The mice were challenged at least 5 weeks following adoptive transfer of LN LEC/mDC-
educated CD8+ T cells. The mice were sacrificed either eight days after challenge to analyze 
T cell responses or, three weeks after challenge to assess the formation of secondary 
memory. For the analysis of bacterial load in the spleen, mice were infected with 104 cfu L.m.- 
OVA at least nine weeks following adoptive transfer of LN LEC/mDC-educated CD8+ T cells 
and sacrificed three days after. Spleens were collected, homogenized and resuspended in 
10ml sterile PBS. Cell suspensions were diluted 1:10, 1:100, 1:500, 1:2000 and 100μl per 
respective dilution were plated on BHI agar plates and incubated overnight at 37oC. The 
following day, colony-forming units were counted and the amounts of L.m.-OVA were 
calculated with respect to the relative dilutions. 
Tissue and cell preparation  
Spleens, LNs (brachial, axillary, inguinal, popliteal), as well as lungs, liver and BM when 
indicated, were harvested at time of killing. LNs were digested 45min, in DMEM 
supplemented with 1mg/ml collagenase D (Roche, Basel, CH). Single-cell suspensions were 
obtained by gently disrupting the spleen and LNs through a 70-μm cell strainer. BM was 
recovered from tibia and femurs by flushing with medium through a 20-gauge needle and 
passed through a 70-μm cell strainer. Lungs were perfused with 10ml PBS, digested in 
medium with collagenase D for 45 min and the remaining tissue disrupted as described 
above. Afterwards, a 30% Percoll (VWR, Dietikon, Switzerland) gradient was applied to the 
cells to isolate lung leukocytes. Liver was perfused with 10ml PBS and gently disrupted 
through a 100-μm and subsequently, 70-μm cell strainer. A 37.5% Percoll gradient was then 
applied to the cells to isolate liver leukocytes. Spleen, BM, liver and blood RBCs were lysed 
with NH4Cl for 4 min. Cells were counted and resuspended in co-culture media.  
Ex vivo restimulation  
Up to 3x106 cells were plated in 96-well plates and cultured in co-culture media for 2 hours at 
37°C in the presence of 1μg/mL SIINFEKL peptide, followed by additional 3h treatment with 
BFA (5μg/mL). Stimulation with PMA/ionomycin served as a control.  For CD107a staining, 
the monoclonal antibody against CD107a was added in the culture together with Monensin at 
5μg/mL for 5 hours. Finally, cells were washed in PBS prior to intracellular staining for flow 
cytometric analysis.   
In vitro killing assay 
To assess the specific killing capacity of reactivated LEC-educated and mDC-educated CD8+ 
T cells, the cells were cultured, following in vivo or in vitro antigen reencounter, with a 1:1 
mixture of CFSEhigh- labelled (5μΜ) SIINFEKL-loaded and CFSElow- labelled (0.1μΜ) 
mismatched-peptide-loaded DCs (mixed target cells) at different effector over target cell 
ratios. We kept the number of mixed target cells stable at 5x104 cells. Mixed target cells alone 
served as a control for non-specific death. After 12-16 hours, the ratio of the surviving 
CFSEhigh and CFSElow cell populations was assessed by flow cytometry to calculate the 
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percentage of specific killing as follows: % specific killing: 100-[100*(CFSEhigh/CFSElow)sample 
/(CFSEhigh/CFSElow)control].  
LN localization studies – Immunofluorescence  
To determine the specific localization of LEC-educated CD8+ T cells in the LN, we adoptively 
cotransferred naïve and LEC-educated CD8+ T cells at a ratio of 1:1 (5x106 total cells). Prior 
to transfer, naïve cells were labeled with CFSE and LEC-educated CD8+ T cells with 
eFluor670 Cell Proliferation Dye (Ebioscience). 24-48h later brachial LNs were removed and 
fixed overnight in 2% PFA in PBS pH 7.4. After three washes in PBS, LNs were embedded in 
a block of 2% agarose, and sectioned (150µm) using a using a vibratome (Leica, Wetzlar 
DE). Sections were blocked in 0.5% of casein, and further labeled using antibodies against 
B220 (Invitrogen, Auckland, NZ, USA) and LYVE-1 (Reliatech, San Pablo, CA US). Images 
were acquired on a Leica SP5 confocal microscope using 20x or 60x objectives, and 
processed using Imaris software (Bitplane, Zürich, CH).  
Flow cytometry 
Cells were washed and stained with a cocktail of surface antibodies in staining buffer, 
containing HBSS (Life Technologies) supplemented with 0.5% bovine serum albumin. Cell 
viability was determined by propidium iodide incorporation in staining buffer after surface 
antibody staining or with live/dead fixable cell viability reagent (Life Technologies) in PBS 
before surface antibody staining. For intracellular/intranuclear staining, cells were fixed and 
permeabilized with the Foxp3/Transcription Factor Fixation/Permeabilization kit 
(eBiosciences) according to the manufacturer’s instructions.  Cells were stained in 
permeabilization buffer with a cocktail of monoclonal antibodies. The following anti-mouse 
antibodies were used: CD62L (MEL-14), CD44 (IM7), KLRG-1 (2F1/KLRG1), PD-1 (RMP1-
30), CXCR3 (CXCR3-173), CD43 (1B11), CD27 (LG.3A10), CD122 (TM-b1), CCR7 (4B12), 
CD127 (A7R34), T-bet (eBio4B10), Eomes (Dan11mag), LFA-1 (H155-78), Sca-1 (D7), Bcl-2 
(BCL/10C4), CD45.1 (F20), CD45.2 (104), CD8 (53-6.7), CD3e (145-2C11), IFN-γ (XMG1.2), 
IL-2 (JES6-5H4), TNF-α (MP6-XT22), CD107 (1D4B), Granzyme-B (NGZB), ki-67 (SolA15). 
Finally, cells were resuspended in staining buffer and analyzed by flow cytometry (CyAn ADP 
Flow Cytometer, DAKO). Data analysis was performed using FlowJo (v9.4, Tree Star Inc., 
Ashland, OR, USA).   
Cytokine ELISAs  
Ready-SET-go! ELISA kits for cytokine detection were purchased from eBioscience, except 
from the IL-7 mouse ELISA kit that was purchased from Abcam (Cambridge, UK), and used 
according to the manufacturer’s instructions. 
Statistical analysis  
Statistical analysis was performed using one-way or two-way analysis of variance (ANOVA) 
followed by Bonferroni post-test with Prism software (Graphpad, San Diego, CA, US) unless 
otherwise stated. Results are shown as mean ± standard deviation with significance indicated 
as *p≤0.05, **p≤0.01, and ***p≤0.001.? 
3.3  Results 
LNSCs can prime CD8+ T cells under steady state conditions in vivo and 
the LNSC-education favors the generation of CD8+ T cells with a central 
memory rather than effector-like phenotype 
We previously showed that LN LECs can actively scavenge exogenous antigens in 
vivo under steady state conditions and cross-present it on MHC I inducing CD8+ T 
cell proliferation in vitro [Chapter 2 and (11)]. We asked whether exogenous antigen 
46 
uptake in LECs can also drive CD8+ T cell proliferation in vivo under homeostatic 
conditions. To this end, we generated bone marrow (BM) chimeric mice in which 
CD45+ cells lacked MHC class I (β2m:WT) and therefore, presentation of the Kb-
restricted SIINFEKL epitope was limited only to radioresistant lymph node stromal 
cells (LNSCs). To further elucidate the contribution of LNSC education in CD8+ T cell 
priming, we also generated reciprocal chimeras (WT:β2m), in which LNSCs were 
excluded from antigen presentation. To address the question of whether non-
hematopoietic LNSCs cross-present the antigen and directly induce proliferation in 
vivo, we transferred naïve CFSE-labeled OT-I CD8+ T cells (CD45.1.2+) in the 
chimeric mice and one day after, we intradermally (i.d.) administered OVA protein or 
saline (PBS), as a control (Fig. 3.1A). Five days after OVA administration, we were 
able to detect the transferred CD8+ T cells in the skin-draining LNs and we observed 
notable levels of proliferation in β2m:WT mice (Fig. 3.1B, bottom panel, on the very 
left), suggesting that indeed, LNSCs can drive antigen-specific CD8+ T cell 
proliferation under steady state-conditions in vivo. As expected, OVA administration 
induced remarkable levels of proliferation in the control WT:WT mice (Fig. 3.1B, 
bottom panel, second from the left) while there was no expansion of the transferred 
CD8+ T cells in β2m:β2m control mice, in which both hematopoietic and non-
hematopoietic cells lack MHC class I (Fig. 3.1B, bottom panel, on the very right). The 
mice that received saline (PBS) served as controls and allowed us to confirm that the 
observed proliferation was antigen-specific, resulting from MHC class I/SIINFEKL 
presentation on the cell surface. We further used the saline controls to separate the 
proliferating cells (g>0) (Fig. 3.1B, top panel, on the very left) from the ones that 
stayed undivided (generation 0, g=0) and determine the levels of non-specific 
background proliferation (Fig. 3.1B, top panel). We quantified the levels of CD8+ T 
cell proliferation by assessing CFSE dilution (Fig. 3.1C). The analysis confirmed that 
OVA administration resulted in CD8+ T cell proliferation at levels significantly higher 
than the background (PBS) when LNSCs, but not CD45+ cells, were able to present 
the antigen (β2m:WT). As anticipated, the transferred cells proliferated more robustly 
in case both hematopoietic and non-hematopoietic cells were capable of MHC class I 
presentation (WT:WT). Interestingly, we detected notably lower levels of proliferation, 
compared to WT:WT mice, when stromal cells did not contribute in antigen 
presentation (WT:β2m), suggesting that LNSCs not only participate, but also might 
be appreciably involved in the induction of CD8+ T cell proliferation in the LN. In the 
β2m:β2m mice, the difference in proliferation levels between PBS and OVA-treated 
mice was not statistically significant, as expected, since in these mice, neither LNSCs 
nor CD45+ cells can present antigen on MHC class I. Next, we wanted to evaluate 
the phenotype of the LNSC-educated CD8+ T cells in terms of activation and effector 
potential. By day 5 after OVA administration, the majority of the transferred CD8+ T 
cells in the LN of β2m:WT , WT:WT and WT:β2m mice were activated, as indicated 
by the expression of CD44 marker (Fig. 3.1D, plots in the middle, OVA). In the 
β2m:β2m mice (Fig. 3.1D, bottom row), as well as in the control mice of any group 
that received saline (Fig. 3.1D, plots on the left, PBS), the cells expressed high levels 
of CD62L and low levels of CD44, preserving a naïve phenotype (CD62L+CD44-), as 
expected. Assessing the phenotype of the proliferating T cells, specifically, (Fig. 
3.1D, plots on the right, g>0, OVA), we detected both subsets of central memory 
(TCM), defined as CD44+CD62L+, and effector or effector memory (Teff /EM), defined as 
CD44+CD62L-, CD8+ T cells in all the groups (β2m:WT , WT:WT and WT:β2m mice),  
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Figure 3.1 LNSCs can prime CD8+ T cells under steady state conditions in vivo and the LNSC-
educated CD8+ T cells display memory-like characteristics. To evaluate the contribution of LNSCs 
in CD8+ T cell proliferation, we generated BM chimeric mice using β2m-/- (lacking MHC I) mice, as 
described in Materials and Methods. β2m:WT, irradiated C57/Bl6 mice reconstituted with β2m-/- BM; 
WT:β2m, irradiated β2m-/- mice reconstituted with WT BM; WT:WT and β2m:β2m served as controls. 
Naïve CFSE-labeled OT-I cells were adoptively transferred and one day after, the mice were vaccinated 
i.d. with OVA or saline control (PBS). 5 days after vaccination, the mice were sacrificed and skin-dLNs 
collected.  Cell suspensions were generated and analyzed by flow cytometry. (A) Experimental timeline. 
LNSCs cross-present the antigen and directly induce proliferation in vivo. (B) Representative dot plots of 
transferred cells displaying CD45.1 (y-axis) and CFSE dye (x-axis) in OVA (bottom) or PBS (top) -
treated mice. Lower levels of expansion when presentation is limited to LNSCs or when they are 
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eliminated from presentation. (C) Percentage of proliferating cells in response to vaccination (gated on 
transferred cells). The stars on top of whiskers indicate statistically significant difference between PBS 
and OVA treatment in the same group. The TCM-like subset appears larger when presentation is limited 
to LNSCs compared to WT:WT controls and smaller when LNSCs are eliminated from presentation. (D) 
Representative zebra plots of the phenotype of transferred cells with regard to CD44 (x-axis) and 
CD62L (y-axis) in response to OVA or PBS for all cells (left and middle column, all generations) or for 
proliferating cells (right column, g>0). (E) Left, the percentage of TCM (CD44+CD62L+) in proliferating 
cells; right, the ratio of TCM (CD44+CD62L+) over Teff (CD44+CD62L-) in proliferating cells in response to 
OVA. LNSC-educated CD8+ T cells induce IFN-γ and IL-2 expression and the levels of IFN-γ+IL-2+ cells 
appear to be lower when LNSCs are excluded from priming. The cells were ex-vivo restimulated with 
SIINFEKL followed by intracellular staining. (F) Representative contour plots displaying cytokine 
expression (in response to OVA) with IFN-γ (top) or IL-2 (bottom) on y-axis and the side scatter on x-
axis. (G) The percentage of IFN-γ+ (top left) or IL-2+ (top right) or IFN-γ+IL-2+ (bottom left) cells (gated 
on transferred cells) in OVA-treated mice. Bottom right, the percentage of IL-2+ cells gated on IFNγ+ 
cells. Representative data from one of two independent experiments (n=5-6, except B-C, PBS group, 
n=3). *p≤0.05, **p≤0.01, ***p≤0.001 by one-way ANOVA followed by Bonferroni posttest. 
with the Teff /EM subset being always the dominant one. However, when we compared 
the relative distribution of these two subsets among the different groups, we 
observed that the percentage of the TCM subset appeared greater in β2m:WT mice, 
when only LNSCs were responsible for the education of CD8+ T cells, in comparison 
to that of WT:WT mice (Fig. 3.1E, on the left). Even though this trend was not 
statistically significant, it suggested that LNSCs might favor the induction of the TCM 
subset. More importantly, we observed that in the absence of LNSC-education 
(WT:β2m mice), the TCM subset was remarkably lower compared to that of β2m:WT 
or WT:WT mice. This indicated that LNSC-education favors the induction of central 
memory-like CD8+ T cells. We noted a similar trend when we examined the ratio of 
TCM versus Teff /EM in the proliferating cells (Fig. 3.1E, on the right), which further 
suggested that LNSC-educated CD8+ T cells are more biased towards a TCM-like 
rather than Teff /EM phenotype. 
To further characterize the effector potential of LNSC-educated CD8+ T cells, we 
analyzed their capacity to produce cytokines upon ex vivo peptide restimulation. 
LNSC-educated CD8+ T cells did express IFN-γ and IL-2 cytokines (Fig. 3.1F, G) at 
levels similar to those observed when CD8+ T cells were educated only by CD45+ 
cells or to those detected in WT:WT mice. More specifically, we did not detect any 
significant differences in the percentage of IFN-γ positive or IL-2 positive cells among 
the groups (Fig. 3.1G, top graphs, left and right respectively and Fig. 3.9A). However, 
we observed a trend for lower levels of IFN-γ in the absence of LNSC (WT:β2m) or 
CD45+ (β2m:WT) cells MHC I presentation compared to WT:WT mice, which 
matched the trend that we noted for its  expression in a per cell basis, by assessing 
the mean fluorescence intensity (MFI) (Fig. 3.9B), still not significant though. 
Additional analysis revealed lower levels of  IFN-γ and IL-2 double positive cells 
when LNSCs were eliminated from T cell priming (WT:β2m) (Fig. 3.1G, bottom 
graphs, left). Moreover, the percentage of IL-2 positive cells among the IFN-γ 
producing ones was significantly higher for exclusively LNSC-educated CD8+ T cells 
(β2m:WT) while in the absence of LNSC-education, the percentage displayed was 
the lowest. The expression of IL-2 has been traditionaly related to the TCM subset (20, 
21, 23, 34). Even though the levels of IL-2 expression were very low to comfortably 
arrive to a safe conclusion, it is intriguing to speculate that the enhanced levels of IL-
2  in IFN-γ producing LNSC-educated CD8+ T cells might be related to the central 
memory-like phenotype that we observed in LNSC-educated CD8+ T cells. 
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By using the β2m-/- BM chimeric mice we cannot exclusively attribute our findings to 
LN LECs and exclude the contribution of the other LNSC subsets, including 
fibroblastic reticular cells (FRCs), blood endothelial cells (BECs) or double negative 
(DN) cells (follicular DCs cannot present antigen to CD8+ cells (35)). Indeed, FRCs 
have been also reported to induce antigen-specific CD8+ T cell priming (9). We, and 
others, have recently demonstrated that LN LECs were the most effective, among 
stromal cells, in the uptake of peripherally administered OVA [Chapter 2 and (11, 
36)], potentially due to its mannosylated pattern (37). Thus, it is likely that CD8+ T cell 
proliferation in this setting might be mainly governed by LECs.   
Collectively, these data demonstrate that LNSCs can prime CD8+ T cells under 
steady state conditions in vivo and that the LNSC-educated CD8+ T cells display 
memory-like characteristics and are able to produce cytokines.  
LECs induce apoptosis but the non-apoptotic CD8+ T cells go into a 
central memory-like phenotype 
To determine the contribution of LEC-educated CD8+ T cells in LNSC-priming, we 
decided to turn to in vitro studies and characterize ex vivo generated LN LEC-
educated CD8+ T cells. Motivated by our in vivo findings of LNSC-educated CD8+ T 
cells being more biased towards a central memory-like phenotype, we sought to 
assess their profile with regard to CD44 and CD62L expression, compared to that of 
mature, bone marrow derived, dendritic cell (mDC)-educated CD8+ T cells. To this 
end, we cocultured LN LEC or mDC together with transgenic OVA-specific OT-I 
CD8+ T cells in the presence (education: LEC/mDC) or absence (education: none) of 
1nM NP-ss-COVA250–264. This 16-aa peptide on the NPs (NP-ss-COVA250–264) 
requires uptake and intracellular processing for MHC class I loading in BMDCs (32) 
and in LECs (11). It is a very efficient tool for cross-presentation studies, that we 
have extensively used and characterized (32). Upon incubation with LN LECs in the 
presence of NP-ss-COVA250–264, OT-I CD8+ T cells proliferated strongly and 
increased in size compared to naive cells, which is consistent with their activated 
state, although they did not develop as large a blastoid size as mDC-educated CD8+ 
T cells (Fig. 3.2A, top panel). Interestingly, when we assessed the expression of 
CD44 and CD62L in LEC/mDC-educated cells on day 3 of the coculture, we  
observed a very particular profile for LEC-educated CD8+ T, characterized by high 
levels of CD62L and CD44 (Fig. 3.2A, bottom panel, middle). This profile was totally 
different from the one of uneducated cells, which maintained a naive CD62L+CD44- 
phenotype (Fig. 3.2A, bottom panel, left), and clearly distinct from the effector-like 
profile of mDC-educated CD8+ T cells, which displayed mainly high levels of CD44 
but mid to low levels of CD62L. CD62L (L-selectin) is a marker widely used to 
distinguish central memory from effector memory T cells. It is shed from the T cell 
membrane following TCR activation (38) and its regulation plays an important role in 
T cell trafficking, since it functions as a homing receptor, facilitating entry to 
secondary lymphoid organs. Recent studies have demonstrated that CD62L 
shedding might also reflect a physiological role in regulating the differentiation and 
function of effector cells  (39, 40). We asked whether activation of CD8+ T cells by 
LECs induced CD62L downregulation or whether CD62L has been maintained in the 
course of a three day coculture. We observed that CD62L was actually 
downregulated for both LEC and mDC-educated CD8+ T cells on the first day of the 
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co-culture (Fig. 3.2B, top), consistent with the cleavage of CD62L from the cell 
surface following TCR engagement reported previously (41). On day 2, we detected 
both CD62L+ as well as CD62L- cells in the LEC-educated population of CD8+ T cells 
Figure 3.2 LEC education induces apoptosis but the non-apoptotic CD8+ T cells go into a central 
memory-like phenotype in vitro. Naive CFSE-labeled OT-I cells were cocultured in the presence of 
NPssCOVA250-264  (1nM) with LN LEC or mature BMDC (mDC). At different time points, LEC/mDC-
educated CD8+ T cells were harvested and evaluated for apoptosis, by assessing the apoptotic marker 
Annexin V (AnV), and expression of CD44 and CD62L. (A) LEC-educated CD8+ T cells display a 
distinctive CD44+CD62L+ phenotype similar to TCM cells. Top, representative dot plots of the size of 
LEC/mDC-educated (LEC/mDC educ.) or non-educated (naïve, none) CD8+ T cells with the forward 
scatter on x-axis and side scatter on y-axis. Bottom, representative dot plots with CD62L on y-axis and 
CD44 on x-axis on day 3 of coculture. (B) Proliferating cells in LEC-educated CD8+ T cells are mainly 
CD62L+ whereas in mDC-educated they are mainly CD62L-. Representative dot plots of CD62L 
expression per generation in a 3-day coculture with CFSE on x-axis and CD62L on y-axis. (C) Counts of 
live LEC/mDC-educated CD8+ T cells on day 1, 2, and 3 of coculture. (D) Percentage of AnV positive 
cells per generation on day 2 of coculture. (E) In LEC-educated CD8+ T cells, AnV- cells display 
increasing levels of CD62L per generation whereas AnV+ cells display lower CD62L levels. Percentage 
of CD62L+ cells per generation, gated on AnV+ (black lines) or AnV- (grey lines) cells on day 2 of 
coculture. (F) Levels of apoptosis per generation in Teff-like (CD44+ CD62L-, grey lines) and TCM-like 
(CD44+CD62L+, black lines) subset of LEC/mDC-educated CD8+ T cells on day 2 of coculture. 
Representative data from one of two independent experiments (n=3). (D-F), stars indicate significant 
difference between groups in the same generation. *p≤0.05, **p≤0.01 by one-way ANOVA (C) or two-
way ANOVA (D-F) followed by Bonferroni posttest. 
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whereas most of the cells maintained mid to low levels of CD62L in the mDC-
educated population (Fig. 3.2B, middle). By day 3, as stated above, almost all LEC-
educated CD8+ T cells expressed high levels of CD62L while DC-educated cells 
were mainly CD62L- (Fig. 3.2B, bottom). Interestingly, by analyzing the expression of 
CD62L with regard to proliferation, we noticed that in LEC-educated CD8+ T cells, 
proliferating cells were mainly CD62L+ during the 3-day coculture, whereas in the 
mDC-educated population there was the opposite trend with proliferating cells being 
mainly CD62L- (Fig. 3.2B). This observation can be interpreted in different ways: 
either LEC-educated CD8+ T cells downregulate or transiently lose CD62L and then 
re-express it, or the gradual predominance of CD62L+ cells is mainly a result of an 
increased proliferation rate relative to CD62L- cells which might have a lower 
turnover rate or even die. In order to better interpret these findings, we assessed 
viability and expansion of CD8+ T cells during the 3 days of coculture (Fig. 3.1C). 
mDC-educated CD8+ T cells expanded continously after priming with a more than 2-
fold increase on day 3. However, we detected a decrease in LEC-educated CD8+ T 
cells on day 2 of the coculture compared to day 1 and the cells expanded to levels 
similar to day 1 on day 3. The fact that we do observe proliferation in LEC-educated 
CD8+ T cells but the overall expansion (from day 3 to day 1) is not significant favors 
the scenario of a lower proliferation rate as well as apoptosis.  
These findings were not surprising since we have previously shown that skin-derived, 
immortalized, LEC-educated CD8+ T cells display a dysfunctionally activated 
phenotype characterized by increased levels of the apoptotic marker annexin V in 
early generations compared to DC-stimulated T cells. In order to address the 
question of whether the difference in expansion in the LEC-educated population  can 
be attributed to apoptosis and more specifically, define whether there is an apparent 
predominance of CD62L+ cells due to higher apoptotic levels in the CD62L- subset, 
we sought to evaluate the levels of Annexin V in LN-LEC-educated CD8+ T cells on 
day 2 of the coculture. We thought that the second day of the coculture would be the 
most appropriate time point since it allowed us to detect both the CD62L+ and 
CD62L- subets in LEC-educated and mDC-educated populations. In agreement with 
our previous findings, LN-LEC-educated CD8+ T cells displayed higher levels of 
apoptosis from the early generations compared to mDC-educated ones (Fig. 3.1D). 
More importantly, when we analyzed the expression of CD62L per generation in the 
Annexin V+ or the Annexin V- subset for LN LEC-educated (Fig. 3.1E, left) and mDC-
educated (Fig. 3.1E, right) CD8+ T cells, we found that that the apoptotic cells 
(annexin V+, black line) displayed lower levels of CD62L compared to the non-
apoptotic cells (grey line) in LEC-educated, while there was not much difference in 
CD62L expression between the two subsets in mDC-educated cells. This 
observation supports the rationale that CD62L- effector-like cells tend to be more 
apoptotic relative to CD62L+ central memory-like cells, which therefore, dominate the 
LEC-educated population. Indeed, monitoring the levels of apoptosis per generation 
in the Teff-like CD62L-CD44+ (Fig. 3.1F, grey line) and TCM-like CD62L+CD44+ (Fig. 
3.1F, black line) subsets revealed that even though both subsets displayed 
increasing levels of apoptosis per generation, LEC-educated CD8+ Teff-like cells are 
significantly more apoptotic from the early generations compared to the TCM-like 
subset, which displays similar levels of apoptosis to mDC-educated CD8+ T cells with 
either phenotype.  
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Taken together, these data suggest that in agreement to our previous studies, 
antigen-specific education of  CD8+ T cells by LN LECs under steady-state conditions 
in vitro induces apoptosis, but the non-apoptotic cells seem to adopt a particular, 
TCM-like phenotype, which is clearly distinct from the profile of conventional APC-
educated cells. 
LEC-educated CD8+ T cells display a divergent phenotype sharing 
characteristics with central memory and stem cell memory cells  
Having shown that LEC-educated CD8+ T cells display a central memory-like 
phenotypic profile (CD44+CD62L+), we wanted to further characterize how they 
related to known memory subsets. We compared the expression of surface markers, 
intracellular proteins, as well as transciption factors in LN LEC-educated OT-I CD8+ T 
cells with those of mDC-educated or naive CD8+ T cells on day 3 of our in vitro 
coculture system. As described above, LEC-educated T cells diplayed high levels of 
CD44 (pink line) similar to those of mDC-educated cells (blue line), but they also 
expressed high levels of CD62L matching the expression of  non-educated (black 
line) naive cells (Fig. 3.3). Since most of the cells in the LEC-educated population 
were CD44+CD62L+ and the majority of cells in mDC-educated CD44+CD62L-, we 
decided to compare these two subsets to better illustrate the phenotypic variation. 
LEC-educated CD8+ T cells expressed CD127 (IL-7R), CD122 (IL-2Rβ) and CCR7 at 
levels similar or slightly higher to mDC-educated cells (Fig. 3.3A, B and Fig. 3.10A). 
They also expressed Eomes and T-bet, two transcription factors that have been 
shown to dynamically regulate effector and memory cells (42, 43). More specifically 
LEC-educated CD8+ T cells presented higher levels of Eomes compared to mDC-
educated ones, while their expression of T-bet was slightly lower.  
Interestingly, we found that LEC-educated CD8+ T cells express additional markers, 
which have been reported to delineate the newly-described subset of stem cell 
memory T cells (TSCM) in humans (44) and mice (45). TSCM cells phenotypically 
resemble both naive cells, being CD44-CD62L+ in mice, as well as antigen-
experienced cells, since they express CD122, CXCR3 and CD27 (46). The 
expression of additional molecules, such as CD95 (FAS), stem cell antigen 1 (Sca-1) 
and the B cell lymphoma 2 (Bcl-2) protein further portray their phenotypic profile. 
LEC-educated CD8+ T cells were positive for Sca-1 and CD27, as well as partly 
positive for Bcl-2, CD95 and CXCR3 at levels greater than mDC-educated CD8+ T 
cells. Surprisingly, LEC-educated CD8+ T cells also expressed CD43 in the same 
range as mDC-educated cells, which has been described to be expressed on effector 
but not memory CD8+ T cells (47). Furthermore, LEC-educated and mDC-educated 
cells also expressed LFA-1 with LEC-educated ones expressing higher levels. 
Trying to better illustrate the divergence in the CD8+ T cell differentiation state 
induced upon antigen-specific interaction with LN LEC or mDC, we analyzed the 
distribution of diverse T cell subsets detected with respect to various markers (Fig. 
3.3C). We observed that the subsets of LN LEC-educated cells fell mostly in the 
CD44+CD62L+ subpopulation (CM-like and SCM-like). The largest subset among this 
population,  was the one that also displayed expression of CD127, CD122, Sca-1 
and medium levels of Bcl-2. The distribution of subsets in LEC-educated cells 
differed clearly from the one of mDC-educated cells that were dominated by the 
CD44+CD62L-CD127+ (EM-like) subset.  
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Figure 3.3 Ex vivo generated LEC-educated CD8+ T cells display a distinct phenotype with 
central memory-like and stem cell memory-like characteristics. Naïve OT-I cells were in vitro 
educated in the presence of NPssCOVA250-264  (1nM) by LN LEC or mDC (education) or not educated 
(none). On day 3 of co-culture, LEC/mDC-educated CD8+ T cells were stained for different surface, 
intracellular and intranuclear markers and analyzed by flow cytometry. (A) CD44+CD62L+ LEC-educated 
cells are also CCR7+, CD127+, CD122+, T-bet+ and Eomes+ but they also display Sca-1, a typical 
marker for stem-cells. They were also partly positive for other markers related to TSCM cells (Bcl-2, 
CD95, CXCR3). Representative histograms of various surface (CD44, CD62L, CD127, CD122, CCR7, 
etc) markers or intracellular proteins (Bcl-2) or transcription factors (T-bet, Eomes) for non-educated 
(black line), mDC-educated (blue line) and LEC-educated (pink line) CD8+ T cells. (B) Normalized mean 
fluorescence intensity (MFI) for the markers shown in (A), in CD44-CD62L+ non-educated (empty bars), 
in CD44+CD62L+ LEC-educated (pink bars), or in CD44+CD62L- DC-educated (blue bars) CD8+ T cells. 
Normalized MFI was determined as (MFIsample-MFIisotype)/MFIisotype. (C) Pie charts representing the 
distribution of various T cell subsets in naïve (left), LN LEC-educated (middle) and mDC-educated 
(right) CD8+ T cells, defined as follows: CD44-CD62L+, naïve; CD44+CD62L+CD127+CD122+Sca-1+Bcl-
2high, stem cell memory (SCM)-like; CD44+CD62L+CD127+CD122+Sca-1+Bcl-2mid/low, central memory 
(CM)-like; CD44+CD62L-CD127+, effector memory (EM)-like; CD44+CD62L-CD127-, effector (Eff)-like. 
Representative data from one of three independent experiments (n=3). *p≤0.05, **p≤0.01, ***p≤0.001 by 
one-way ANOVA followed by Bonferroni posttest.  
Although it is hard to ultimately classify LN LEC-educated CD8+ T cells among one of 
the known T cell subsets, we can observe that their phenotypic profile appeared to lie 
somewhere between the TCM and TSCM subsets, and it was distinct from the one of 
mDC-educated cells that resembled more with the TEM/eff subset. It is important to 
note that the particular phenotypic profile described here for LN LEC-educated CD8+ 
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T cells was not specific to the model antigen and TCR transgenic system used, nor it 
was dependent on the cross-presentation mechanism; By altering NP-ss-COVA250–264 
with the SIINFEKL peptide (Fig. 3.10C, D), as well as using the pmel transgenic mice 
bearing the TCR specific for the gp100 peptide, yielded the same profile (Fig. 3.10E). 
In any case, the extensive phenotypic complexity and diversity among T cell subsets 
reflects also their functional heterogeneity. Therefore, the phenotypic profile 
constitutes only one of the steps towards the identification of the differentiation state 
of LN LEC-educated CD8+ T cells. 
CD62L expression in LEC-educated CD8+ T cells reflects their LN 
homing ability and the memory-like phenotype is preserved upon in vivo 
transfer 
The characterization of the T cell differentiation state also involves the evaluation of 
tissue-homing properties. One of the very distinct characteristics of LEC-educated 
CD8+ T cells was the enhanced  expression of CD62L. Since naive T cells and TCM 
engage CD62L to localize to lymphoid tissue, we next investigated whether ex vivo 
generated LN LEC-educated CD8+ T cells can migrate to secondary lymphoid 
organs. To address this question, we adoptively transferred ex vivo generated 
LEC/mDC-educated or naive OT-I CD8+ T cells and subsequently analyzed their 
distribution among lymphoid and non-lymphoid organs (Fig. 3.4A). LEC-educated 
CD8+ T cells homed primarily to secondary lymphoid organs (LN, spleen) whereas 
mDC-educated cells migrated mainly to the periphery (lung, liver) (Fig. 3.4B). More 
specifically, although we observed LEC-educated cells in both lymphoid and non-
lympoid organs, 53% of the transferred LEC-educated cells were detected in the LN 
and spleen, while only 33% of the mDC-educated cells were found in the same 
organs. As expected, naive CD8+  T cells were almost exclusively detected in 
lymphoid tissue (91%).  
Additionally, analyzing the phenotype of the detected cells, we observed that LEC-
educated CD8+ T cells retained their central memory-like phenotype after in vivo 
transfer (Fig. 3.4C, D). Precisely, the CD44+CD62L+ TCM-like subset dominated in the 
population of LEC-educated cells detected in the LN (77.0±3.5) and spleen 
(56.5±9.4) (Fig. 3.4D, left), as well as in the rest of the organs examined (Fig. 3.11A), 
one week after the transfer. In mDC-educated cells, the subset of CD44+CD62L+ was 
the predominant one in the LN (67.5±0.3) but not in the spleen (Fig. 3.4D) or any of 
the other organs, where it was actually much smaller (Fig. 3.11A). Evaluating the 
ratio of CD44+CD62L+ TCM-like versus CD44+CD62L- Teff-like (Fig. 3.4D, right) nicely 
illustrated the polarization of LEC-educated CD8+ T cells versus a TCM-like rather 
than Teff/EM-like phenotype. Those ratios were found to be greater than one in LEC-
educated for all the organs examined (Fig. 3.4D and Fig. 3.11B, C) whereas in mDC-
educated cells, the ratios were always lower than one, except from the LN. Yet in the 
LN, where both LEC and mDC-educated were more inclined to the TCM-like subset, 
the indicative ratio was significantly higher in LEC-educated, highlighting the 
phenotypic differences between the two populations. Interestingly, the predominance 
of the TCM-like subset in LEC-educated CD8+ T cells was much more pronounced in 
the LN (Fig. 3.4D and Fig. 3.11B, C), suggesting a specific enrichment at this 
location compared to other organs. Furthermore, these findings suggest that the 
differentiation state might be flexible to some extent and dynamically reprogrammed 
in response to the local microenvironment. 
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Figure 3.4 CD62L expression in LEC-educated CD8+ T cells translates to LN homing where they 
retain their memory-like phenotype. (A) CD45.1+ OT-I cells were educated in the presence of 
NPssCOVA250-264  (1nM) by LN LEC or mDC (educated T cells). On day 3 of coculture, LEC/mDC-
educated or naive OT-I CD8+ T cells were transferred i.v. in C57/Bl6 WT mice. One week after, mice 
were sacrificed; spleen, skin-dLNs, liver and lungs were collected and analyzed by flow cytometry. (B) 
LEC-educated CD8+ T cells home primarily to secondary lymphoid organs (LN, spleen) whereas DC-
educated cells home mainly to non-lymphoid tissues (liver and lungs). Pie charts displaying the 
distribution of transferred cells in lymphoid versus non-lymphoid organs. Percentages are calculated as 
number of cells detected in lymphoid or non-lymphoid organs over total cells in all organs analyzed. 
LEC-educated CD8+ T cells retain the TCM-like phenotype after in vivo transfer. (C) Representative 
zebra plots of transferred LEC/mDC-educated cells in LN and spleen with CD44 on x-axis and CD62L 
on y-axis (left) or with CD127 on the x-axis and CD62L on the y-axis (right). (D) Left, percentage of TCM-
like (CD44+CD62L+, pink), Teff/EM-like (CD44+CD62L-, blue) and naïve (CD44-CD62L+, yellow) cells in 
LEC/mDC-educated cells before transfer (day 0) and one week after (day 7) in LN and spleen. Right, 
ratio of TCM-like (CD44+CD62L+) over Teff-like (CD44+CD62L-) cells in each organ in transferred 
LEC/mDC-educated CD8+ T cells. Representative data from one of two independent experiments (n=3). 
**p≤0.01, ***p≤0.001 by two-way ANOVA followed by Bonferroni posttest. (E) LEC-educated CD8+ T 
cells are situated at the outermost regions of the LN, in the subcapsular sinus area, close to B cell 
follicles and the interfollicular areas of the LN. LEC-educated (green) and naive (pink) OT-I CD8+ T cells 
were cotransfered in C57/Bl6 WT mice. Mice were sacrificed 24-48h later and brachial LNs were 
collected. Top left, brachial lymph node section stained with Lyve-1 (white), marking lymphatic 
structures, and B220 (cyan) marking B cells for orientation. The orange frames indicate regions of close-
up images. Top right and bottom right, close-up images showing the particular distribution of LEC-
educated cells on the edges of B cell follicles compared to broadly-distributed naive cells in the T cell 
zone (bottom left and top left images). Scale bars in μm.   
This particular pattern of homing and distribution among the different organs 
prompted us to explore the specific sub-anatomical sites in the LN, in which LEC-
educated cells reside. To this end, we co-transferred differentially fluorochrome-
labeled LEC-educated or naive CD8+ T cells and analyzed their localization pattern 
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using confocal microscopy of thick sections of the brachial LN. The cotransfer of the 
two populations allowed us to identify whether there was a difference in distribution in 
the different LN compartments. We observed the naive population residing mainly 
around the T cell zone, in the paracortex, (Fig. 3.4E, top left, bottom left), consistent 
with previous reports (48, 49) describing the localization of naive CD8+ T cells in the 
LN. Noticeably, most of the LEC-educated CD8+ T cells were found close to the 
cortical and medullary sinuses, around B cell follicles and particularly in the 
interfollicular areas (Fig. 3.4E, top left, top right, bottom right), in a position similar to 
the one recently described for central memory CD8+ T cells (48, 49). 
Collectively, these data suggest that CD62L expression in LEC-educated CD8+ T 
cells is functional and is actually employed for preferential homing to secondary 
lymphoid organs. The migrating cells retain their memory-like phenotype and display 
a characteristic sublocalization pattern in the LN, similar to that of CD8+ TCM cells. 
Upon antigen re-encounter on mature DCs in vitro, LEC-educated CD8+ 
T cells can be reactivated and generate effector cells 
Having demonstrated that LEC-educated CD8+ T cells display a memory-like 
phenotype with lymphoid tissue homing properties, we asked whether they can be 
reactivated upon antigen re-encounter, a property ascribed to memory cells. To this 
end, we educated OT-I CD8+ T cells with LECs or mDCs (in the presence of NP-ss-
COVA250–264), labeled them with CFSE and incubated them with mDCs loaded with 
the SIINFEKL peptide (mDC-recall, + antigen) for 24h (Fig. 3.5A). We subsequently 
analysed their proliferation and differentiaton potential. Reactivation with mDCs not 
bearing the SIINFEKL peptide served as control (- antigen). By assessing CFSE 
dilution, we detected proliferation upon mDC-recall in LEC-educated CD8+ T cells 
(Fig. 3.5B), even though at low levels likely due to the short length of the reactivation 
period. mDC-educated cells did not manage to proliferate at higher levels compared 
to control during the same period, indicating lower proliferative potential upon antigen 
re-encounter compared to LEC-educated cells. We have previously characterized 
CD8+ T cells educated by LECs as dysfunctionally activated since we detected very 
low levels of cytokines in the supernatant of a 3-day coculture, much lower than 
mDC-educated cells [Chapter 2 and (11)]. Therefore, we sought to investigate 
whether the cells maintain this dysfunctional state or whether they can respond, 
displaying functional potential. Interestingly, LEC-educated CD8+ T cells exited the 
non-responsive state and produced cytokines (Fig. 3.5C). More specifically, (upon 5h 
mDC-recall) we detected slightly lower levels of IFN-γ but significantly higher levels 
of TNF-α and IL-2 in LEC-educated compared to mDC-educated cells, as determined 
by intracellular staining.  Naïve OT-I CD8+ T cells were also stimulated with 
SIINFEKL-bearing DCs, as a control. We failed to detect significant cytokine 
expression in naïve cells at this time interval, suggesting that antigen-experienced 
cells can respond more quickly, as previously anticipated. In agreement with these 
data, we observed the same trends when we assessed the secretion of cytokines in 
the supernatant of the 24h mDC-recall assay (Fig. 3.12). The enhanced proliferation 
potential and the increased levels of IL-2 production upon reactivation in LEC-
educated CD8+ T cells add up to their memory-like characteristics and suggest a less 
differentiated state compared to mDC-educated ones. 
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Figure 3.5 LEC-educated CD8+ T cells can be reactivated by mature DCs in vitro, giving rise to 
effector cells. OT-I cells were cultured in the presence of NPssCOVA250-264 (1nM) with LN LEC or mDC 
for 3 days (education). LEC/mDC-educated CD8+ T cells were subsequently harvested, labeled with 
CFSE and re-plated in the presence of mDCs (mDC recall), bearing or not the SIINFEKL peptide (A) 
Schematic of the experiment. (B) Upon 24h restimulation with SIINFEKL-loaded DCs, LEC-educated 
CD8+ T cells rapidly proliferate, as determined by flow cytometry. Left, representative dot plots with 
CFSE on x-axis and the forward scatter on y-axis. Right, percentage of proliferating cells in CD8+ T cells 
upon DC recall with (+Ag) or without (-Ag) SIINFEKL. (C) LEC-educated CD8+ T cells can exit the non-
responsive state and produce cytokines upon mDC-recall. From left to right: percentage of IFN-γ+, TNF-
α+, and IL-2+ cells (gated on CD8+ T cells) after 5h mDC-recall. D) LEC-educated CD8+ T cells 
downregulate CD62L and turn to more Teff-like phenotype after mDC recall. Representative flow 
cytometry dot plots with CD62L on y-axis and CD44 on x-axis for LEC/mDC-educated cells re-activated 
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by DCs bearing the SIINFEKL peptide (+Ag), or not (-Ag). LEC-educated CD8+ T cells display cytotoxic 
effector characteristics upon mDC recall. (E) Representative histograms of CD62L (top) and Granzyme 
B (GzB, bottom) in LEC-educated CD8+ T cells before (black dotted line) or after mDC-recall (black line) 
and in mDC-educated CD8+ T cells after mDC-recall (grey line). Isotype/FMO control in solid grey. (F) 
LEC-educated CD8+ T cells express cytolytic molecules upon mDC recall. Top, percentage of GzB+ 
cells (gated on CD8+ T cells) upon recall, as determined by intracellular staining. Bottom, secreted GzB 
(ng/ml) in the supernatant after 24h mDC recall. (G) LEC-educated CD8+ T cells display specific killing 
capacity. Reactivated LEC/mDC-educated OT-I CD8+ T cells were cultured on top of DCs loaded with 
SIINFEKL or non-congenic peptide for 16-20h at different effector to target ratios. Percent specific killing 
for LEC-educated versus mDC-educated cells. E:T; effector to target ratio. **p≤0.01, ***p≤0.001 by two-
way ANOVA (B) or one-way ANOVA (C) followed by Bonferroni posttest or by two-tailed unpaired 
Student’s t test (F). 
We further investigated the differentiation potential of LEC-educated CD8+ T cells by 
assessing the phenotype of the cells upon reactivation. LEC-educated T cells 
downregulated CD62L and turned to a more effector-like phenotype (CD44+CD62L-) 
after DC-recall, similar to the one of mDC-educated cells (Fig. 3.5D, E). However, 
they still preserved a CD44+CD62L+ subset. We also detected Granzyme-B (GzB) 
expression upon reactivation (Fig. 3.5E, F), as determined by intracellular staining 
(Fig. 3.5F top) as well as by assessing the amount secreted in the supernatant by 
ELISA  (Fig. 3.5F bottom), at lower levels though compared to mDC-educated cells. 
The production of cytolytic molecules upon DC-recall suggests that the differentiated 
cells display cytotoxic effector characteristics. Consistent with the acquisition of 
effector function, LEC-educated CD8+ T cells also displayed specific killing activity 
(Fig. 3.5G), although they appeared less potent compared to their DC-educated 
counterparts. 
Taken together, these data suggest that LEC-educated CD8+ T cells can escape the 
non-responsive state and retrieve their functional potential upon antigen re-encounter 
in vitro. They are situated higher than the terminal effector stage in the scale of 
differentiation and, similar to TCM CD8+ T cells, they can differentiate and give rise to 
effector cells. 
LEC-educated CD8+ T cells undergo rapid expansion following re-
exposure to the antigen in vivo, even after prolonged periods in the 
absence of encounter, and differentiate into effector CTLs upon recall 
The next step was to assess the ability of LEC-educated CD8+ T to undergo rapid 
recall responses to secondary antigen exposure under inflammatory conditions in 
vivo. For that purpose, we transferred ex vivo generated CFSE-labeled LEC/mDC-
educated OT-I CD8+ T cells in mice and shortly after (short-term recall), we 
administered OVA plus LPS (+RECALL), or not (-RECALL) (Fig. 3.6A). Three days 
following antigen plus adjuvant administration, we observed robust expansion of the 
transferred cells in the LN and the spleen for LEC-educated as well as mDC-
educated CD8+ T cells (Fig. 3.6B, C). More specifically, we detected a significant 4-
fold increase in the percentage of transferred LEC-educated cells in the LN and the 
spleen upon recall, suggesting that similar to our in vitro findings, the cells can 
respond to secondary exposure to the antigen. The relative increase in mDC-
educated cells was lower than the one in LEC-educated cells. In addition to that, we 
found LEC-educated cells at a higher percentage (out of live cells) in the LN, 
compared to the spleen, whereas mDC-educated cells appeared at higher levels in 
the spleen. We attributed this finding to the early time point following the challenge 
as well as to the different homing properties that we previously described, since the 
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fold increase in expansion was similar in both organs. We also noticed that LEC-
educated cells were detected at lower numbers in both the spleen and the LN in the 
mice that did not receive the antigen recall, suggesting that LEC-educated CD8+ T 
cells might not engraft as well as their mDC-educated counterparts upon in vivo 
transfer.  
Along with the vigorous expansion, and in agreement with our in vitro observations, 
LEC-educated CD8+ T cells also exhibited functional potential, inducing the 
expression of cytokines. Upon ex vivo restimulation, we noted increased production 
of IFN-γ and TNF-α upon recall (Fig. 3.6D, Ε), and the transferred cells acquired 
effector function expressing GzB (Fig. 3.6E, right), and being capable of direct 
specific cytolysis (Fig. 3.6F). mDC-educated CD8+ T cells displayed greater potency 
in specific killing, similar to what we observed in vitro. 
Next, we sought to assess the survival properties of LEC-educated CD8+ T cells in 
the absence of antigen encounter and confirm their expansion capacity in this 
setting. To this end, we let the mice rest for more than five weeks before we 
administered OVA+LPS. Yet, LEC-educated cells were able to expand (Fig. 3.6G) 
showing more than a 2-fold increase, while their mDC-educated counterparts 
displayed a 4-fold expansion in the LN.  Furthermore, LEC-educated CD8+ T cells 
generated effector-like cells after the challenge with the majority of the detected cells 
being CD62L- (Fig. 3.6H, I). The phenotype of LEC-educated cells upon recall 
appeared similar to the one of mDC-educated cells, however, they still maintained a 
clear CD44+CD62L+ subset (Fig. 3.6H). Indeed, the percentage of CD44+CD62L- 
effector/memory effector cells in the LN and spleen was about 60% in LEC-educated 
upon recall, yet significantly lower to the one of mDC-educated that displayed about 
80% effector cells (Fig. 3.6I, left). This was better illustrated by assessing the ratio of 
TCM (CD44+CD62L+) over Teff (CD44+CD62L-); The ratio was lower than one in LEC-
educated cells, manifesting the polarization versus an effector phenotype after recall, 
but still significantly higher than the relative ratio in mDC-educated cells (Fig. 3.6I, 
middle). Additionally, LEC-educated and mDC-educated cells displayed similar levels 
of short-lived effector cells (TSLEC, KLRG-1+CD127-) with a trend for more TSLEC in 
mDC-educated cells in the spleen, where the TSLEC subset was the predominant one 
for both populations  (Fig. 3.6H, I, left). There were also no significant differences 
observed between the two populations with regard to the memory precursor effector 
subset (TMPEC, KLRG-1-CD127+).  
Taken together, these data confirm the ability of LEC-educated CD8+ T cells to 
proliferate and differentiate into functional effectors that produce cytokines and 
display specific killing activity upon antigen re-encounter in an inflammatory setting in 
vivo. The ability of antigen-experienced T cells to undergo rapid recall responses 
upon antigen reexposure constitutes a hallmark of immunological memory, allowing 
for protective immunity. 
 
60 
 
Figure 3.6 LEC-educated CD8+ T cells expand rapidly upon short and long-term antigen re-
encounter in vivo and differentiate into effector CTLs upon recall. Ex vivo generated LEC/mDC-
educated OT-I cells (CD45.2+) were CFSE-labeled and transferred in C57/Bl6 mice (CD45.1+). Two 
days (short-term recall) or at least 5 weeks (long-term recall) after transfer, mice were administered 
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(+recall) OVA+LPS, or not (- recall), and sacrificed 3-5 days after challenge. Cell suspensions of the 
spleen and skin-dLNs were generated and analyzed by flow cytometry. (A) Experimental timeline. LEC-
educated CD8+ T cells proliferate rapidly and expand when they re-encounter the antigen in vivo. (B) 
Representative dot plots with CD45.2 on y-axis and CFSE on x-axis in spleen and LN 3 days after short-
term recall. (C) Percentage of OT-I cells (gated on live cells) in LN (left) and spleen (right). (D) 
Percentage of IFN-γ+ cells (gated on CD8+ T cells) after short-term recall, following 5h ex vivo 
restimulation. (E) TNF-α (left) and GzB (right) detected in the supernatant (pg/ml) after 3-day ex vivo 
restimulation. (F) LEC-educated CD8+ T cells display higher levels of specific killing activity after recall. 
3 days after short-term recall, spleen cell suspensions were cultured on top of splenocytes loaded with 
SIINFEKL or non-congenic peptide for 16-20h at different effector to target ratios to assess killing 
activity. Percent specific killing in LEC-educated that received (black line) or not (black dotted line) the 
recall vaccine versus mDC-educated cells after recall (grey line). Even after prolonged absence of the 
antigen, LEC-educated CD8+ T cells survive and display effector phenotype when they re-encounter the 
antigen in vivo. More than 5 weeks (long-term recall) after transfer, mice were challenged with 
OVA+LPS and sacrificed 5 days later. (G) Percentage of OT-I cells (gated on live cells) in LN. LEC-
educated CD8+ T cells generate Teff-like cells after challenge with the majority of cells being CD62L-. (H) 
Representative dot plots of LEC/mDC-educated cells displaying CD44 on x-axis and CD62L on y-axis 
(right), or CD127 on x-axis and KLRG-1 on y-axis (left) in LN and spleen. (I) From left to right: 
percentage of Teff (CD44+CD62L-), ratio of TCM (CD44+CD62L+) over Teff (CD44+CD62L-) and 
percentage of early short-lived effector cell (KLRG-1+CD127-) in OT-I cells in LN and spleen. 
Representative data from one of two independent experiments (n=3-4). *p≤0.05, ***p≤0.001 by two-
tailed unpaired Student’s t test (C-E, G) or by one-way ANOVA followed by Bonferroni posttest (F, I).  
LEC-educated CD8+ T cells not only contribute to anti-infectious 
protection but also preserve a secondary memory persistent population 
Our findings raised the question whether LEC-educated CD8+ T cells can mediate 
protective immunity. Therefore, we sought to assess their contribution to immune 
responses against a real pathogen as well as evaluate their protective ability in direct 
competition to mDC-educated T cells. To this end, we co-transferred ex vivo 
generated LEC-educated OT-I CD8+ T cells together with mDC-educated cells in 
mice at a 1:1 ratio. We let the mice rest for five weeks and then, we challenged the 
mice with Listeria Monocytogenes (L.m.)-expressing OVA (Fig. 3.7A). Tracking the 
transferred cells in the blood at different time points after bacterial infection, we 
noticed that LEC-educated CD8+ T cells expanded after challenge with a 15-20–fold 
increase, as a percentage of total CD8+ T cells, from day 4 to day 6 or day 8 (Fig. 
3.7B). mDC-educated CD8+ T cells exhibited a greater expansion in the blood during 
the same time period. We also detected slightly higher numbers of mDC-educated 
CD8+ T cells in the spleen on day 8 after challenge (Fig. 3.7C), while the two 
populations were detected at similar levels in the LN (Fig. 3.13A). Both populations 
appeared at much lower numbers in the LN, which was expected at this time point 
since L.m.-OVA infection acts primarily in the spleen and liver. Most importantly, 
LEC-educated cells exhibited effector function with cytotoxic potential, since they 
expressed cytokines (Fig. 3.7D, 7E and Fig. 3.13B) and underwent cytolytic granule 
release. More specifically, upon ex vivo restimulation, LEC-educated CD8+ T cells 
displayed similar levels of IFN-γ (Fig. 3.7E), as well as TNF-α and IL-2 (Fig. 3.13B), 
with their mDC-educated counterparts and they were on par in the expression of 
CD107, a marker of cytolytic granule exocytosis (Fig. 3.7E) in the spleen. By 
assessing the percentage of single, double or triple positive cells for IFN-γ, TNF-α 
and IL-2 in order to evaluate the polyfunctionality of the cells, we observed a similar 
distribution between the two populations (Fig. 3.7F). In LEC-educated cells, we 
detected a dominant subset of cells positive for one of the three cytokines 
(42.18±5.35), a subset of cells positive for two of the three cytokines (30.37±6.25), a 
smaller subset of triple positive cells (2.85±0.60), while 25.11% (±6.75) of the cells  
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Figure 3.7 LEC-educated CD8+ T cells can participate in anti-infectious immunity and might give 
rise to a persistent secondary-memory population. To evaluate the functional potential of LEC-
educated CD8+ T cells, we assessed expansion, phenotype and functionality after bacterial pathogen 
encounter, in competition to DC-educated CD8+ T cells. Ex vivo generated (CD45.1.2) LEC-educated 
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together with (CD45.1) DC-educated OT-I CD8+ T cells were mixed at 1:1 ratio and transferred in 
C57/Bl6 mice (5x104 total cells/mouse). 5 weeks after, mice were i.v. challenged with L.m.-OVA (103 
cfu) and sacrificed either on day 8 or 3 weeks after. Cell suspensions of the spleen were generated and 
analyzed by flow cytometry. (A) Experimental timeline. LEC-educated CD8+ T cells expand after 
challenge. (B) Percentage of OT-I cells (gated on CD8+ T cells) in blood on day 4, 6 and 8 following 
infection. (C) Percentage of OT-I cells (gated on CD8+ T cells) in spleen on day 8 after infection. LEC-
educated CD8+ T cells can induce cytokines and cytolysis-related molecules at levels similar to mDC-
educated CD8+ T cells. (D) Representative dot plots of OT-I cells in spleen showing IFN-γ (top plots), 
TNF-α (middle plots) and IL-2 (bottom plots) on y-axis and forward scatter on x-axis upon 5h ex vivo 
restimulation. (E) Percentage of IFN-γ+ and CD107+ cells (gated on OT-I cells) in spleen. (F) Percentage 
of single, double, triple positive cells for IFN-γ, TNF-α, and IL-2 in spleen. On day 8 after infection, most 
LEC-educated CD8+ T cells display effector phenotype , as well as a TCM-like subset at levels higher 
compared to mDC-educated cells. (G) Representative dot plots of OT-I cells displaying CD62L on y-axis 
and CD44 on x-axis (top), CD62L on y-axis and CD127 on x-axis (middle) and KLRG-1 on y-axis and 
CD127 on x-axis (bottom) in spleen. (H) Ratio of TCM (CD44+CD62L+) over Teff (CD44+CD62L-) cells 
(top) and ratio of short-lived effector cells (CD44+CD127-KLRG1+) over memory precursor effector cells 
(CD44+CD127+KLRG1-) in OT-I cells in spleen. LEC-educated CD8+ T cells not only contribute to CTL 
generation against infectious pathogens but also control bacterial load. Ex vivo generated LEC-
educated or mDC-educated or naïve OT-I CD8+ T cells were transferred in C57/Bl6 mice (5x104 total 
cells/mouse). Mice that did not receive any cells served as positive control (no transfer). 9 weeks after, 
mice were i.v. challenged with L.m.-OVA (104 cfu/mouse) and sacrificed 3 days later. Spleens were 
collected, homogenized and resuspended in sterile PBS. Different dilutions of the cell suspensions were 
generated, plated on BHI plates and incubated overnight at 37oC. The day after, cfu were counted and 
the amounts of L.m.-OVA were calculated with respect to the relative dilutions. (I) Left, representative 
images of bacterial culture plates for the differentially educated cells. Right, bacterial burden in spleen; 
the number of cfu in each group normalized to the one in the “no transfer” group. LEC-educated CD8+ T 
cells may give rise to a persistent memory subset upon challenge. To evaluate the formation of 
secondary memory, we assessed the expression of phenotypic markers in OT-I cells 3 weeks after 
challenge. (J) From left to right: ratio of TCM (CD44+CD127+CD62L+) over TEM (CD44+CD127+CD62L-) 
cells, percentage of TCM (CD44+CD62L+) cells, percentage of CD122+CD62L+ cells, in OT-I cells in the 
spleen (top) and LN (bottom). Pooled data from two independent experiments (B-I, n=10) or data from 
one experiment (J, n=5). *p≤0.05, **p≤0.01, ***p≤0.001 by one-way ANOVA (B) or by two-way ANOVA 
(F) followed by Bonferroni posttest or by two-tailed unpaired Student’s t test (C, E, H-J).  
did not produce any cytokine. Interestingly, there was a trend for a greater subset of 
double positive and triple positive cells (p=0.07) in LEC-educated compared to mDC-
educated. Furthermore, by assessing the actual cell number of the same subsets in 
LEC/mDC-educated cells, we observed a trend for more of the double positive cells 
in LEC-educated cells (Fig. 3.13C), suggesting that after ex vivo restimulation, LEC-
educated cells might generate more of the polyfunctional effector cells in absolute 
numbers. 
In agreement with our findings following in vivo antigen administration, on day 8 after 
pathogen infection, the majority of LEC-educated CD8+ T cells displayed a 
predominant effector phenotype (Fig. 3.7G, H). Most of the cells exhibited low levels 
of CD62L (CD44+CD62L-, CD127+/-) and analyzing their distribution with respect to 
KLRG-1 and CD127, the majority of cells were found in the TSLEC (KLRG-1+CD127-) 
subset. Remarkably, we also identified a noteworthy TCM-like (CD44+CD62L+) subset 
in LEC-educated cells at the peak of the immune response. Evaluating the ratio of 
TCM (CD44+CD62L+) over Teff (CD44+CD62L-), we remarked a consistent trend for 
this ratio to be significantly higher in LEC-educated cells than in mDC-educated cells 
(Fig. 3.7H, top). Along the same lines, the ratio of TMPEC (KLRG-1-CD127+) over TSLEC 
(KLRG-1+CD127-) was enhanced in the LEC-educated population compared to the 
relative ratio in DC-educated cells. Similar trends were observed in the LN (Fig. 
3.13D). 
Most importantly, LEC-educated CD8+ T cells not only contributed to the generation 
of effector CTLs against infectious pathogens but also controlled the bacterial load 
during infection with L.m.-OVA (Fig. 3.7I). To assess the protective capacity of LEC-
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educated cells, we adoptively transferred ex vivo generated (CD45.1.2) LEC-
educated or mDC-educated or naïve OT-I CD8+ T cells. Mice that did not receive any 
cells served as a positive control (no transfer). Nine weeks after, we challenged the 
mice with a high dose of L.m.-OVA and sacrificed them three days later to assess 
bacterial burden in the spleen. LEC-educated CD8+ T cells exhibited a trend for lower 
bacterial load compared to control mice, allowing for protection. Surprisingly, they 
also appeared to display greater protective capacity compared to mDC-educated 
cells, although the difference was not statistically significant. This might be attributed 
to the generation of greater numbers of polyfunctional effector cells in LEC-educated 
CD8+ T cells and it might be associated with the less differentiated state of the cells 
compared to the mDC-educated ones.  
The observation that LEC-educated CD8+ T cells manifested a persistent TCM-like 
(CD44+CD62L+) population at the peak of the infection raised the question whether 
LEC-educated cells might not only generate effector cells upon challenge but also 
give rise to a secondary TCM-like subset. In order to evaluate the establishment of a 
secondary TCM subset in LEC-educated CD8+ T cells, we assessed the expression of 
different phenotypic markers three weeks after the L.m.-OVA challenge in the spleen 
and LN, while we also tracked the transferred cells in the blood during this time. We 
observed that already between day 7 and day 9, the percentage of CD44+CD62L+ 
cells in the blood significantly increased in LEC-educated cells, with the subset being 
always greater than the relative one in mDC-educated cells (Fig. 3.13E, F). 
Interestingly, during this time period, the percentage of cytotoxic effector-like cells 
(CD44+GzB+) in the blood gradually decreased at the same rate between LEC and 
mDC-educated cells (Fig. 3.13F). This suggested that the increase in CD44+CD62L+ 
cells might be subset-specific and not an overall population trend. Furthermore, LEC-
educated cells in the spleen and the LN, presented a higher TCM (CD127+CD62L+) to 
TEM (CD127+CD62L-) ratio at this time point (Fig. 3.7J). Actually, this ratio was 
greater in the LN, where TCM cells preferentially home, with the TCM subset being the 
principal among antigen-experienced cells. We observed similar trends for the ratio 
of TCM over TEff as well as the ratio of TMPEC over TSLEC (Fig. 3.13G). In addition to 
that, there was a noticeable trend for a larger subset of CD44+CD62L+ in LEC-
educated compared to mDC-educated while the subset of CD44+CD62L+ cells that 
also expressed CD122 was significantly higher in LEC-educated cells both in LN and 
spleen. These data are consistent with our hypothesis that LEC-educated CD8+ T 
cells might also favor the maintenance of a secondary central memory-like subset 
following reactivation.  
Overall, our findings indicate that LEC-educated CD8+ T cells can participate in 
protective immunity, being at least equally potent to mDC-educated cells in fighting 
the infection. Additionally, memory-like LEC-educated CD8+ T cells might display 
self-renewing capacity, giving rise to a secondary memory persistent population. 
LN LEC-educated CD8+ T cells require CD28 costimulation and 
proinflammatory signals in order to generate polyfunctional effector 
cells 
Finally, we sought to determine the necessary signals for functional reactivation of 
LEC-educated CD8+ T cells. To this end, we replaced mDCs from our previous 
studies with an artificial APC system and assessed the response of LEC- educated 
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Figure 3.8 LN LEC-educated CD8+ T cells need to be reactivated in the presence of CD28 
costimulation and proinflammatory signals in order to generate functional effector cells. To 
determine the required signals for functional reactivation of LEC-educated CD8+ T cells, we assessed 
their response upon stimulation with an artificial APC, aCD3/CD28 system. OT-I CD8+ T cells were 
cultured in the presence of NPssCOVA250-264 (1nM) with LN LEC for 3 days (education). LEC-educated 
CD8+ T cells were then harvested, washed and cultured in the presence or absence of plate-bound anti-
CD3 (5μg/ml) and soluble anti-CD28 (2μg/ml). (A) Schematic of the assay. LEC-educated cells fail to 
induce polyfunctional effectors in the absence of costimulation. (B) From left to right: percentage of IFN-
γ+ and IL-2+ cells (gated on live cells) after 20h restimulation, as determined by intracellular staining 
followed by flow cytometric analysis. To evaluate the physiological conditions under which LEC-
educated CD8+ T cells may give rise to CTLs, we assessed their response following reactivation with 
immature DCs (iDCs) loaded with SIINFEKL (iDC-recall), in the presence or absence of different 
immunogenic (LPS, IFN-α and IL-12) or immunosuppressive (IL-10 and TGF-β) molecules or none of 
the aforementioned for 5h. (C) Schematic of the assay. Reactivated LEC-educated CD8+ T cells give 
rise to cytotoxic effectors only when reactivation takes place under inflammatory conditions. (D) From 
left to right: percentage of IFN-γ+ and GzB+ positive cells (gated on CD8+ cells) after reactivation with 
iDCs loaded with SIINFEKL. (E) From left to right: percentage of IFN-γ+ and GzB+ cells (gated on CD8+ 
cells) after 5h reactivation with iDCs in the absence of SIINFEKL. The data are representative from one 
of two independent experiments (n=3-4). ***p≤0.001 using two-way ANOVA followed by Bonferroni 
posttest. 
cells upon anti-CD3/CD28 stimulation. Ex vivo generated LEC-educated CD8+ T cells 
were cultured in the presence or absence of plate-bound anti-CD3 and soluble anti-
CD28 (Fig. 3.8A). LEC-educated CD8+ T cells that were stimulated neither with anti-
? ?
?
?????????????????
??????
?????????
?????????
????????????? ???
???????
?????????????
??
???
???
???
????
???
???
??
???? ???? ?????
?????
?
??
??
?? ???
???
?
?
?
?
?
??
???
???
??
???
??
???
????
???
???
??
???? ???? ?????
?????
?????????????????
?????
?????????
?????????
?????????????
???????
?? ????????
???????
?? ????????
??????????????????
??
???????
?? ????????
?????????????
?
??
??
??
??
???
???
???
?
??
??
??
??
???
???
???
?
??
???
???
???
??
??
? ??
???
??
??
??
??
???
??
??
?? ?
???
??
???? ??????????? ???????????????
???????
? ????????????????
?????? ??? ???
?
?
??
??
??
??
??
??
??
??
???
??
??
?? ?
???
??
?
??
??
??
??
??
???
???
??
???
???
???
??
??
?? ?
???
??
???
???
???? ??????????? ???????????????
???????
? ???????
?????? ??? ??? ??? ???
66 
CD3 nor with anti-CD28 (none) served as controls. After 20h, we observed that anti-
CD3 stimulation alone was enough to induce IFN-γ production, however, both anti-
CD3 and anti-CD28 were required to induce polyfunctional IFN-γ and IL-2 producing 
cells (Fig. 3.8B).  
We moved forward to investigate the physiological conditions under which LEC-
educated CD8+ T cells might give rise to CTLs. To address this question, we 
assessed their functional profile following reactivation with immature DCs (iDCs) 
loaded with antigen in the presence or absence of different immunogenic or 
immunosuppressive molecules. LEC/mDC-educated CD8+ T cells were cultured 
together with iDCs (iDC-recall), bearing or not the SIINFEKL peptide, in the presence 
of either LPS together with IFN-α and IL-12 or IL-10 together with TGF-β, or none of 
the aforementioned (Fig. 3.8C). Interestingly, reactivated LEC-educated CD8+ T cells 
gave rise to cytotoxic effectors only when reactivation took place under inflammatory 
conditions (LPS+IFN-α+IL-12)  (Fig. 3.8D). In contrast, they failed to induce 
functional effectors in a more suppressive setting (IL-10+TGF-β), as indicated by the 
lower levels of IFN-γ and the absence of GzB production. mDC-educated CD8+ T 
cells that were restimulated under the same conditions displayed similar trends; we 
observed decreased levels of effector cytokines in the presence of 
immunosuppressive molecules. However, the effect of the different treatments was 
much more pronounced in LEC-educated CD8+ T cells, which required 
proinflammatory cytokines in order to induce effectors producing noticeable levels of 
GzB. Importantly, restimulation with iDCs in the absence of the cognate peptide 
failed to induce significant levels of IFN-γ or GzB production in LEC-educated CD8+ T 
cells under any of the conditions described above. On the contrary, LPS with IFN-α 
and IL-12 stimulation was enough to induce both IFN-γ and GzB in mDC-educated 
CD8+ T cells, similar to conventional memory cells (Fig. 3.8E). Our observations 
suggest that LEC-educated CD8+ T cells might display a higher threshold of 
reactivation compared to conventional memory cells in order to display effector 
function. 
3.4  Discussion 
Recently, there has been mounting evidence on the active involvement of the 
lymphatic system in the regulation of immune responses. In addition to expressing 
self-antigens or scavenging and cross-presenting exogenous antigens on MHC I for 
the maintenance of peripheral tolerance, this study highlights a previously 
unanticipated role for LECs in immunomodulation: the generation of antigen-
experienced CD8+ T cells, which survive in an inactive state but can escape and be 
functional upon antigenic inflammatory challenge.  
The temporarily inert state of LEC-educated CD8+ T cells can be interpreted as an 
indication of tolerance or senescence and may act as a tolerizing mechanism against 
self-reactive T cells [Chapter 2 and (11)]. Our current findings do not challenge this 
notion but rather put it in a different perspective. We propose a model in which LECs 
constantly sample peripheral antigens present in the lymph, of both self and foreign 
origin. LECs then educate naïve antigen-specific CD8+ T cells to remain silent as 
apoptotic or dysfunctionally activated effectors, but also as surviving memory-like 
cells. This is until they are re-activated by professional APCs in the presence of 
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danger signals and/or proinflammatory cytokines. In this broader perspective, LN 
LECs can contribute to the maintenance of peripheral tolerance without eliminating 
antigen-specific CD8+ T cells from the T cell repertoire.  
The generation of antigen-experienced CD8+ T cells by LECs introduces the 
possibility that LECs may also participate in the induction of immunological memory. 
The ability of non-hematopoietic APCs to induce the formation of memory has been 
reported in an earlier study (50). The generation and persistence of long-lived 
immunological memory, which can provide life-long protection against pathogens is 
one of the hallmarks of adaptive immunity. It is intriguing to speculate that along with 
professional APCs, LECs educate CD8+ T cells to further supplement the memory 
pool following pathogenic infection.  
Our findings support this possibility, as LEC-educated CD8+ T cells displayed diverse 
molecules related to the development of TCM cells, such as CD62L, CD127 (IL-7R), 
CD122 (IL-2Rβ), CCR7, CD27, LFA-1 and CXCR3 (Fig. 3.3). The relative expression 
of some of the transcriptional regulators that are known to balance effector versus 
memory CD8+ T-cell development (51, 52), such as T-bet and Eomes, was also in 
favor of a TCM-like differentiation state in LEC-educated cells.  
Apart from the phenotypic and molecular characteristics, LEC-educated CD8+ T cells 
also manifested functional properties of TCM cells. Behaving similar to TCM cells, in 
accordance with their CD62Lhi phenotype, they preferentially migrated to secondary 
lymphoid organs (LN, spleen), in which they mainly preserved their CD44+CD62L+ 
memory-like phenotype (Fig. 3.4B-D). In addition to the specific homing pattern, we 
also observed that LEC-educated CD8+ T cells resided to particular locations inside 
the LN (Fig. 3.4E), distinct from naive cells, in which CD8+ TCM cells have been 
previously described to localize (48, 49): in the outermost regions of medullary, 
interfollicular, and subcapsular areas and beneath B cell follicles, at sites with 
potential direct contact with lymph-borne pathogens or infected cells under stready-
state (48) and/or during infection (48, 49). Interestingly, regulation of this localization 
pattern involved signalling via CXCR3 expressed on TCM cells (48, 49), a chemokine 
receptor also expressed in LEC-educated CD8+ T cells (Fig. 3.3).  
The ability to produce IL-2 is a well-established functional characteristic of central 
memory T cells (34, 46, 53).  Consistent with this, LEC-educated CD8+ T cells 
mounted proliferative responses and produced increased levels of IL-2 upon 
secondary stimulation in vitro (Fig. 3.5B-C). This was also in agreement with our in 
vivo data showing that LNSC-education might be involved in the induction of IL-2 –
producing cells (Fig. 3.1F-G). Furthermore, ex vivo generated LN FRC-educated 
CD8+ T cells, which also displayed a CD44+CD62L+ phenotype, however less 
polarized towards the TCM subset with lower levels of CD62L (Fig. 3.14A, B), failed to 
produce cytokines at levels similar to LEC-educated ones following reactivation (Fig. 
3.14C, D). In vivo inflammatory antigenic stimulation confirmed our in vitro findings 
and LEC-educated CD8+ T cells showed high proliferative and survival capacity, 
even when they had not encountered the antigen for long periods of time, a key 
characteristic of memory cells (Fig. 3.6). Most importantly, LEC-educated CD8+ T cell 
generated highly potent CTL effectors following pathogenic challenge with L.m.-OVA 
(Fig. 3.7B-F) and controlled the bacterial load providing protection to the host (Fig. 
3.7I). Interestingly, LEC-educated CD8+ T cells also appeared to sustain a persistent 
68 
secondary TCM-like population indicating that they may display self-renewing capacity 
(Fig. 3.7G-H, J and Fig. 3.13E-G).  
It follows that LEC-educated CD8+ T cells also displayed expression of molecules 
that are known to characterize the TSCM subset (Fig. 3.3), such as Sca-1, Bcl-2 and 
CD95 (44, 45, 54). TSCM cells share a lot of characteristics with naïve cells but they 
also have properties of antigen-experienced cells. More importanly, they can self-
renew and further differentiate into TCM and TEM cells (44). We observed that LEC-
educated CD8+ T cells underwent homeostatic turnover and displayed increased 
survival in response to IL-15 stimulation in vitro (Fig. 3.15B), an attribute of both TCM 
and TSCM cells (44, 55, 56). In contrast, Teff/EM-like, mDC-educated cells showed lower 
sensitivity to IL-15 signaling. Interestingly, following IL-15 dependent proliferation, 
LEC-educated cells retained their initial CD44hiCD62Lhi phenotype (Fig. 3.15C), 
which may indicate self-renewal capacity, whereas mDC-educated ones did not 
enhance their relative subset. Aditionally, Cieri et al. recently demonstrated the 
generation of T cells resembling the TSCM population by activating naive T cells with 
anti-CD3 and anti-CD28 antibody-conjugated beads in the presence of low doses of 
IL-7 and IL-15 (57), which are also produced by LN LECs.  
Nevertheless, the TSCM subset in mice has been only described in the setting of 
chronic antigen exposure (graft-versus-host disease, GVHD) (45) and it has not been 
yet identified in a traditional infection model. Instead, Graef et al. have recently 
demonstrated, conducting a set of very elegant serial single-cell adoptive transfer 
experiments, that adult tissue stem cells reside within the CD62L+CD44+ TCM cell 
subset (58). The TCM cells described in this study and ascribed stemness, displayed 
a similar phenotypic profile to LEC-educated CD8+ T cells being positive for CXCR3, 
CD122, CD27, CD127, T-bet and Eomes. Further studies should be performed to 
determine whether LEC-educated CD8+ T cells can exhibit multipotency and self-
renewal potential at the level of individual cells. 
The traditional model of CD8+ T cell differentiation dictates that, following pathogen 
elimination, a small percentage of antigen-specific CD8+ T cells survives to form the 
memory pool (59-61). Alternatively, the developmental model suggests that memory 
cells can arise directly from naive cells based on signal strength and the extent of 
activation (52, 62, 63). This model includes the generation of antigen-specific CD8+ T 
cells with a wide spectrum of differentiation states.  
Along this spectrum, cell differentiation and the acquisition of effector function are 
accompanied by the gradual loss of memory potential and longevity, leading 
eventually to senescence (52, 63). The unique differentiation state of LEC-educated 
CD8+ T cells finds its place in the intermediate range of the two extremes, that being 
TSCM/TCM cells and terminal effector T cells: LEC-educated CD8+ T cells appeared to 
be in a more differentiated position than TSCM cells, since they expressed CD44, 
while they also evidently differed from mDC-educated CD8+ T which displayed 
characteristics closer to an effector profile (Fig. 3.3).  
The divergence in differentiation states reflects the conditions under which CD8+ T 
cells are educated by LECs compared to those by professional APCs, such as 
mDCs. This is apparent in the molecular interactions between APCs and CD8+ T 
cells, such as the LEC education under low costimulation coupled with inhibitory 
signaling via the PD-L1 – PD-1 pathway [Chapter 2 and (7, 11)]. Antigenic 
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stimulation in the absence of costimulatory signals is traditionally considered to 
induce a tolerogenic outcome (23, 53). Besides costimulation, a variety of signals, 
including the strength of TCR, the duration of antigen exposure, the type of APCs, 
cytokines and many more factors regulate the outcome of T cell differentiation (64-
67). For instance, it has been shown that high levels of TCR stimulation can 
overcome the requirement for costimulation in the induction of efficient CD8+ T cell 
responses and the generation of memory (68).  
Furthermore, the conditions during LEC-education, as described above, may relate 
to the setting of reduced inflammatory signaling. Transient inflammation has been 
correlated to favoring a memory rather than terminal effector differentiation; IL-12 is a 
key regulator of effector T cell generation and can negatively regulate memory 
generation (25, 26) while low levels of IL-2 during priming have been associated with 
the induction of a memory rather than effector phenotype (27, 69). LEC-educated 
CD8+ T cells produce very low amounts of cytokines (IFN-γ, ΙL-2), as detected in the 
supernatant of LEC-CD8+ T cell cocultures [Chapter 2 and (11)], in which we have 
also failed to detect significant levels of IL-12 (data not shown). Moreover, CD25low 
CD8+ T cells have been shown to preferentially upregulate CD127 and CD62L 
generating long-lived memory cells (28). LEC-educated CD8+ T cells express CD25, 
though at lower levels compared to their DC-educated counterparts [Chapter 2 and 
(11)].  
Two cytokines, which are well known for mediating survival and self-renewal of 
memory CD8+ T cells, IL-7 and IL-15, have been previously shown to support the 
preferential generation of functional TCM (69, 70). While we are currently trying to 
evaluate their production by qPCR analysis, as we have not detected significant 
secreted amounts of IL-7 and IL-15 in the supernatant of LEC-CD8+ T cell cocultures 
(Fig. 3.10B), LN LECs have been demonstrated to be a primary source of IL-7, in 
human and mouse LNs, as well as IL-15, under steady-state and/or inflammatory 
conditions (71-74). All the above suggest that the conditions during LEC-education 
may support the generation of memory cells and thus, endorse our observations for 
the TCM-like differentiation state of LEC-educated CD8+ T cells. 
It is important to note that we observed an evident heterogeneity within the mDC-
educated population, displaying different levels of CD62L, similar to what has been 
previously demonstrated for mature DCs in the context of infectious inflammation 
generating a wide range of T cell subsets (52, 75). This may further explain some of 
the discrepancies in the expression of different phenotypic markers. However, the 
observed variation may be also related to the heterogeneity of the in vitro generated 
BMDC population itself (76). Nevertheless, the phenotypic and functional 
characteristics of LEC- and mDC-educated CD8+ T cells reflect distinct differentiation 
states, with the former approaching more TCM cells and the latter Teff/EM. 
LEC-educated CD8+ T cells do not replace, but add diversity to the memory T cell 
states. As much as they have in common, they differ in some functional properties of 
conventional TCM cells. Conventional TCM cells are known to produce IFN-γ upon 
stimulation with IL-12 (or IL-18) in the absence of antigen-specific TCR stimulation, 
as a bystander effect during inflammation (77-79). By contrast, LEC-educated CD8+ 
T cells failed to do so and instead, required the combination of TCR cross-linking, 
costimulatory signals and proinflammatory cytokines to generate functional effector 
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cells (Fig. 3.8). Although the need for CD28-mediated costimulation to induce 
memory recall responses has been under debate (68), our findings suggest that 
LEC-educated CD8+ T cells have a stricter threshold of reactivation and they appear 
to require all three signals, similar to naïve cells, to display effector function. Further 
mechanistic studies should be performed to quantify the reactivation threshold 
requirements in LEC-educated versus conventional TCM cells. Along the same lines, 
LSEC cross-primed CD8+ T cells required combinatorial signaling via TCR, CD28 
and IL-12 to exhibit functional effector function (17). In the setting of the iFABP-tOVA 
mouse model, in which CD8+ T cells are tolerized to OVA, OVA-specific OTI-I CD8+ T 
cells were reactivated upon VSV-OVA infection and the amount of antigen as well as 
the presence of virally-induced inflammatory signaling dictated the outcome of the 
reactivation (16). Such stringent prerequisites to reactivation may safeguard 
undesired reactions and restrict the harmful prospect of autoimmunity. 
At least two scenarios can be imagined for these antigen recognizing LEC-educated 
CD8+ TCM-like cells. They may be very important in containing systemic spread of 
antigen before innate immunity kicks in. Both viral and bacterial pathogens employ 
different strategies to avoid detection by the innate immune system, which can result 
in serious disease (80). Therefore, LEC-education may act as a reserve mechanism 
that spares pathogen-specific T cells in the absence of inflammation, while 
contributing to self-tolerance. A very similar function has been recently suggested for 
CD8+ T cells cross-primed by LSEC that share many common characteristics as non-
professional APCs with LECs (17). 
In addition, LEC-education may act as an early trigger for the generation of antigen-
experienced CD8+ T cells following an infection. Antigens arrive to the LN much 
earlier than the migrating DCs bearing the antigen. Early after vaccinia virus (VV) or 
vesicular stomatitis virus (VSV) infection, virions were reported to drain to the LN and 
infect cells resident in the SC region (50, 81), close to the interfollicular ridges, at the 
same location in which viral antigen was found to be archived in LECs (36). Being 
situated in one of the prime anatomical sites for antigen sampling, LECs may provide 
a supplementary pool of antigen-experienced T cells, awaiting to expand following 
interaction with professional APCs. When LNSCs could not participate in antigen 
presentation, we observed a significant decrease in CD8+ T cell proliferation, 
indicating that LECs may significantly contribute to the expansion of CD8+ T cells in 
an antigen-specific manner. Previous reports have also highlighted the contribution 
of antigen presentation by non-hematopoietic stromal cells in CD8+ T cell immune 
responses (50, 82, 83). Along with the pathogenic stimuli, differences in kinetics of 
the infection model as well as other parameters may balance antigen presentation by 
professional APCs versus LECs. In line with our hypothesis for an early trigger, 
radioresistant stromal cells were able to induce recruitment and activation of naïve T 
cells during the early stages of VV-OVA, VSV-OVA and L.m.-OVA infection, even 
though their sustained expansion examined at later time points was markedly limited 
(82).  
These differentiation states and the strict reactivation requirements are also 
consistent with the tolerizing role of cross-presenting LECs in the tumor stroma and 
tumor-draining LN, as we previously reported (10). In a VEGF-C-overexpressing 
tumor model, education by tumor-draining LN LECs resulted in the proliferation of 
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tumor-specific CD8+ T cells, which were dysfunctional and apoptotic, and thus, 
promoted tumor growth. Efficient reactivation of LEC-educated CD8+ T cells and 
subsequent generation of cytotoxic effectors would be quite unlikely due to the strong 
regulatory factors present in the suppressive microenvironment of the tumor-draining 
LN. On the contrary, the local microenvironment rather resembles the reactivation, 
which failed to induce functional IFN-γ and GzB expressing effector cells, as we 
described earlier in the presence of IL-10 and TGF-β. Alternatively, in the setting of 
chronic inflammation or following transplants, with the microenvironment being rich in 
inflammatory cytokines and danger signals, reactivation would likely favor the 
generation of cytotoxic effectors. Indeed, while still being under debate, 
lymphangiogenesis has been frequently associated with inflammatory diseases and 
transplant rejection (84, 85). 
Site-specific immune responses and antigen targeting to modulate T cell 
differentiation fate offer a potential therapeutic benefit in the design of prophylactic 
and therapeutic vaccines. Thus, a better understanding of the relative importance of 
CD8+ T cell education by LN LECs as opposed to professional APCs may be useful 
in identifying novel strategies to advance effective immunomodulation and pathogen-
specific immunity. LEC-education may allow the generation of antigen-specific CD8+ 
T cells with direct acquisition of memory characteristics, specific homing features and 
the ability to respond to boost immunization. In this context, it may be exploited to 
enhance protection against infectious pathogens and cancer.  
Our findings demonstrate a new role for LN LECs in the modulation of immune 
responses; exogenous antigen presentation by LN LECs can induce an expandable 
pool of memory-like T cells, leading to the generation of effector cells under 
inflammatory conditions to fight an ongoing infection while preserving a subset of 
long-lived memory cells to combat future pathogen encounter. In addition to the 
maintenance of peripheral tolerance via presentation of PTAs (7-9) or scavenged 
exogenous antigens (11) under homeostatic conditions and contact-dependent 
immunosuppression of APCs (86), LECs can also participate in anti-infectious 
immunity. Our work reveals the multifaceted function of LEC education and highlights 
its dynamic role in response to the local microenvironment for the regulation of 
immunity. These findings also help to explain and reconcile the seemingly 
contradictory effects of lymphangiogenesis in tumors versus chronic inflammatory 
diseases or transplants, with lymphangiogenesis being tumor-promoting while at the 
same time being associated with aggravation of chronic inflammation as well as 
transplant rejection (84, 85). As we begin to better understand the impact of antigen 
presentation by LECs in immunomodulation and unravel the various signals 
implicated, the new challenge that emerges is how we can harness this function to 
improve protection against pathogens and tumors, or to prevent autoimmunity and 
transplant rejection.  
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3.6 Appendix 
 
Figure 3.9 (Related to Fig. 3.1), LNSC-educated CD8+ T cells can induce expression of IFN-γ and 
IL-2 and the per cell expression levels of IL-2+ cells tend to be lower when stromal cells are 
excluded from CD8+ T cell priming. We generated BM chimeric mice using β2m-/- (β2 microglobulin 
knockout, lacking MHC class I) mice, as described in the Materials and Methods. Irradiated C57/Bl6 WT 
mice were reconstituted with β2m-/- BM to limit presentation of the Kb-restricted SIINFEKL epitope to 
radioresistant lymph node stromal cells (β2m:WT); Irradiated β2m-/- mice were reconstituted with BM  
from C57/Bl6 WT mice (WT:β2m)  to exclude LNSCs cells from antigen presentation; the relative 
(positive and negative) control mice (WT:WT, β2m: β2m) were also generated. Naïve CFSE-labeled OT-
I CD8+ T cells (CD45.1.2+) were transferred in the chimeric mice and one day after, the mice were 
vaccinated intradermally with OVA or saline control (PBS). 5 days after vaccination, the mice were 
sacrificed and the skin-draining LNs were collected. To determine the capacity of LNSC-educated cells 
to produce cytokines, the cells were ex-vivo restimulated with SIINFEKL peptide (or not) for 5h followed 
by intracellular staining for flow cytometric analysis. (A) Representative contour plots displaying IFN-γ 
top) or IL-2 (bottom) on y-axis and the side scatterer on x-axis, in the controls samples in which the cells 
were not restimulated with SIINFEKL (unpulsed controls). (B) Normalized mean fluorescence intensity 
(MFI) of IFN-γ+ cells (top) or IL-2+ (bottom) cells. The normalized MFI was determined as (MFIpulsed 
sample)/MFIunpulsed control. Representative data from one of two independent experiments (n=5).  
? ?
???
??
???
?
??
??
???
???
??
???
???
???
???? ? ??? ? ??????
?
?
?
?
?
???
???
??
?
???
???
??
??
???
??
???
?????????????????
???
???
???
???
???
???
???
??
???
???
??
??
???
??
????
??
???
??
???
???
????
??
???
??
???
???
77 
 
Figure 3.10 (Related to Fig. 3.3), LEC-educated CD8+ T cells display a particular phenotype with 
central memory-like and stem cell memory-like characteristics, distinct from the one of mDC-
educated cells. OT-I CD8+ T cells were educated in the presence of NPssCOVA250-264  (1nM) by LN 
LEC or mDC (education) or not educated (none). On day 3 of co-culture, LEC/mDC-educated CD8+ T 
cells were harvested, stained for different surface, intracellular and intranuclear markers and analyzed 
by flow cytometry. (A) Percent positive expression of surface markers (CD44, CD62L, CD127, CD122, 
CCR7, etc) or intracellular proteins (Bcl-2) or transcription factors (T-bet, Eomes) in naive CD44-CD62L+ 
(empty bars), CD44+CD62L+ LEC-educated (black bars), or CD44+CD62L- DC-educated (white bars) 
CD8+ T cells. (B) Low levels of IL-15 and IL-7 in the supernatant of LEC/mDC - CD8+ T cell coculures. 
Levels of IL-15 and IL-7 secreted in the supernatant (pg/ml), as assessed by ELISA. The CD44+CD62L+ 
phenotypic profile of LN LEC-educated CD8+ T cells is neither specific to the model antigen and TCR 
transgenic system used, nor it is dependent on the cross-presentation mechanism. (C) OT-I CD8+ T 
cells educated by LN LECs in the presence of SIINFEKL (1nM) display a similar phenotype to those 
educated in the presence of NP-ss-COVA250–264. Representative dot plots with CD44 on x-axis and 
CD62L on y-axis. (D) Representative histograms of various surface markers (CD127, CD122, CD27, 
CD43, CD95, Sca-1). (E) pmel CD8+ T cells educated by LN LECs in the presence of gp10025–33 peptide 
displayed a similar CD44+CD62L+ phenotype to OT-I LEC-educated CD8+ T cells in the presence of NP-
ss-COVA250–264. Representative dot plots with CD44 on x-axis and CD62L on y-axis and representative 
histograms of various surface and intranuclear markers (CCR7, CD127, CD122, T-bet). Representative 
data from one of three independent experiments (A, n=3) Representative data from one of three 
independent experiments (A, n=3) or out of two experiments (C-E, n=3). **p≤0.01, ***p≤0.001 by two-
way ANOVA (A) or one-way ANOVA (B) followed by Bonferroni posttest. 
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Figure 3.11 (Related to Fig. 3.4), Ex vivo generated LEC-educated CD8+ T cells mainly preserve 
their central memory-like phenotype after in vivo transfer, even when they migrate in the 
periphery. OT-I CD8+ T cells were educated in the presence of NPssCOVA250-264  (1nM) by LN LEC or 
mDC. After 3 days of coculture, ex vivo LEC/mDC-educated were transferred i.v. in C57/Bl6 WT mice. 
One week after the transfer, the mice were sacrificed; the liver and lungs were collected and analyzed 
by flow cytometry. The CD44+CD62L+ TCM-like subset dominates in LEC-educated cells in the liver and 
lung, even though at lower levels compared to LN. (A) Percentage of TCM (CD44+CD62L+) in OT-I cells 
in liver and lung. LEC-educated CD8+ T cells are more polarized to TCM-like rather than Teff/EM 
phenotype, in constrast to mDC-educated cells. (B) Ratio of TCM (CD44+CD62L+) over Teff 
(CD44+CD62L-) in OT-I CD8+ T cells. (C) Ratio of TCM (CD44+CD127+CD62L+) over TEM 
(CD44+CD127+CD62L+) in OT-I cells in liver and lung. Representative data from one of two independent 
experiments (n=3). *p≤0.05, **p≤0.01 by two-way ANOVA followed by Bonferroni posttest.   
 
 
 
 
 
 
 
Figure 3.12 (Related to Fig. 3.5), Following reactivation, LEC-educated CD8+ T cells exit the non-
responsive state and release high levels of cytokines. OT-I CD8+ T cells were cultured in the 
presence of NPssCOVA250-264 (1nM) with LN LEC or mDC for 3 days . LEC/mDC-educated CD8+ T cells 
were subsequently harvested and re-plated in the presence of mDCs (mDC recall), bearing (+Ag, white 
bars) or not (-Ag, black bars) the SIINFEKL peptide, for 24h. (A) Following mDC-recall, LEC-educated 
CD8+ T cells produce IFN-γ, TNF-α, as well as IL-2. The graphs (from left to right) display the levels of 
IFN-γ, TNF-α, and IL-2 (ng/ml) secreted in the supernatant of the 24h reactivation coculture, as 
assessed by ELISA. The stars on top of the bars indicate significant difference compare to -Ag control. 
Pooled data from two independent experiments (n=6). **p≤0.01, ***p≤0.001 by one-way ANOVA 
followed by Bonferroni posttest.  
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Figure 3.13 (Related to Fig. 3.7), LEC-educated CD8+ T cells can mediate protection against 
infectious pathogens while preserving a secondary memory persistent population. Ex vivo 
generated (CD45.1.2) LEC-educated were transferred together with (CD45.1) DC-educated CD8+ T 
cells a 1:1 ratio in C57/Bl6 mice (5x104 total cells/mouse). 5 weeks after, mice were i.v. challenged with 
L.m.-OVA (103 cfu) and sacrificed either on day 8 or 3 weeks after challenge. Cell suspensions of 
spleens and skin-dLNs were generated and analyzed by flow cytometry. (A) Percentage of OT-I cells 
(gated on CD8+ T cells) in LN on day 8 after infection. (B) Percentage of ΤΝF-a+ and IL-2+ cells (gated 
on OT-I cells) in spleen. (C) Counts of single, double or triple positive OT-I cells for IFN-γ, TNF-α and IL-
2 (D) Left, ratio of TCM (CD44+CD62L+) over Teff (CD44+CD62L-) in OT-I cells on day 8 after challenge in 
the LN. Right, ratio of short-lived effector cells (CD44+CD127-KLRG1+) over memory precursor effector 
cells (CD44+CD127+KLRG1-). A secondary memory-subset in LEC-educated CD8+ T cells persists upon 
challenge. In order to evaluate the formation of secondary memory in LEC-educated CD8+ T cells, we 
assessed their phenotypic profile 3 weeks after challenge. (E) Representative dot plots displaying 
CD62L on y-axis and CD44 on x-axis at different time points following challenge in the blood. The TCM
subset increases in LEC-educated CD8+ T cells after the peak of infection. (F) Top, percentage of 
CD44+CD62L+ cells in blood (gated on OT-I cells) at different time points following challenge. Bottom, 
percentage of CD44+GzB+ cytotoxic Teff-like cells (gated on OT-I cells) in blood. (G) Top, ratio of TCM 
(CD44+ CD62L+) over TEM/eff, (CD44+ CD62L-) in OT-I cells in spleen and LN on day 21 after challenge. 
Bottom, ratio of memory precursor effector cells (CD127+KLRG1-) over short-lived effector cells (CD127-
KLRG1+) in spleen and LN on day 21 after challenge. Pooled data from two independent experiments 
(A-D, n=5) or data from one experiment (E-G, n=5). **p≤0.01, by two-way ANOVA followed by 
Bonferroni posttest (C, F) or by two-tailed unpaired Student’s t test (D, G) 
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Figure 3.14 LN FRC-educated CD8+ T cells display lower levels of CD62L, compared to LEC-
educated ones, and fail to produce cytokines upon reactivation. OT-I CD8+ T cells were educated 
in the presence of NPssCOVA250-264  (1nM) by LN LEC or FRC (education) or not educated (none). After 
3 days of co-culture, LEC/FRC-educated CD8+ T cells were harvested, stained for different surface and 
analyzed by flow cytometry.  FRC-educated CD8+ T cells displayed a less «polarized» phenotype 
towards the TCM subset, compared to LEC-educated, with lower levels of CD62L. (A) Representative dot 
plots with CD62L on y-axis and CD44 on x-axis on day 3 of coculture. (B) Representative histograms 
displaying the expression of CD44 and CD62L for LEC-educated (pink line) and FRC-educated (green 
line) CD8+ T cells. FRC-educated CD8+ T cells failed to produce cytokines upon mDC-recall. LEC/FRC-
educated OT-I cells were harvested on day 3 of the coculture and re-plated in the presence of mDCs, 
bearing or not the SIINFEKL peptide. (C) Representative dot plots with IFN-γ on y-axis and forward 
scatter on x-axis after 5h restimulation with mDCs bearing the SIINFEKL peptide, as determined by 
intracellular staining followed by flow cytometric analysis. (D) Percentage of IFN-γ+, TNF-α+, and IL-2+ 
cells (gated on CD8+ cells). The stars on top of bars indicate significant difference with respect to naïve 
group. Data from one experiment (n=3). **p≤0.01, ***p≤0.001 by one-way ANOVA followed by 
Bonferroni posttest. 
 
Figure 3.15 LN LEC-educated CD8+ T cells display increased survival in response to homeostatic 
signals while retaining their phenotype. To determine whether LEC-educated CD8+ T cells have the 
capacity to self-renew in response to homeostatic signals, we evaluated survival, proliferation and 
phenotype of LEC/mDC-educated CD8+ T cells upon exposure to IL-15. OT-I CD8+ T cells were 
educated in the presence of NPssCOVA250-264  (1nM) by LN LEC or mDC. After 3 days of co-culture, 
LEC/mDC-educated CD8+ T cells were harvested, washed and subsequently cultured in the presence 
(+ IL-15) or absence (- IL-15) of IL-15 (100ng/ml). At different time points (24h, 48h, 72h), the cells were 
harvested and assessed for viability, proliferation (ki-67) and TCM–like phenotype (CD44+CD62L+) by 
flow cytometry. (A) Schematic of the experiment. LEC-educated CD8+ T cells undergo homeostatic 
turnover and display increased survival in response to IL-15 stimulation, whereas mDC-educated cells 
appear less sensitive to IL-15 treatment. (B) Left, fold change in live cells in groups treated with IL-15 
over non-treated, at different time points. Right, fold change in ki67+ cells in groups treated with IL-15 
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over non-treated, at different time points. LEC-educated CD8+ T cells preserve their TCM–like phenotype. 
(C) Percentage of CD44+CD62L+ cells in LEC-educated cells (pink) or mDC-educated (blue), treated 
(filled symbols) or non-treated (empty symbols) with IL-15. Stars indicate significant difference between 
groups at the specific time point. Data from one experiment (n=3). ***p≤0.001 by two-way ANOVA 
followed by Bonferroni posttest. 
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Chapter 4    
Investigating the contribution of 
antigen presentation by LECs in CD8+ 
T cell immune responses 
Lymph nodes (LNs) display remarkable enlargement during inflammation induced by 
pathogen infection or vaccination. The expansion and remodeling of the stromal 
elements has been previously claimed to accommodate the vigorous infiltration of 
lymphocytes and dendritic cells in the LN at the onset of the immune response. We 
asked whether proliferation of lymphatic endothelial cells (LECs) in the LN during 
inflammation might play a direct immunological role in the initiation of the response, 
via their antigen-presenting function. First, we demonstrated that LN LECs can 
perceive inflammatory signals, dynamically regulating their phenotype, and actively 
scavenge exogenous antigen under inflammatory conditions. To answer the 
questions raised, we pursued two different approaches to control the number of 
LECs. We exploited a VEGFR3 blocking antibody in order to inhibit LEC expansion 
following immunization with a subunit vaccine. However, it only partially induced LEC 
contraction and thus, minimally affected the frequency, phenotype and functional 
potential of antigen-specific CD8+ T cells. As an alternative approach, we developed 
the Prox1-Cre-DTR mouse model, which allows for specific ablation of LECs in vivo 
following administration of diphtheria toxin (DT). We attained local ablation of 
lymphatic vessels in the ear as we tried to optimize the conditions for LEC deletion in 
the LN. Our findings contributed towards the development of models to investigate 
the immunological significance of LEC expansion following inflammatory antigenic 
challenge and advanced our understanding of it. Nevertheless, further studies need 
to be performed, integrating the knowledge obtained here, in order to elucidate the 
active role of LN LEC in the establishment of adaptive immunity. 
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4.1 Introduction 
Lymph nodes (LNs) undergo considerable expansion during inflammation induced by 
infectious pathogen invasion or following vaccination. Lymphangiogenesis, the 
proliferation and remodeling of the lymphatic endothelium, has been widely observed 
in the LN draining the inflammatory site (1-5). Different cellular mediators, including 
immune and non-immune cells, orchestrate inflammatory lymphangiogenesis via the 
secretion of vascular endothelial growth factors (VEGFs) (6-8). Among them, VEGF-
C and VEGF-D bind to the VEGFR3 receptor, which is primarily expressed on the 
lymphatic endothelium (9). Inflammation-induced NF-κB signaling has been 
suggested to further amplify the lymphangiogenic signals by upregulating VEGFR-3 
expression on lymphatic endothelial cells (LECs) (10).  
This expansion of the stromal elements in the LN has been primarily attributed to the 
need to support the robust infiltration of lymphocytes at the onset of immune 
responses (11-13) and has been associated with enhanced DC migration and 
antigen drainage to the LN (14). Additionally, remodeling of the lymphatic structures 
has been shown to facilitate lymphocyte egress during prolonged inflammation at 
later stages of the immune response (15). However, it still remains unknown whether 
proliferation of LECs during inflammation might also actively influence the outcome of 
the response. Accumulating evidence suggests a direct immunological role for LN 
LECs during immune responses. Supporting this hypothesis, LN LEC proliferation in 
the course of a vaccine-elicited immune response was demonstrated to be 
necessary for antigen archiving in LECs, which subsequently led to enhanced long-
term protection (16).  
We have previously demonstrated that LN LECs can actively scavenge exogenous 
antigen under steady-state conditions for MHC class I presentation to CD8+ T cells 
[Chapter 2 and (17)], contributing to the generation of antigen-experienced CD8+ T 
cells. LN LEC-educated CD8+ T cells appear temporarily inactive but can be 
functionally reactivated following inflammatory antigenic challenge (Chapter 3). It is 
currently unclear whether LN LECs retain their capacity for antigen presentation 
under inflammatory conditions, and how they may interact with and impact the 
education of antigen-specific CD8+ T cells in this setting.  
Given our findings highlighting the active contributions of LN LEC-educated CD8+ T 
cells in protective immunity, we hypothesized that LEC expansion during 
inflammation might be directly associated with the initiation of the immune response 
and act as an additional determinant of its outcome. To explore this hypothesis, we 
exploited the model of CpG-induced inflammatory LN lymphangiogenesis, and by 
incorporating CpG in a subunit vaccine, we triggered robust CD8+ T cell responses 
while promoting significant LEC proliferation in the LN. 
In this model, we investigated the scavenging ability of LN LECs during inflammation 
and evaluated the expression of the antigen presentation machinery components in 
response to inflammatory signals to confirm their APC function in the course of an 
inflammatory immune response. We also determined the phenotypic profile of CD8+ 
T cells educated by LN LECs during inflammation, which was not significantly 
different from their homeostatic phenotype.  
85 
From here, we adopted two different strategies in order to evaluate the potential 
direct immunological function of LECs in the establishment of immune responses. 
We first exploited an anti-VEGFR3 blocking antibody to inhibit lymphangiogenesis 
following immunization and therefore, assess the impact of limited LEC-education in 
the outcome of immune responses. Alternatively, we attempted to identify the 
contribution of LECs in the induction of immune responses by evaluating the effect of 
their absence. To eliminate LECs, the LYVE-1-Cre-DTR mouse model had been 
previously developed for the ablation of LYVE-1 - expressing lymphatic vessels in an 
inducible, diphtheria toxin – dependent manner (18). However, following systemic 
diphtheria toxin administration, these mice died from sepsis due to distortion of blood 
capillaries in the intestine, induced by the loss of lymphatic lacteals. To counter the 
drawbacks of this model, we established the Prox1-DTR transgenic mouse model, in 
which Prox1-expressing LECs can be selectively ablated. Because of the potential 
lethality of a systemic ablation approach, we mainly focused on locally deleting LECs 
in the LN. Our findings provide valuable hints for the immunological significance of 
LN lymphangiogenesis and further studies on the established models might offer 
useful insight for the design of vaccines, as well as the treatment of inflammatory 
disorders.  
4.2 Materials and Methods 
Reagents  
All chemicals were from Sigma-Aldrich (Buchs, CH) unless otherwise noted. The mature 
MHC I epitope for ovalbumin, OVA256-264 (SIINFEKL) peptide, was from GenScript 
(Piscataway, NJ, US). The Endotoxin-free OVA was purchased from Hyglos GmbH, (Bernried 
am Starnberger See, DE). CpG-B 1826 oligonucleotide (CpG) was obtained from Microsynth 
(Balgach, CH). Recombinant murine IFN- γ was purchased from R&D systems (Abingdon, 
U.K.) and TNF-α from Invitrogen (Zug, CH). Diphtheria toxin (Corynebacterium diptheriae 
CALBIOCHEM) was acquired from Merck&Cie (Schaffhausen, CH). Tamoxifen (T5648) was 
purchased from Sigma-Aldrich (Buchs, CH) and was dissolved according to the 
manufacturer’s instructions. Antibodies used in flow cytometry were from eBioscience or 
BioLegend (Luzern, CH) unless otherwise noted. 
Mice 
The following mice strains were used in this study at age 6-12 weeks unless noted otherwise. 
Female C57BL/6 (CD45.2 or CD45.1 Ly5) wild-type mice and OT-I CD45.2 transgenic mice, 
(C57BL/6-Tg(TcraTcrb)1100Mjb/J), were purchased from Harlan Laboratories (Gannat, FR). 
Transgenic OT-I CD45.1.2 mice were a kind gift of the laboratory of Prof. Dietmar Zehn 
(CHUV) and were bred in our SPF facilities. Prox1-CreERT2 mice (Prox1-Cre mouse) were a 
kind gift of the laboratory of Prof. Tatiana Petrova (UNIL) and were re-derived and bred in our 
SPF facility. C57BL/6-Gt(ROSA)26Sortm1(HBEGF)Awai/J mice (DTR-Floxed mouse) were 
from Jackson Laboratory (Bar Harbor, ME, USA). All experiments were conducted with age- 
or sex-matched mice, with the exception of the experiments involving Prox1-Cre+/--DTR mice. 
Animals were housed in pathogen-free facilities and all procedures were approved by the 
Cantonal Veterinary Committee of Vaud, Switzerland (Protocol number 2687 and 2992). 
Cell lines 
Conditionally immortalized dermal LECs (iLECs; Immortomice) were isolated and cultured as 
previously described (19). Cell culture surfaces used in all assays were coated with collagen 
(10μg/ml PureCol; Advanced Biomatrix, San Diego, CA) and human fibronectin (10μg/ml, 
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Millipore, Billerica, MA) prior to seeding. Cells were grown in 40% DMEM low glucose, 40% 
F12, 20% FBS (all from Invitrogen, Zug, CH), supplemented with 10 μg/ml native bovine 
endothelial mitogen (AbD Serotec, Dusseldorf, DE) and 56 μg/ml heparin sodium salt from 
porcine intestinal mucosa (Sigma-Aldrich). To induce large T Ag expression, IFN-γ (R&D 
Systems, Abingdon, U.K.) was added to the media at 100U/ml, and cells were propagated at 
33 ̊C. Prior to all experiments, cells were grown for 72h in the absence of IFN-γ at 37 ̊C and 
maintained as such. 
Synthesis of OVA-conjugated nanoparticles (NP-OVA) 
For the immunization studies, poly (propylene sulfide)-nanoparticles (NPs) were synthesized 
by emulsion polymerization, surface-functionalized and characterized as previously described 
(20, 21). Endotoxin-free OVA was incubated overnight at room temperature with NPs in the 
presence of guanidinium hydrochloride (GndHCl, Sigma-Aldrich) and subsequently purified 
on a Sepharose CL-6B column (Sigma-Aldrich). OVA concentration on NPs was determined 
by BCA protein assay (Thermo Fisher Scientific, Waltham MA, USA). The size of NPs, before 
and after protein conjugation, was determined by dynamic light scattering with a Nano ZS 
Zetasizer (Malvern Instruments) and was measured in the range of 35-40nm. Endotoxin 
levels of antigens were routinely assessed by a colorimetric assay based on the HEK-Blue ™ 
TLR4 cell line (InvivoGen, San Diego, CA, USA) according to the manufacturer’s protocol 
using a standard curve generated from the E-Toxate ™ endotoxin standard (Sigma). 
Primary LEC isolation 
To obtain primary LN LECs, LNs were harvested and digested with 0.25mg/ml Liberase DH 
and 100µg/ml DNase (both from Roche, Basel, CH) to obtain a single cell suspension, and 
cultured as described (22). Cells were cultured for 5 days until confluent, detached by 
Accutase (Biological Industries, Kibbutz Beit-Haemek, Israel), and stained with mAbs against 
gp38 (clone 8.1.1), CD31 (clone 390), and CD45 (clone 30-F10) and FACS sorted (FACS 
Aria II, BD, Basel, CH) into the following subpopulations: FRCs (gp38+CD31-) LECs 
(gp38+CD31+), BECs (gp38-CD31+), and DN (gp38-CD31-) as described (23).   
CD8+ T cell purification 
Splenic CD8+ T cells from OT-I mice were isolated by immunomagnetic CD8 negative 
selection using the EasySep Mouse CD8+ T Cell Isolation Kit from Stemcell Technologies 
(Vancouver, BC, Canada) according to the manufacturer’s instructions.  
Adoptive CD8+ T cell transfer  
Following CD8+ T cell purification, cells were collected, washed in basal medium IMDM (Life 
Technologies, Carlsbad, CA, USA), and resuspended in 100μl volume prior to tail vein 
injection. To assess the effect of anti-VEGR3 treatment in the immune response, 106 naïve 
OT-I CD8+ T cells (CD45.1.2) were adoptively transferred into C57Bl/6 mice (CD45.2).  
Immunization studies  
In order to induce inflammatory lymphangiogenesis, mice were injected intradermally with 
15μg of CpG-B in all four limbs at a volume of 10μl/limb. As a negative control, saline (PBS) 
was administered instead.  The subunit vaccine, consisting of 10μg of NP-OVA and 10μg of 
CpG-B was also administered intradermally in all four limbs. To inhibit LEC proliferation, the 
mice received intraperitoneally 500μg of a VEGFR-3 neutralizing antibody (mF4-31C1, 
ImClone/Eli Lilly), or the isotype control IgG one day prior to vaccination. Where stated, 
repeat administrations were injected at 3-day intervals between injections. 
Tissue and cell preparation 
Spleens and LNs (brachial, axillary, inguinal, popliteal) were harvested and weighed at time of 
killing. For lymphocyte collection, LNs were digested for 45min, in DMEM supplemented with 
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1mg/ml collagenase D (Roche, Basel, CH). Single-cell suspensions were obtained by gently 
disrupting the spleen and LNs through a 70μm cell strainer. Spleen red blood cells were lysed 
by treatment with ammonium chloride–potassium bicarbonate (ACK) buffer for 4min. To 
obtain lymph node stromal cells (LNSCs), LNs were processed as previously described (23, 
24). Briefly, LNs were poked and slightly disrupted before digestion in DMEM (1.2mM CaCl2, 
2% FBS, Pen/Strep) containing collagenase IV (1mg/mL) and DNAse I (40µg/ml). This first 
fraction contained mainly CD45+ cells and was collected for lymphocyte analysis. Undigested 
cells were further digested with 1mg/ml Collagenase D and 40μg/ml DNase I (Roche). The 
reaction was stopped by addition of 5mM EDTA. Following digestion, single-cell suspensions 
were obtained by filtering through a 70μm cell strainer. Cells were subsequently counted, 
stained and analyzed by flow cytometry. 
In vivo antigen drainage during inflammation  
To determine whether LN LECs can actively capture Ags under inflammatory conditions in 
vivo, we injected fluorescently labeled OVA protein into the limbs of mice that had been 
pretreated with CpG, and determined its distribution within stromal cells. Endotoxin-free OVA 
was labeled with Alexa Fluor 647 NHS (OVA-AF647; Dyomics) and purified by size-exclusion 
chromatography using a Sephadex G-25 column with PBS as eluent. Five days after CpG 
administration, C57BL/6 mice were injected intradermally (i.d.) with 15μg OVA-AF647 in the 
limbs. After 90min, mice were transcardially perfused with a heparinized saline solution 
containing 1g/l glucose and 20mM HEPES (pH 7.2). Brachial LNs were collected for 
immunostaining and flow cytometric analysis. For flow cytometric analysis, brachial LNs from 
individual mice were pooled and processed as described above to obtain LNSCs. Cells were 
counted, stained with gp38, CD31, CD45, and analyzed by flow cytometry. 
Immunohistochemistry and confocal microscopy 
Mice were transcardially perfused with a heparinized saline solution containing 1g/l glucose 
and 20mM HEPES (pH 7.2). Brachial LNs were removed and fixed overnight in 2% PFA in 
PBS pH 7.4. After three washes in PBS, LNs were embedded in a block of 2% agarose, and 
sectioned (150µm) using a using a Vibratome (Leica, Wetzlar DE). Sections were blocked in 
0.5% of casein, and further labeled using antibodies against B220 (Invitrogen, Auckland, NZ, 
USA) and LYVE-1 (Reliatech, San Pablo, CA, US). Images were acquired on a Leica SP5 
confocal microscope using 20x or 60x objectives, and processed using Imaris software 
(Bitplane, Zürich, CH).  
In vitro LEC stimulation with inflammatory cytokines  
iLECs were incubated for 24h in the presence of IFN-γ (100ng/ml) or IFN-γ and TNF-α 
(10ng/ml). The cells were subsequently stained for CD40, CD86, MHC I and MHC II and 
analyzed by flow cytometry. 
In vitro CD8+ T cell education by LN LECs 
Naïve CD8α+ T-cells from OT-I mice were purified and directly cocultured with LN LECs in the 
presence of 1nM NP-ss-COVA250-264. When indicated, the following molecules were also 
added in the coculture media (IMDM with 10% FBS and 1% penicillin/streptomycin - all from 
Life Technologies, Carlsbad, CA, USA): IFN-γ (100ng/ml), IFN-γ (100ng/ml) and TNF-α 
(10ng/ml) or CpG-B (100ng/ml). More specifically, 104 LECs were cocultured with naïve OT-I 
CD8+ T cells in 96-well plates for 72h at a ratio of 1:10 APC:T cells in 200μl of co-culture 
media. Cells were then processed and stained for immunological markers to be analyzed by 
flow cytometry.  
Ex vivo restimulation 
Up to 3x106 cells were plated in 96-well plates and cultured in coculture media for 2h at 37°C 
in the presence of 1μg/mL SIINFEKL peptide, followed by additional 3h treatment with 
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brefeldin-A (BFA, 5μg/mL). Stimulation with PMA (50ng/ml) and ionomycin (300ng/ml) served 
as a control.  For CD107a staining, the monoclonal antibody against CD107a was added in 
the culture together with Monensin at 5μg/mL for 5 hours. Finally, cells were washed in PBS 
prior to intracellular staining for flow cytometric analysis.   
Ablation of LECs in vivo 
Prox1-CreERT2 mice were bred with Rosa26-DTR mice to generate Prox1-Cre-DTR mice. 
Prox1-Cre+-DTR mice, in which Prox1+ cells expressed the diphtheria toxin receptor (DTR), 
and the Prox1-Cre--DTR littermate control mice were injected intraperitoneally with tamoxifen 
(TAM) daily for 3-5 days to induce expression of the Cre recombinase, two weeks prior the 
beginning of the study for all studies. For systemic LEC ablation, the mice received 100ng of 
diphtheria toxin (DT) intraperitoneally and were sacrificed 24h later to assess the efficiency of 
ablation in the skin-draining LNs by flow cytometry. For local ablation of LECs in the LN, the 
mice received either 15ng of DT intradermally in the upper footpads and sacrificed 48h later, 
or 1ng of DT and sacrificed at 24h, 48h and 72h following DT injection. The draining LNs 
were collected and analyzed by flow cytometry to evaluate LEC-specific ablation. For local 
ablation of lymphatic vessels in the ear, the mice were injected with 1ng of DT intradermally in 
the top of the ear dorsal skin, administered with a Hamilton syringe. The mice received three 
doses of DT with a two-day and three-day interval respectively. Three days after the last 
dose, the mice were sacrificed and the ear skin was collected to determine the efficiency of 
ablation by flow cytometry. 
Lymphangiography 
To assess the ablation of lymphatic vessels in the ear skin of live mice, we performed 
lymphangiography with the use of a fluorescent agent, followed by live imaging. The mice 
were anesthetized with 50mg/kg ketamine and 10mg/kg xylazine before the procedure. The 
head and the ears of the Prox1-Cre+-DTR and the Prox1-Cre--DTR littermate control mice 
were depilated at the beginning of the study. Together with the administration of DT, the mice 
were injected with fluorescent streptavidin (SA-AF647) in the top of the ear skin and directly 
subjected to live imaging of the ear under a fluorescence stereomicroscope with a motorized 
stage (M250 FA, Leica Microsystems CMS GmbH, Wetzlar, DE) to visualize the network of 
the draining lymphatic vessels. 
Flow cytometry 
Cells were washed and stained with a cocktail of surface antibodies in staining buffer, 
consisting of HBSS (Life Technologies) supplemented with 0.5% bovine serum albumin. Cell 
viability was determined by propidium iodide incorporation in staining buffer (performed after 
surface antibody staining) or with live/dead fixable cell viability reagent (Life Technologies; 
performed according to manufacturer’s instructions before surface antibody staining). 
Apoptotic cells were identified by annexin V staining (BioVision, Milpitas, CA, USA). Pentamer 
staining for H-2kb-SIINFEKL-PE (Proimmune, Oxford, UK) was performed according to 
manufacturer’s guidelines. For VEGFR3 staining, the Goat Anti-Mouse VEGFR3 (Flt-4) 
polyclonal Antibody (R&D systems, Abingdon, U.K.) was used with donkey anti-goat 
secondary antibodies in AF647. For intracellular/intranuclear staining, cells were fixed and 
permeabilized with the Foxp3/Transcription Factor Fixation/Permeabilization kit 
(eBiosciences) according to the manufacturer’s instructions.  Cells were stained in 
permeabilization buffer with a cocktail of monoclonal antibodies. The following anti-mouse 
antibodies were used: CD40 (HM40-3), CD80 (16-10A1), CD86 (GL-1), MHC I (AF6-88.5), 
MHC II (M5/114.15.2), PD-L1 (MIH5), CD25 (PC61.5), CD69 (H1.2F3), CD4 (RM4-5), CD8a 
(53-6.7), B220 (RA3-6B2), CD11b (M1/70), CD11c (N418), CD62L (MEL-14), CD44 (IM7), 
KLRG-1 (2F1/KLRG1), CD127 (A7R34), CD45.1 (F20), CD45.2 (104), CD8 (53-6.7), CD3e 
(145-2C11), IFN-γ (XMG1.2), IL-2 (JES6-5H4), TNF-α (MP6-XT22), CD107 (1D4B), 
Granzyme-B (NGZB), ki-67 (SolA15). Finally, cells were resuspended in staining buffer and 
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analyzed by flow cytometry (CyAn ADP Flow Cytometer, DAKO). Data analysis was 
performed using FlowJo (v9.4, Tree Star Inc., Ashland, OR, USA).   
Statistical analysis 
Statistical analysis was performed using either unpaired Student’s t test, or two-way analysis 
of variance (ANOVA) followed by Bonferroni post-test with Prism software (Graphpad, San 
Diego, CA, US) unless otherwise stated. Results are shown as mean ± standard deviation 
with significance indicated as *p≤0.05, **p≤0.01, and ***p≤0.001.  
4.3  Results 
CpG-B induces inflammatory lymph node lymphangiogenesis 
In order to evaluate the direct effect of LN LEC proliferation in the induction and the 
outcome of immune responses, we employed a subunit vaccine model involving 
CpG-B as the adjuvant. We have previously observed that intradermal administration 
of the TLR-9 adjuvant CpG-B induces inflammatory LN lymphangiogenesis, 
characterized by a remarkable expansion of the LN coupled with increased 
proliferation and dynamic remodeling of the lymphatic structures in the draining LNs  
 
Figure 4.1 CpG-induced inflammatory lymph node lymphangiogenesis. Administration of the TLR-9 
adjuvant CpG-B induces remarkable cellular expansion in the draining LN (dLN) coupled with 
remodeling of the lymphatic structures. 15μg of CpG-B or saline (PBS) were intradermally (i.d.) 
administered in the footpads of C57Bl/6 mice. 5 days after, we collected the skin-dLNs. Cell 
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suspensions were generated and analyzed by flow cytometry. (A) Experimental timeline. (B) Brachial 
lymph node section stained with LYVE-1 (white), marking lymphatic structures, CD3 (red) marking the T 
cel zone and B220 (green) marking B cell follicles, acquired by confocal microscopy. Scale bar, 200μm. 
CpG administration results in significant expansion of the LN. (C) Weights of LNs isolated from saline- 
or CpG-treated mice. CpG administration leads to expansion of LNSC populations. (D) Representative 
dot plots showing the distribution of LNSC subsets (FRCs gp38+CD31-, LECs gp38+CD31+, BECs gp38-
CD31+, DNs gp38-CD31-) with gp38 on y-axis and CD31 on x-axis, gated on CD45- cells. (E) Number of 
LNSCs within indicated subsets (LECs, FRCs, BECs, DNs) in saline (white bars) and CpG (pink bars) 
treated mice. (F) Pie charts displaying the distribution of LNSC subsets (LECs, pink; FRCs, blue; BECs, 
green; DNs, purple) in saline and CpG-treated mice as a percentage of CD45- cells. Representative 
data from one of two independent experiments (n=4). *p≤0.05, **p≤0.01, ***p≤0.001, by two-tailed 
unpaired Student’s t test (C) or by two-way ANOVA followed by Bonferroni posttest (E). 
(dLNs). Indeed, five days following CpG administration in the footpads of C57Bl/6 
mice (Fig. 4.1A), we noted a significant expansion of the dLNs, accompanied by a 
noticeable increase in LYVE-1+ structures, as determined by confocal imaging of LN 
sections (Fig. 4.1B). The observed expansion in size for the CpG-inflamed LNs 
translated to increased weight compared to the LNs of saline-treated control mice 
(Fig. 4.1C). Flow cytometric analysis (Fig. 4.1D, E) demonstrated a significant, two-
fold, enhancement in the number of both LN LECs (determined as CD45-
gp38+CD31+) and fibroblastic reticular cells (FRCs, determined as CD45-gp38+CD31-
). The subset of blood endothelial cells (BECs, determined as CD45-gp38-CD31+) 
was only slightly affected while the one of double negative cells (DNs, CD45-gp38-
CD31-) appeared enlarged but non-significantly (Fig. 4.1D). Interestingly, when we 
analyzed the overall distribution of the four LNSC subsets as a percentage of CD45- 
cells in CpG-treated mice and compared to the one in control mice, the effect was 
much less pronounced, suggesting that the relative LNSC subset composition was 
maintained (Fig. 4.1F).
LN LECs can take up exogenous antigen under inflammatory conditions 
in vivo 
We have previously shown that LN LECs can scavenge exogenous antigen in vivo
under steady-state conditions [Chapter 2, (17)]. Here, we wanted to verify whether 
LECs in the CpG-inflamed LN would also exhibit such function.  
Figure 4.2 LN LECs take up exogenous antigen not only under steady-state but also under 
inflammatory conditions. Following i.d. injection into the footpads, inflamed LECs in the dLNs take up 
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OVA rapidly. 15μg of CpG-B or saline (PBS) were i.d. administered in the footpads of C57Bl/6 mice. 
Mice rested for five days before fluorescently-labeled OVA (OVA-AF647) was administered. 90 min after 
injection, the mice were sacrificed and skin-dLNs were collected. Cell suspensions of skin-dLNs were 
generated and analyzed by flow cytometry. Almost 3-fold higher uptake of OVA in LECs from CpG-
inflamed LNs. (A) Experimental timeline. (B) Representative dot plots with OVA-AF647 on y-axis and 
the forward scatter on x-axis showing OVA positive cells gated on gp38+CD31+ LECs in saline (PBS, 
middle) and CpG-treated (right) mice. As a negative control, LECs from an untreated mouse are shown 
(naïve, left) and served to set the gate for OVA+ cells. (C) The graph displays the percentage of OVA+ 
LECs in saline and CpG-treated mice. Pooled data from 2 independent experiments (n=5). *p≤0.05, by 
two-tailed unpaired Student’s t test. 
To address this, we administered fluorescently labeled OVA protein (OVA-AF647) i.d. 
in the footpad of C57Bl/6 mice that have been injected with CpG five days earlier 
(Fig. 4.2A). Flow cytometric analysis revealed OVA uptake by LECs in the CpG-
inflamed LN (Fig. 4.2B, C). More importantly, we observed that LN LECs (CD45-
gp38+CD31+) in the CpG-treated (CpG) mice more avidly internalized OVA-AF647 
compared to the LN LECs in saline-treated (PBS) control mice (Fig. 4.2C). Our 
findings validate that LN LECs can actively scavenge soluble exogenous antigen not 
only during homeostasis but also under inflammatory conditions. 
LECs in the CpG-inflamed LN retain the low levels of costimulation and 
further upregulate MHC II, PD-L1 and VEGFR3 
We have earlier demonstrated that Ag-specific interactions between LECs and CD8+ 
T cells result in activated CD8+ T cells, which appear temporarily inactive and display 
central memory-like characteristics [Chapter 3 and (17)]. Such an outcome was 
associated with the phenotypic profile of LECs characterized by high levels of the 
inhibitory ligand PD-L1 coupled to very low levels of costimulation. We asked 
whether the phenotype of LN LECs would be altered following CpG-administration. 
To this end, we assessed the expression of different costimulatory or coinhibitory 
molecules and receptors in LECs in the LNs of mice that had been treated with CpG 
five days earlier and compared it to that of control mice (Fig. 4.3A). Treatment with 
CpG only slightly affected the expression of the costimulatory molecules CD40, 
CD86 and CD80 in LN LECs (Fig. 4.3B, C), an effect that has been previously 
observed following administration of other adjuvants (25). More specifically, the 
expression of CD80 was three-fold increased relative to LECs from control saline-
treated mice, although low levels were detected (Fig. 4.3C). Interestingly, we 
observed a notable increase in the levels of the MHC class II receptor, the inhibitory 
ligand PD-L1 as well as the lymphatic endothelium receptor, VEGFR3. Taken 
together, LEC phenotype is influenced by CpG administration, in a fashion that is 
similar to our previous findings following direct interactions of LN LECs with CD8+ T 
cells in vitro [Chapter 2 and (17)].  
In previous studies, in which we had assessed the cytokine microenvironment of the 
CpG-inflamed LN using an ELISA multiplex system (data not shown), we have 
observed abundance of inflammatory cytokines, including high levels of IFN-γ and 
TNF-α. By incubating skin-derived immortalized lymphatic endothelial cells (iLEC) for 
24h in the presence of IFN-γ with or without TNF-a, we detected a similar phenotype 
to the one observed upon CpG treatment in vivo (Fig. 4.3D). We detected almost no 
expression of the costimulatory molecules CD40 and CD86 and increased levels of 
the MHC class I and II receptors following IFN-γ or combinatory IFN-γ plus TNF-a 
treatment. Taken together, our data suggest that the balance between costimulatory  
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Figure 4.3 Immune status of inflamed LECs. LECs in the CpG-inflamed LN retain the low levels of 
costimulation and further upregulate MHC II, PD-L1 and VEGFR-3. 15μg of CpG-B or saline (PBS) were 
i.d. administered in the footpads of C57Bl/6 mice. 5 days after, the mice were sacrificed and dLNs 
collected. Cell suspensions were generated and the expression levels of CD40, CD86, CD80, MHC 
class I, MHC class II, PD-L1 and VEGFR-3 were determined by flow cytometric analysis. (A) 
Experimental timeline. (B) Representative histograms for each marker in gp38+CD31+-gated LN LECs 
from PBS (black line) or CpG (pink line) treated mice. (C) Percentage of positive cells for each marker 
within gp38+CD31+-gated LN LECs from saline (white bars) and CpG (pink bars) treated mice. (D) 
Treatment of LECs with IFN-γ or IFN-γ and TNF-α induces increase in the expression of MHC I and 
MHC II but does not alter the expression of costimulatory molecules in vitro. iLECs were incubated for 
24h in the presence of IFN-γ (100ng/ml, blue line) or IFN-γ and TNF-α (10ng/ml, orange line). The 
expression levels of costimulatory molecules CD40, CD86, MHC I and MHC II were determined by flow 
cytometric analysis.  Representative histograms for each marker in gp38+CD31+-gated LN LECs. Solid 
gray line: isotype/FMO control. Representative data from one of two independent experiments (n=4). 
**p≤0.01, ***p≤0.001, by two-way ANOVA followed by Bonferroni posttest (C). 
and coinhibitory ligand expression in LECs is not altered under inflammatory 
conditions.  
The phenotype of in vitro LEC-educated CD8+ T cells is not altered in the 
presence of CpG or inflammatory cytokines 
We next sought to determine whether the phenotype of CD8+ T cells educated by 
inflamed LN LECs would be different than the one observed under steady-state 
conditions. To address this question, we cocultured OT-I CD8+ T cells with LN LECs 
in the presence of NP-ss-COVA250-264, as previously performed [Chapter 2 and (17)], 
adding IFN-γ, IFN-γ and TNF-α, or CpG in the coculture media (Fig. 4.4A). Following 
three days of coculture, we assessed the expression of different activation markers 
(CD25, CD44, CD69, CD62L) on the surface of LEC-educated CD8+ T cells. We 
failed to detect any remarkable differences in the expression levels of CD25, CD44 
and CD69 whether the cells were educated in the presence of IFN-γ, IFN-γ and TNF-
α or CpG (Fig. 4.4B), compared to being cultured in the presence of the antigen 
alone (none). Adding to that, LEC-educated CD8+ T cells cultured in the presence of 
IFN-γ or CpG displayed high levels of CD62L (Fig. 4.4C) with the percentage of the 
CD44+CD62L+ subset, among educated CD8+ T cells, being maintained at levels 
similar to those observed following incubation with antigen alone (Fig. 4.4C, D). 
Collectively, our findings indicate that the activation status and the central memory-
like phenotypic profile of LEC-educated CD8+ T cells are retained under inflammatory 
conditions. 
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Figure 4.4 The phenotype of in vitro LEC-educated CD8+ T cells is not altered in the presence of 
CpG or inflammatory cytokines. OT-I CD8+ T cells were educated by LN LEC in the presence of 
NPssCOVA250-264  (1nM) alone (black line) or together with either IFN-γ (100ng/ml, blue line), IFN-γ and 
TNF-α (10ng/ml, orange line) or CpG (100ng/ml, pink line). After 3 days of coculture, LEC-educated 
CD8+ T cells were harvested, stained for different surface markers and analyzed by flow cytometry. (A) 
Experimental timeline. The expression levels of activation markers in LEC-educated CD8+ T cells are 
not affected by the presence of inflammatory cytokines or CpG. (B) Representative histograms of T cell 
activation markers (CD25, CD44, CD69). Grey line: isotype/FMO control. (C) Representative flow 
cytometry dot plots with CD62L on y-axis and CD44 on x-axis on day 3 of the coculture in  LEC-
educated CD8+ T cells in the presence of NPssCOVA250-264 alone (none), or together with IFN-γ or CpG. 
(D) Percentage of TCM-like CD44+CD62L+ cells within LEC-educated CD8+ T cells. Representative data 
from one of two independent experiments (B, n=3) or data are from one experiment (C, D) n=3. 
The cellular composition of the stromal and hematopoietic compartment 
in the lymph node following immunization is not greatly affected by 
treatment with the anti-VEGFR3 blocking antibody 
Having confirmed that LN LECs can take up exogenous antigen under inflammatory 
conditions, as well as that the costimulatory/coinhibitory molecule balance on their 
surface is not reversed during inflammation, we moved forward to evaluate the direct 
impact of LEC-education in the induction of immune responses. For that purpose, we 
decided to employ a subunit vaccine model and exploit the anti-VEGFR3 antibody 
(aR3), which has been previously used in our laboratory and shown to reduce 
lymphangiogenesis in the context of solid tumors and ovarian follicles [(26, 27) and 
unpublished observations]. As a subunit vaccine model, we decided to combine the 
nanoparticle (NP) vaccine platform established in our laboratory (NP-OVA) together 
with the CpG-B adjuvant. This particular subunit vaccine induces remarkable 
expansion of the LN accompanied by robust CD8+ T cell responses, while LN LECs 
can also take up and process the NP-OVA formulation for MHC I presentation, as 
previously shown (20). 
We first sought to evaluate the effect of aR3 treatment on the cellular composition of 
the lymph node in the course of an immune response. We intraperitoneally 
administered the aR3 antibody or the IgG control into C57Bl/6 mice one day prior to 
intradermal immunization in the footpad with NP-OVA plus CpG-B. The mice 
received one more dose of the blocking antibody or the IgG control and were 
sacrificed five days after immunization (Fig. 4.5A) to analyze the cellular distribution 
in the dLNs. Immunofluorescence microscopy of LN sections demonstrated some 
noticeable changes in the morphology and organization of the lymphatic network 
following treatment with the aR3 blocking antibody (Fig. 4.5B), which might indicate a 
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Figure 4.5 Treatment with anti-VEGFR3 does not significantly affect the relative cellular 
distribution of stromal and hematopoietic cells subsets in the LN following immunization. The 
anti-VEGFR3 (aR3) antibody or IgG control antibody (500μg) were administered intraperitoneally (i.p.) in 
C57Bl/6 mice one day prior to i.d. immunization in the footpads with CpG-B (10μg) and NP-OVA(10μg). 
2 days after, the mice received a second dose of aR3 or IgG (i.p.). They were sacrificed 5 days after 
immunization and the dLNs were collected., Cell suspensions were generated and analyzed by flow 
cytometry. (A) Experimental timeline. (B) Popliteal LN sections from IgG or aR3 –treated mice stained 
with LYVE-1 (red) and gp38 (green), acquired by confocal microscopy. Scale bar, 150μm. (C) Weights 
of LNs isolated from IgG- (light orange) or aR3- (green) treated mice. Only slight changes were 
observed in the percentage and counts of LECs in response to aR3 treatment. (D) Pie charts showing 
the distribution of LNSC subsets, with respect to IgG or aR3 treatment, among CD45- cells, defined as: 
LEC (pink), gp38+CD31+; FRC (blue), gp38+CD31-; BEC (green), gp38-CD31+; DN (purple), gp38-CD31-. 
(E) Percentage of LECs, FRCs and BECs within CD45- cells in response to IgG (light orange bars) or 
aR3 (green bars) treatment. (F) Percentage of CD4 (CD4+) and CD8 (CD8+) T cells, B cells (B220+) and 
different antigen-presenting cell subsets (CD11b+, CD11c+MHC IIhi, CD11c+ MHC IImid) in live cells in 
response to IgG or aR3 treatment. The various cells subsets are defined as it follows: CD4+, CD3+CD8-
CD4+; CD8+, CD3+CD4-CD8+; B220+, CD3-B220+; CD11b+, MHC II+CD11b+; CD11c+MHC IIhi, CD11b- 
CD11c+MHC IIhigh; CD11c+MHC IImid, CD11b- CD11c+MHC IImid. (G) Counts of LECs in IgG- or aR3-
treated mice. (H) Percentage of ki-67 positive cells within LECs in response to IgG or aR3 treatment.  (I) 
The expression levels of the costimulatory molecules CD86 and CD80, the MHC class II receptor and 
the coinhibitory ligand PD-L1 in LECs are not altered with respect to aR3 treatment. Representative 
histograms of each marker within gp38+CD31+-gated LN LECs in IgG (light orange line) or CpG (green 
line) treated mice. Solid grey line: isotype/FMO control . Pooled data from two (C, n=8) or three 
independent experiment (F, n=11) or representative data from one out of two independent experiments 
(D-E, n=3; G-H, n=5). Two-tailed unpaired Student’s t test (C, G-H) or two-way ANOVA followed by 
Bonferroni posttest (D-F). 
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decrease in the density of LYVE-1 positive structures. However, systematic 
quantitative analysis should be performed in order to confirm those qualitative 
observations. We also detected a slight, non-statistically-significant, decrease in LN 
weight in mice treated with aR3 compared to the IgG-treated control mice (Fig. 4.5C).  
Modest changes were also observed in the frequency of LECs (gp38+CD31+) and the 
other LNSC subsets among CD45- cells in response to aR3 treatment (Fig. 4.5D, E). 
More specifically, we noted a small decrease in the percentage of LECs while FRCs 
(gp38+CD31-) and BECs (gp38-CD31+) appeared slightly enhanced; however, these 
changes were not statistically significant. We also failed to detect any alteration in the 
composition of the hematopoietic cell compartment; there were no differences in the 
frequencies of CD4 (CD4+) and CD8 (CD8+) T cells, B cells (B220+) or various 
professional antigen-presenting cell subsets (CD11b+, CD11c+MHC IIhi, CD11c+ MHC 
IImid) among all live cells (Fig. 4.5F) in aR3-treated relative to IgG-treated mice. 
Although VEGFR3 expression has been mainly known to be limited in the lymphatic 
endothelium in adult tissue, it has been also reported in activated macrophages (28) 
and specialized monocytic populations in the ocular region (29). Macrophages have 
been well described to drive lymphangiogenesis in inflamed tissues and dLNs via the 
secretion of VEGFs (7).  Surprisingly, we did not observe any significant changes in 
the subset of CD11b+ cells in response to aR3 treatment, but only slightly lower 
frequencies in aR3-treated mice (Fig. 4.5F, on the right). Further characterization of 
the macrophage subset in the inflamed LN, including the use of more detailed 
markers, might be necessary in order to verify our observations. Along with the 
observed trend for lower frequency of LECs in the aR3-treated mice, we further 
noted a trend for lower absolute LEC counts per LN (Fig. 4.5G) as well as lower 
levels of the ki-67 protein (Fig. 4.5H), which is indicative of cell proliferation. More 
specifically, while aR3 treatment reduced the number and proliferation levels of LECs 
by 11% and 20% respectively, relative to control-treated mice, none of these trends 
were statistically significant. Additional analysis of the phenotype of LN LECs in 
response to aR3 treatment revealed no effect in the expression of costimulatory 
molecules (CD86 and CD80), MHC class II receptor or PD-L1 (Fig. 4.5I). 
Although we observed a consistent trend for a slight contraction of the LEC 
population as well as a decreased proliferation rate, treatment with aR3 did not seem 
to significantly inhibit LN lymphangiogenesis following subunit vaccine immunization. 
Treatment with anti-VEGFR3 only moderately influences the induction 
and the functional outcome of the primary and secondary CD8+ T cell 
immune response 
Even though the effects of aR3 treatment in limiting lymphangiogenesis were mild at 
best, we attempted to evaluate its impact in the induction of immune responses. 
Yang et al. have very recently shown that FRC expansion in the LN following 
immunization relied primarily on trapping of naïve lymphocytes (13), while a  
pharmacologic inhibitor of VEGF-receptor signaling only partially affected the 
cellularity and proliferation of FRCs. Therefore, a variety of factors might affect the 
expansion of stromal cells in the dLN at the onset of immune responses and thus, 
mask the effects of aR3 treatment. However, we thought that we might still be able to 
detect its influence in the initiation of adaptive immunity, as reflected in antigen-
specific CD8+ T cells. To address this question, we adoptively transferred OT-I CD8+ 
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Figure 4.6 Anti-VEGFR3 treatment does not greatly impact the induction and the outcome of the 
primary CD8+ T cell immune response in an adoptive transfer model. CD45.1.2 OT-I CD8+ T cells 
(106 cells/mouse) were transferred i.v. in CD45.2 C57Bl/6 mice (day -2). The day after (day -1), aR3 or 
control IgG antibody (500μg) were administered i.p. After 24h, (day 0), the mice were immunized (i.d) 
with CpG-B (10μg) and NP-OVA (10μg) in the footpads. 2 days after immunization, the mice received a 
second dose of aR3 or IgG antibody (i.p.). The mice were sacrificed 5 days after immunization and the 
dLNs and spleen were collected. Cell suspensions were generated and analyzed by flow cytometry. The 
expansion and phenotype of OT-I CD8+ T cells following immunization is not altered in response to aR3 
treatment. (A) Experimental timeline. (B) Percentage of OT-I cells within CD8+ T cells in the LNs and 
spleen of IgG (light orange bars) and aR3 (green bars) –treated mice. (C) Number of OT-I cells. (D) 
Percentage of TCM-like (CD44+CD62L+CD127+), TEM-like (, CD44+CD62L- CD127+) and Teff-like 
(CD44+CD62L- CD127-) cells in OT-I cells in the LNs (left) and spleen (right) of IgG/aR3-treated mice. 
(E) Percentage of memory precursor effector cells (MPECs, CD44+KLRG-1-CD127+) among OT-I cells 
in the LNs and spleen of IgG/aR3-treated mice. The functional potential of OT-I CD8+ T cells is not 
substantially affected by aR3 treatment. The cells were subjected to 5h ex vivo restimulation with 
SIINFEKL peptide, followed by intracellular staining. (F) Percentage of IFN-γ+, TNF-α+, IL-2+ and GzB+ 
cells (in OT-I cells) in the LNs (left) and spleen (right) of IgG/aR3-treated mice. Pooled data from two (F, 
n=10) or three (B-E, n=15) independent experiments. *p≤0.05, using two-tailed unpaired Student’s t test. 
T cells (CD45.1.2) in C57Bl/6 (CD45.2) mice (day -2) one day prior to treating the 
mice with the aR3 or IgG control antibody (day -1). The adoptive transfer system was 
selected because it provides a larger number of easily traceable antigen-specific 
CD8+ T cells. We subsequently immunized the mice with the NP-OVA plus CpG 
subunit vaccine (day 0). Two days after immunization (day 2), the mice received a 
second dose of the aR3 or IgG antibody and we sacrificed the mice on day 5 after 
immunization to analyze the phenotype and function of the antigen-specific OT-I 
CD8+ T cells (Fig. 4.6A). The cellular expansion of OT-I CD8+ T cells following 
immunization was not altered in response to treatment with the aR3 antibody, as 
determined by analyzing the percent frequency of CD45.1+ OT-I cells in total CD8+ 
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cells (Fig. 4.6B), as well as in terms of absolute OT-I cell counts in the LN and spleen 
(Fig. 4.6C). Adding to that, we failed to detect any significant differences in the 
phenotype of OT-I cells in the LNs and spleen of IgG/aR3-treated mice (Fig. 4.6D, 
E). More specifically, we assessed the percentage of central memory-like (TCM, 
CD44+CD62L+CD127+), memory effector-like (TEM, CD44+CD62L- CD127+) and 
effector-like (Teff, CD44+CD62L- CD127-) cell subsets within OT-I CD8+ T cells in the 
LNs and spleen of IgG/aR3-treated mice and did not observe any significant 
differences between the two groups (Fig. 4.6D). Along the same lines, the 
percentage of memory precursor effector cells (MPECs, CD44+KLRG-1-CD127+) 
among OT-I CD8+ T cells in the LN and spleen of IgG/aR3-treated mice was similar 
(Fig. 4.6E). More importantly, the functional potential of OT-I CD8+ T cells was also 
not substantially affected by aR3 treatment (Fig. 4.6F).  Following ex vivo 
restimulation with the SIINFEKL peptide, the percentage of IFN-γ, TNF-α, IL-2 and 
GzB positive cells, among OT-I CD8+ T cells, in the LN was quite similar in IgG 
versus aR3-treated mice with a trend for lower levels of IFN-γ and TNF-α positive 
cells in the aR3-treated. We observed identical trends in the spleen, in which the 
frequency of IFN-γ – producing cells in aR3-treated mice was decreased by 
approximately 3% relative to IgG-treated mice.  
The next step was to determine whether aR3 treatment would impact the secondary 
immune response. The lower levels of IFN-γ positive cells might indicate a smaller 
pool of functional antigen-specific cells in aR3-treated mice. We speculated that the 
effect of aR3 treatment might be more pronounced following a recall response. To 
investigate this, we performed adoptive transfer studies following the same timeline 
described above, however this time, the mice received an additional dose of IgG/aR3 
on day 5 and were left to rest for approximately 6 weeks following immunization (Fig. 
4.7A). We then challenged the mice (day 45) with the re-administration of NP-OVA 
plus CpG (i.d.). We sacrificed the mice seven days after the challenge immunization 
and analyzed the cellular expansion and phenotypic profile of OT-I CD8+ T cells in 
the LN and spleen. Similar to our observations in the course of the primary immune 
response, we did not detect any differences in the frequency of OT-I cells (Fig. 4.7B) 
or the OT-I counts (Fig. 4.7C) in the LN and spleen between IgG and aR3-treated 
mice following secondary challenge. In addition to that, there was no noticeable 
difference in the distribution of the TCM, TEM, and Teff subsets among antigen-specific 
OT-I CD8+ T cells in the LN and spleen (Fig. 4.7D) of IgG/aR3-treated mice. The 
cytokine-producing capacity of OT-I CD8+ T cells following ex vivo antigen-specific 
restimulation was also analyzed and was not markedly affected by aR3 treatment. 
More specifically, the frequency of IFN-γ, IL-2 and GzB positive cells (among OT-I 
CD8+ T cells) in the LN was identical in IgG/aR3-treated mice with a non-statistically-
significant trend for lower levels of TNF-α positive cells in aR3-treated mice (Fig. 
4.7E). A similar trend, still non-significant, for a smaller compartment of IFN-γ and 
TNF-α expressing cells in aR3-treated mice was observed whereas we noticed a 
two-fold decrease in the percentage of IL-2 producing cells in the mice that received 
the aR3 antibody (Fig. 4.7F). Along with the lower frequency, we further noted 
decreased counts of IL-2 positive cells in terms of absolute numbers in the spleen 
(Fig. 4.7G). The smaller IL-2 positive subset might reflect a smaller memory 
compartment established after the primary immune response. 
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Figure 4.7 Treatment with anti-VEGFR3 only slightly influences the functional outcome of the 
secondary CD8+ T cell response in an adoptive transfer model. CD45.1.2 OT-I CD8+ T cells (106 
cells/mouse) were transferred i.v. in CD45.2 C57Bl/6 mice (day -2). The day after (day -1), aR3 or 
control IgG antibody (500μg) were administered i.p. After 24h, (day 0), the mice were immunized (i.d) 
with CpG-B (10μg) and NP-OVA(10μg). 2 days and 5 days after immunization, the mice received a 
second dose of aR3 or IgG (i.p.). The mice rested for 6 weeks before they were challenged with the 
administration (i.d) of CpG-B (10μg) and NP-OVA (10μg). 7 days after challenge the mice were 
sacrificed and the dLNs and spleen collected. Cell suspensions were generated and analyzed by flow 
cytometry. The cellular expansion and phenotypic profile of OT-I CD8+ T cells in a secondary response 
are not altered in response to aR3 treatment. (A) Experimental timeline. (B) Percentage of OT-I cells 
within CD8+ T cells in the LN and spleen of IgG (light orange bars) and aR3 (green bars) –treated mice . 
(C) Number of OT-I cells. (D) Percentage of TCM-like (CD44+CD62L+CD127+), TEM-like (CD44+CD62L- 
CD127+) and Teff-like (CD44+CD62L- CD127-) cells within OT-I cells in the LNs (left) and spleen (right) of 
IgG/aR3-treated mice. The cytokine-producing capacity of OT-I CD8+ T cells following a secondary 
challenge is not markedly affected by aR3 treatment. The cells were subjected to 5h ex vivo 
restimulation with SIINFEKL peptide, followed by intracellular staining. Percentage of IFN-γ+, TNF-α+, IL-
2+ and GzB+ cells (within OT-I cells) in the LNs (E) and spleen (F) of IgG/aR3-treated mice. (G) Number 
of IL-2+ OT-I cells in the LN and spleen of IgG/aR3-treated mice. Pooled data from two independent 
experiments (n=12). *p≤0.05, using two-tailed unpaired Student’s t test. 
We speculated that the adoptive transfer system might not allow us to clearly identify 
the differences between the aR3 and IgG-treated mice due to the great abundance of 
antigen-specific CD8+ T cells available and thus, hinder the impact of aR3 treatment 
in immune responses. Therefore, we performed similar studies analyzing the 
capacity, phenotype and functional potential of endogenous antigen-specific CD8+ T 
cells following primary immunization as well as secondary antigenic challenge. In the 
setting of a primary immune response (Fig. 4.8A), five days following immunization 
with the NP-OVA plus CpG subunit vaccine, we detected a non-significant trend for 
decreased levels of antigen-specific CD8+ T cells in the LN and spleen of aR3-
treated mice (Fig. 4.8B), as determined by staining with the H2kb-SIINFEKL 
pentamer. The absolute counts of pentamer positive cells in the LN and spleen 
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reflected the same trend (Fig. 4.8C). Analyzing the phenotype of the antigen-specific 
CD8+ T cells, we observed a significantly lower frequency of the TEM (CD44+CD62L- 
CD127+) subset in the LN of mice that received the aR3 antibody but not in the 
spleen (Fig. 4.8D). 
 
Figure 4.8 The expansion capacity, phenotype and functional potential of endogenous antigen-
specific CD8+ T cells are not remarkably altered in response to anti-VEGFR3 treatment following 
primary immunization as well as secondary antigenic challenge. The aR3 or the control IgG 
antibody (500μg) were administered (i.p.) in C57Bl/6 mice one day prior to i.d. immunization in the 
footpads with CpG-B (10μg) and NP-OVA (10μg). 2 days after immunization, the mice received a 
second dose of aR3 or IgG (i.p.). The mice were sacrificed 5 days after immunization and the dLNs and 
spleen were collected. Cell suspensions were generated and analyzed by flow cytometry. (A) 
Experimental timeline. (B) Percentage of antigen-specific cells (within total CD8+ T cells) in the LNs and 
spleen of  IgG (light orange bars) and aR3 (green bars) –treated mice, as determined by SIINFEKL-
pentamer staining. (C) Number of antigen-specific CD8+ T cells. (D) Percentage of TEM-like 
(CD44+CD62L- CD127+) cells in pentamer+ cells. Treatment with aR3 only moderately affects the 
phenotypic and functional profile of endogenous CD8+ T cells in a secondary response. The mice were 
treated as in (A), but 5 days after immunization, they received an extra dose of aR3/IgG (i.p.). The mice 
rested for six weeks before they were challenged with the administration (i.d) of CpG-B (10μg) and NP-
OVA(10μg) in the footpads. 7 days after the challenge immunization, the mice were sacrificed and the 
dLNs and spleen were collected. (E) Experimental timeline. (F) Percentage of pentamer+ cells (within 
CD8+ T cells) in the LNs and spleen of  IgG/aR3-treated mice. (G) Number of pentamer+ cells. (H)
Percentage of TEM-like (CD44+CD62L- CD127+) cells in pentamer+ cells.. (I) Percentage of MPECs, 
among pentamer+ cells . (J) Percentage of IFN-γ+ and CD107+ cells (within CD8+ T cells) in the spleen 
of IgG/aR3-treated mice. Data from one experiment (n=5). *p≤0.05, **p≤0.01, by two-way ANOVA 
followed by Bonferroni posttest (A-D, F-H, J or by two-tailed unpaired Student’s t test (I). 
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Along the same lines, seven days following secondary immunization (Fig. 4.8E), we 
noted a similar trend for reduced frequency of antigen-specific cells, among total 
CD8+ T cells, in the LN and spleen of aR3-treated mice (Fig. 4.8F) while the absolute 
counts of pentamer positive cells in the spleen were almost two-fold lower (Fig. 
4.8G). Adding to that, phenotypic analysis revealed that the TEM subset contracted 
both in the LN (by 29%) and spleen (by 40%) in mice that received the aR3 antibody 
relative to the IgG-treated ones (Fig. 4.7H). Together with that, the TMPEC 
compartment among pentamer positive CD8+ T cells was also decreased in the 
spleen of aR3-treated mice and a similar non-significant trend was observed in the 
LN (Fig. 4.8I). More importantly, following antigen-specific ex vivo restimulation, we 
observed that the percentage of IFN-γ and CD107 expessing cells (among CD8+ T 
cells) in the spleen of aR3-treated mice was reduced by 46% and 40% respectively, 
compared to control-treated mice (Fig 4.8J). Furthermore, similar observations were 
noted with regard to the expansion capacity, the phenotypic characteristics as well as 
the functional potential of antigen-specific CD8+ T cells when we employed a 
bacterial pathogen (Listeria monocytogenes – expressing OVA), instead of the 
subunit vaccine, for the secondary challenge immunization (data not shown). 
Collectively, our findings indicate that by using an adoptive transfer model, we did not 
manage to detect a notable effect of aR3 treatment in the outcome of the primary 
and secondary antigen-specific CD8+ T cell response following immunization with a 
subunit vaccine. Instead, studying the endogenous CD8+ T cell compartment 
suggested that the administration of the aR3 antibody might slightly limit LEC 
proliferation and subsequently result in a contracted pool of antigen-specific CD8+ T 
cells with decreased effector function potential upon secondary challenge. Although 
these studies give us a first hint for the direct immunological role of LEC proliferation, 
they still need to be repeated in order to confirm our findings. Further investigation is 
required to better understand how LEC expansion might be linked to antigen-specific 
CD8+ T cell proliferation and thus, determine the impact of LECs in the generation of 
adaptive immunity.  
Generation of the Prox1-DTR transgenic mouse model in which LECs 
can be selectively ablated 
Our second approach to evaluate the contribution of CD8+ T cell priming by LECs in 
the induction of an immune response was the generation of a mouse model that 
would allow selective deletion of LECs. We used the Cre/lox site-specific 
recombination system to establish and study such a transgenic mouse model. Our 
system involved the inducible diphtheria toxin receptor (DTR), part of the heparin-
binding epidermal growth factor-like growth factor, which has been established as a 
tool for conditional lineage ablation (30). Unlike primate cells, murine cells are not 
susceptible to diphtheria toxin (DT) due to the low affinity of DT for rodent heparin-
binding epidermal growth factor-like growth factor. Expression of DTR on the cell 
surface enables endocytosis of DT and subsequently, rapid apoptosis of the target 
cell. To obtain a model that allows for specific deletion of LECs, we crossed mice 
with the gene encoding the DTR downstream of a loxP- flanked transcriptional stop 
element in the Rosa26 locus (31) (Floxed mouse) to Prox1-CreERT2 mice (Cre 
mouse) (Figure 4.9). Prox1-CreERT2 mice express Cre recombinase under the 
control of the Prox1 promoter and the Cre enzyme is only active upon treatment with  
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Figure 4.9 Generation of the Prox1-DTR transgenic mouse model in which LECs can be 
selectively ablated. To evaluate the contribution of CD8+ T cell priming by LECs in the induction of 
immune responses, we sought to generate a mouse model that would allow selective deletion of LECs. 
Briefly, we crossed mice with the gene encoding the simian diphtheria toxin receptor (DTR) downstream 
of a loxP-flanked transcriptional stop element (Floxed mouse) to Prox1-CreERT2 mice (Cre mouse), 
which express Cre recombinase under the control of the Prox1 promoter. The expression of Cre 
recombinase in the Cre mouse is an inducible phenotype. The Cre enzyme is only active upon 
treatment with tamoxifen (TAM). In the progeny of interest, cells bearing the Prox1 promoter (LEC) 
express the DTR and are prone to toxin-induced apoptosis once exposed to DT (LEC ablation). 
Administration of tamoxifen is previously required to activate Cre recombinase in LECs. For our studies, 
we used mice of the Prox1-Cre+-DTRfl/fl genotype to achieve specific deletion of LECs and used the 
littermate mice that did not bear the Cre transgene (genotype: Prox1-Cre--DTRfl/fl) as controls.  
tamoxifen (TAM). Therefore, in the progeny of interest (Prox1-Cre+-DTRfl/fl), cells 
bearing the Prox1 promoter (LECs) express the DTR and are prone to apoptosis 
once exposed to DT (LEC ablation). Administration of tamoxifen is previously 
required to activate Cre recombinase in LECs. For our studies, we used mice of the 
Prox1-Cre+-DTRfl/fl genotype (Cre+-DTR mouse) to achieve specific deletion of LECs 
while the littermate mice of a Prox1-Cre--DTRfl/fl genotype, that did not bear the Cre 
transgene (Cre--DTR mouse), served as control.  
Administration of diphtheria toxin (DT) in Prox1-Cre+- DTR mice induces 
selective ablation of LECs but the mice do not survive more than 24-48h 
First, we sought to confirm the specific ablation of LECs in the generated Prox1-Cre+-
DTR mice. Cre+-DTR and the littermate Cre--DTR (Cre--DTR) control mice were 
injected with tamoxifen (TAM, 1mg) intraperitoneally, daily for 3-5 days to induce 
expression of the Cre recombinase. The mice rested for two weeks before we 
intraperitoneally administered 100ng of DT. The following day, the Cre+-DTR mice 
displayed a sub-lethal phenotype and therefore, we sacrificed all mice and collected  
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Figure 4.10 Phenotypic changes in the LN following diphtheria toxin (DT) administration in 
Prox1-Cre+- DTR mice suggest selective ablation of LECs but the mice do not survive more than 
24h or 48h following intraperitoneal or intradermal administration of DT, respectively. Cre+-DTR 
and the littermate Cre--DTR control mice were administered with tamoxifen (1mg, i.p.) daily for 3-5 days 
and rested for 2 weeks before they were i.p. injected with DT (100ng/mouse). Up to 24h later,  the mice 
were sacrificed and the skin-dLNs were collected. Cell suspensions were generated and analyzed by 
flow cytometry. (A) Experimental timeline. (B) Left, percentage of LECs (defined as gp38+CD31+) and 
FRCs (gp38+CD31-) among CD45-gp38+ cells. Right, percentage of apoptotic cells (AnV+) within LECs 
and FRCs. The population of LECs was selectively diminished 48h following local administration of DT 
while the cellularity of other LNSC subsets and hematopoietic cells in the LN was not altered. Two 
weeks after tamoxifen treatment, Cre+-DTR and Cre--DTR control mice were (i.d.) injected in the 
footpads with DT (15ng/mouse). The mice displayed sublethal phenotypes 48h after DT administration; 
they were sacrificed and the skin-dLNs were collected. Cell suspensions were generated and analyzed 
by flow cytometry. (C) Experimental timeline (D) Intestinal hemorrhage and abnormal liver morphology 
in Cre+-DTR mice. Images of the liver and abdominal contents of Cre--DTR and Cre+-DTR mice. (E) 
Representative dot plots showing the distribution of LNSC subsets (FRCs gp38+CD31-, LECs 
gp38+CD31+, BECs gp38-CD31+, DNs gp38-CD31-) gated on CD45- cells. (F) Percentage of LECs, 
FRCs and BECs among CD45- cells in Cre--DTR (empty bars) and Cre+-DTR (light blue bars) mice. (G) 
Percentage of B cells, CD4+ and CD8+ T cells and different antigen-presenting cell subsets (CD11b+, 
CD11c+ MHC IImid ) within CD45+ cells in response to DT treatment. Cell subsets are defined as follows: 
B220+, CD3-B220+; CD4+, CD3+CD8-CD4+; CD8+, CD3+CD4-CD8+; CD11b+, MHC II+CD11b+; 
CD11c+MHC IImid, CD11b- CD11c+MHC IImid. (H) Weight of LNs in Cre--DTR and Cre+-DTR mice. Data 
from one experiment (B, n=4; D-H, n=5). *p≤0.05, **p≤0.01by two-tailed unpaired Student’s t test (B, D-
H) or two-way ANOVA followed by Bonferroni posttest (G). 
the skin-dLNs (Fig. 4.10A). Flow cytometric analysis revealed a slight but insignificant 
decrease in the frequency of LECs (defined as gp38+CD31+) among CD45-gp38+ 
cells in the LN of mice bearing the Cre transgene (Cre+-DTR) compared to their 
counterparts in negative littermates (Cre-DTR, Fig. 4.10B left). We further observed 
an increase in the percentage of apoptotic cells in LN LECs of Cre+-DTR mice, as 
determined using the annexin V (AnV) marker for apoptosis. We also detected a 
slight but insignificant increase in the frequency of AnV+ FRCs in these mice (Fig. 
4.10B, right). In a similar model that had been also developed for the specific 
ablation of LECs using the LYVE-1 promoter (LYVE-1 - Cre/iDTR mouse), the 
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authors reported that the mice died without visible edema following systemic 
administration of DT (18). They discovered that ablation of LYVE-1+ intestinal lacteals 
destroyed the blood capillaries and deformed the structure of the villi, resulting into 
severe inflammation of the proximal part of the intestine. We speculated that this 
phenomenon may have been identically responsible for the poor health of the Prox1-
Cre+-DTR mice following systemic DT application, and therefore, we asked whether 
local administration of DT might induce LEC ablation without distortion of the 
intestinal barrier. To this end, two weeks after the last dose of TAM, we i.d. injected 
DT in the upper limbs of Cre+/--DTR mice at a dose of 15ng/mouse (Fig. 4.10C), 
based on previous publications reporting local ablation in a Cre-DTR system (32). 
The mice again displayed sub-lethal phenotypes, although this time, the symptoms 
appeared later, at 48h after DT administration.  Examination of the liver and 
abdominal contents revealed intestinal hemorrhage and abnormal liver morphology 
in Cre+-DTR mice whereas the organs appeared intact in the control Cre--DTR mice 
(Fig. 4.10D). Flow cytometric analysis of the skin-dLNs demonstrated specific 
ablation of LECs in Cre+-DTR mice (Fig. 4.10E, F). More specifically, the percentage 
of LECs, among CD45- cells, was decreased by 56% in Cre+-DTR compared to Cre--
DTR mice, whereas the percentage of FRCs and BECs was not altered (Fig. 4.10F). 
The specificity of LEC deletion was also confirmed by investigating the hematopoietic 
cell compartment; no significant changes were detected in the percentage of B cells 
(B220+), CD4 (CD4+) and CD8 (CD8+) T cells and different antigen-presenting cell 
subsets (CD11b+, CD11c+ MHC IImid) among live cells following DT treatment in Cre+/-
-DTR mice (Fig. 4.10G). Adding to that, the weight of the LN was not affected (Fig. 
4.10H). 
Local ablation of lymphatic vessels in the ear of Prox1-Cre+- DTR mice is 
achieved by local administration of low-dose DT into the ear skin 
Although we achieved specific ablation of LECs in Prox1-Cre+-DTR mice by local DT 
administration, the mice did not survive, probably due to systemic dissemination of 
DT and subsequent distortion of the intestinal barrier. We next attempted to minimize 
adverse side effects on the subject mice by optimizing the administered dose of DT, 
and opted for a lymphangiography-based approach to assess the presence of 
lymphatic vessels on a living mouse. This is accomplished by injecting a fluorescent 
protein into the ear skin, which is easily mounted onto a stereomicroscope, allowing 
for non-invasive assessment of lymphatic drainage function. This system provides 
the added advantage of enabling us to minimize the number of animals used, as 
lymphatic drainage of each ear is independent of the other ear, allowing us to 
administer multiple doses on the same subject, as well as examine effects in real 
time as the fluorescent protein was cleared. Two weeks after the last dose of 
tamoxifen, we injected (i.d.) 1ng of DT in the top of the ear of Cre+/--DTR mice mixed 
with a fluorescent streptavidin antibody (as the fluorescent protein) and directly 
performed live imaging of the ear of the anaesthetized mice under a fluorescence 
stereomicroscope (Fig. 4.11A). Streptavidin fluorescence (shown in green), being 
rapidly drained, illuminated the network of collecting lymphatic vessels (Fig. 4.11B, 
left column), demonstrating no differences between Cre--DTR and Cre+-DTR mice, 
as expected. The mice received two more doses of DT with a two-day and three-day 
interval respectively. Administration of DT was always followed by fluorescent 
streptavidin injection and live imaging. Three days after the second dose of DT, we  
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Figure 4.11 Ablation of lymphatic vessels in the ear of Prox1-Cre+-DTR mice by intradermal 
injection of low-dose DT into the ear skin. Cre+-DTR and the littermate Cre--DTR control mice were 
administered with tamoxifen (1mg, i.p) daily for 3-5 days. After 2 weeks, the mice were injected with DT 
(1ng) in the ear dorsal skin, 3 times with a 2-day and 3-day interval respectively. DT injection was 
coupled to administration of fluorescent streptavidin and followed by live imaging under the 
stereomicroscope to assess lymphatic vessel ablation (lymphangiography). 3 days after the last dose of 
DT, the mice were sacrificed and the ear skin was collected. Cell suspensions were generated and 
analyzed by flow cytometry. (A) Experimental timeline. Ablation of lymphatic vessels in the ear following 
local administration of low-dose DT in the ear skin. (B) Images of the ear skin upon administration of 
fluorescent streptavidin (green) before DT administration (left column) and 3 days after the second dose 
of DT (day 25) in control Cre--DTR (top row) and Cre+-DTR (bottom row) mice. The injection point is 
marked by increased fluorescence intensity on the bottom left corner of each image. (C) Left, 
percentage of LECs, FRCs and BECs among CD45- cells in the ear of Cre--DTR (empty bars) and Cre+-
DTR (light blue bars) mice 3 days after the last dose of. Right, percentage of LYVE-1+ cells among 
CD45- cells. Data from one experiment (n=3). *p≤0.05, **p≤0.01, by two-tailed unpaired Student’s t test. 
observed deletion of lymphatic vessels in the ear skin of Cre+-DTR mice while they 
remained intact in Cre--DTR mice (Fig. 4.11B, right column, bottom and top images 
respectively). This was indicated by the absence of drainage visualized by 
streptavidin fluorescence and its accumulation and leakage at the injection point 
(bottom left corner in every image). Three days after the last dose of DT, the mice 
were sacrificed and the ear skin was collected. Flow cytometric analysis validated the 
observed LEC ablation and demonstrated that the percentage of LECs among CD45- 
cells in the ear skin of Cre+-DTR mice was reduced by 45% compared to Cre--DTR 
ones, while the frequency of FRCs and BECs was not altered (Fig. 4.11C, graph on 
the left). Additionally, the percentage of LYVE-1 positive cells among CD45- cells was 
diminished in Cre+-DTR mice (Fig. 4.11C, graph on the right), in consistency with our 
analysis defining LECs as gp38+CD31+. Finally, lymphangiography performed at later 
time points demonstrated that lymphatic vessels had been completely regenerated 2 
weeks after the last dose of DT (data not shown). Although the live imaging assay 
clearly displayed the ablation of lymphatic vessels in response to DT treatment and 
the subsequent flow cytometric analysis confirmed our observations, those studies 
need to be repeated in order to confirm the validity of our findings. Together with our 
qualitative observations, quantitative analysis of the acquired images at different time 
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points might provide us with more accurate information with regard to the kinetics of 
DT-inducible LEC ablation.  
Low-dose local DT administration in Prox1-Cre+- DTR mice failed to 
induce ablation of LECs in the draining LNs 
The next step was to evaluate LEC ablation in the dLNs upon local administration of 
the same low dose of DT that induced deletion of lymphatic vessels in the ear skin. 
For that purpose, we injected (i.d.) 1ng of DT in the upper limbs of Cre+/--DTR mice, 
in which the Cre enzyme had been previously activated, and collected the dLNs 24h, 
48h and 72h after DT administration (Fig. 4.12A). Flow cytometric analysis revealed 
no significant differences in the percentage of LECs, as well as FRCs, among 
gp38+CD45- cells between Cre--DTR and Cre+-DTR mice at any of the different time 
points examined (Fig. 4.12B). We also failed to detect any changes in the absolute 
LEC counts between the two groups (data not shown). Our data show that, at non-
lethal DT dose levels that successfully led to local LEC ablation, insufficient DT 
remains to affect the LECs at the LNs. Therefore, while local depletion of LECs 
following local DT administration in the Prox1-Cre+-DTR model is feasible, further 
optimization is required in order to determine non-lethal yet effective doses for 
deletion of LECs within a greater region, including the injection site and the LN.  
 
Figure 4.12 Low-dose DT administration in the footpad of Prox1-Cre+- DTR mice failed to induce 
local ablation of LECs in the draining LNs. Cre+-DTR and the littermate Cre--DTR control mice were 
administered with tamoxifen (1mg, i.p.) daily for 3-5 days. The mice rested for 2 weeks before they were 
i.d. injected with diphtheria toxin (DT, 1ng/mouse) in the footpads. The mice were sacrificed at 24h, 48h 
and 72h after DT injection and the dLNs were collected. Cell suspensions were generated and analyzed 
by flow cytometry. (A) Experimental timeline. (B, C) Percentage of LECs (B) and FRCs (C) among 
gp38+CD45- cells in the LNs of Cre--DTR (empty bars) and Cre+-DTR (light blue bars) mice at 24, 48 
and 72h following DT administration. Data from one experiment (24h, n=3; 48h, 72h n=7). Two-way 
ANOVA followed by Bonferroni posttest. 
Once the model of LN LEC-specific ablation is established, we speculate it would be 
a very useful tool to evaluate how the absence of LN LECs might affect the outcome 
of the primary and secondary immune response. 
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4.4  Discussion 
Our previous studies have demonstrated that LECs can actively scavenge and cross-
present exogenous antigens for subsequent MHC I presentation to CD8+ T cells 
[Chapter 2 and (17)]. LEC-CD8+ T cells interactions under steady-state conditions 
result in the generation of antigen-experienced cells that remain temporarily inactive, 
however, they can be functionally reactivated following inflammatory antigenic 
challenge (Chapter 3). This suggests that, in addition to contributing to the 
maintenance of peripheral tolerance, antigen uptake by LN LECs might be also 
directly implicated in the induction of immune responses following infection. Here, we 
sought to better understand and interpret the impact of LEC-education in the 
generation of immunity. We first demonstrated that LN LECs can also take up 
exogenous antigen under inflammatory conditions in vivo and evaluated their 
phenotypic profile in response to inflammatory signals. Then, we showed that LEC-
education in the course of inflammation does not alter the phenotype of the educated 
CD8+ T cells. We employed a subunit vaccine model that triggers robust CD8+ T cell 
responses while inducing remarkable expansion of the lymph node, characterized by 
increased LEC proliferation. By using an anti-VEGFR3 blocking antibody, we 
attempted to inhibit lymphangiogenesis following immunization and thus, assess the 
impact of LEC-education in the outcome of immune responses. Treatment with anti-
VEGFR3 only partially limited LEC proliferation in the lymph node and thus, 
moderately influenced the expansion capacity, phenotype and functional potential of 
antigen-specific CD8+ T cells following primary immunization as well as secondary 
antigenic challenge. In an alternative approach, we generated the Prox1-DTR 
transgenic mouse model, in which LECs can be selectively ablated. We achieved 
local ablation of lymphatic vessels in the ear as we tried to optimize the conditions for 
LEC deletion in the LN, aiming to evaluate the impact of their absence in the 
induction of immune responses. 
LNs can undergo considerable expansion following pathogen infection or 
immunization, observed already at the early onset and further maintained after the 
peak of the immune response (11, 15), as well as under various inflammatory 
conditions, such as chronic inflammatory diseases or tumors (2, 3). Inflammation-
induced LEC proliferation, or lymphangiogenesis, is coupled to significant alterations 
in the lymphatic vessel network and orchestrated by different vascular endothelial 
growth factors (VEGFs) (4). Here, we exploited a subunit vaccine system, consisting 
of the model antigen OVA conjugated to our NP platform together with the TLR-9 
adjuvant CpG-B. Administration of CpG-B triggered a vigorous expansion of the LN 
draining the injection site (Fig. 4.1). The size and cellularity of the LN were markedly 
increased and accompanied by significant alterations in the lymphatic vessel 
network, as identified by LYVE-1 staining. Similar outcomes have been observed 
using other adjuvants to trigger LN expansion, such as complete Freund’s adjuvant 
(11), LPS (33, 34) or Montanide (13), as well as following infection with bacterial or 
viral pathogens (35, 36). 
Adding to our previous studies, demonstrating antigen uptake by LECs under steady-
state conditions [Chapter 2 and (17)], we showed that LN LECs, in mice previously 
treated with CpG, took up fluorescently labeled OVA early after intradermal 
injection in vivo (Fig. 4.2). Earlier studies on the presentation of self-expressed 
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antigens by LNSCs have demonstrated reduced expression of endogenous OVA in 
FRCs from PolyI:C-treated mice (25). However, here, we observed higher levels of 
OVA uptake under inflammatory conditions than during homeostasis. Previous 
studies have also reported that LNSCs, and LECs among them, responded quickly to 
the co-administration of the TLR-4 adjuvant LPS together with OVA antigen by 
upregulating the expression of molecules related to antigen-processing and antigen-
presentation pathways (34). Along the same lines, our data indicate that LECs can 
actively perceive and integrate inflammatory signals. Our findings are consistent with 
a recent study which reported that antigen co-administered with PolyI:C and anti-
CD40 was captured by LECs and persisted for more than three weeks following 
vaccination (16). Interestingly, antigen persistence was dependent on the TLR 
agonist used.  
The phenotype of LECs was altered following CpG administration. This might be 
attributed to direct sensing of the danger signal, since LECs express various 
members of the TLR family (25, 37, 38) as well as to indirect inflammatory signals 
released from TLR9+ cells. Treatment with CpG or in vitro stimulation with 
inflammatory cytokines, that are present in the CpG-inflamed LN, induced identical 
changes in the phenotype of LECs (Fig. 4.3). Following CpG treatment, we observed 
upregulation of the MHC class II receptor, the inhibitory ligand PD-L1 and VEGF 
receptor 3 in LN LECs. The increase in MHC II and PD-L1 is consistent with similar 
studies showing upregulation of the same molecules under various inflammatory 
settings (25, 34, 39-41). Inflammation-induced NF-κB signaling has been previously 
shown to activate VEGFR-3 transcription in cultured LECs (10). These data suggest 
that LECs are poised to sense inflammatory triggers and actively regulate the 
expression of key components of the antigen presentation machinery. However, the 
levels of costimulation in LN LECs remained low and were only slightly affected by 
CpG treatment, as previously reported following treatment with polyI:C (25) or in the 
presence of IFN-γ and TNF-α (39).  
The balance of costimulatory and coinhibitory molecules in LECs was not reversed 
under inflammatory conditions. This was reflected on the outcome of antigen-specific 
LEC-CD8+ T cell interactions in the presence of CpG or inflammatory cytokines; LEC-
educated CD8+ T cell retained their activation status and displayed high levels of 
CD62L (Figure 4.4), as observed under steady-state conditions in vitro. Taken 
together, our findings indicate that LN LECs constantly scavenge exogenous 
antigens, under both homeostatic as well as inflammatory conditions and thus, 
support the hypothesis for a dual role of LEC-mediated antigen presentation.  
The capacity of LN LECs to generate antigen-experienced CD8+ T cells might be 
directly linked to the previously discussed LEC proliferation, and subsequent LN 
expansion, following pathogen infection. We have mentioned earlier that CpG 
administration might increase VEGFR3 expression on the surface of LECs (Fig. 4.3). 
With the use of the anti-VEGFR3 blocking antibody (mF4-31C1), we attempted to 
inhibit LN lymphangiogenesis following immunization with a subunit vaccine and 
thus, evaluate the effect of the contracted LEC population in the elicited immune 
response. Treatment with the anti-VEGFR3 antibody is known to block exclusively 
the new lymphatic growth without abrogating the function of existing lymphatic 
structures (42). The cellular composition of the stromal cell compartment was not 
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greatly affected by anti-VEGFR3 treatment (Fig. 4.5). While we observed a 
consistent trend for a slight contraction of the LEC population among the 
independent experiments performed, which was not observed for the other stromal 
cells or the different cell subsets of the hematopoietic compartment, there were no 
statistically significant effects noted. This might be attributed to decreased efficiency 
of the blocking antibody with respect to our experimental setup. Alternatively, the 
inflammatory effects induced by the adjuvant portion of our subunit vaccine might 
have induced too strong a magnitude of a lymphangiogenic response that the 
selected dose or administration frequency of the anti-VEGFR3 antibody were unable 
to counteract. Despite being very effective in abrogating lymphangiogenesis in the 
context of a tumor at the same dose, as determined by studies performed in our 
laboratory [(26) and unpublished data], the setting of CpG-induced inflammation 
might require more radical treatment. More importantly, in addition to VEGFR3, 
VEGFR2-signaling has also been associated with inflammatory LN 
lymphangiogenesis (1, 7, 11) and the processed form of VEGF-C can also bind 
VEGFR2 (43). Additionally, B cells, as well as macrophages and neutrophils have 
also been associated with the expansion of the lymphatic network following 
immunization via expression and regulation of VEGF-A, which signals through 
VEGR2, or VEGF-D (1, 8, 11). Furthermore, medullary FRCs, which come to close 
contact with LECs have been suggested to promote the expansion of the lymphatic 
network by providing VEGFs (13). Therefore, other growth factors might also be 
implicated in CpG-induced inflammatory lymphangiogenesis and combinatory 
blocking might be required in order to impede it in a more potent way. However, anti-
VEGFR2 treatment can also inhibit angiogenesis and possible collateral effects 
should be taken into consideration. Additionally, Yang et al. recently demonstrated 
that expansion of FRCs in the LN following immunization was primarily determined 
by naïve lymphocyte trapping induced by DCs, while homeostatic T-cell proliferation 
efficiently induced FRC growth (13). Therefore, other than several growth factors, 
different features of the immune response might be also associated with the 
enlargement of the LN. 
We tried to evaluate how the observed mild contraction of LN LEC upon treatment 
with anti-VEGFR3 might influence the induction and the functional outcome of the 
primary and secondary CD8+ T cell immune response (Fig. 4.6, 7, 8). We first 
employed an adoptive transfer system for our studies presuming that it would allow 
for detection of antigen-specific CD8+ T cells to a greater degree and thus, enable us 
to better evaluate the impact of anti-VEGFR3 treatment. Treatment with anti-
VEGFR3 only slightly influenced the functional outcome of the primary and 
secondary immune response using the adoptive transfer model (Fig. 4.6, 7). We 
failed to detect any significant alterations in the expansion and phenotype of OT-I 
cells with respect to anti-VEGFR3 administration. However, we did observe a 
moderate decrease in the frequency of IFN-γ positive cells in the spleen following 
primary immunization (Fig. 4.6), as well as slightly lower IL-2 positive cells following 
secondary challenge (Fig. 4.7). Although the impact of anti-VEGFR3 treatment 
appeared quite moderate, those findings might be attributed to a smaller, or less 
competent, pool of early antigen-specific CD8+ T cells following the shrinkage of 
LECs’ population. Fewer proliferating LECs would mean fewer CD8+ T cells being 
educated by LECs. This would, in turn, result in fewer IFN-γ positive cells upon 
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primary immunization and subsequently, in the establishment of a smaller memory 
compartment and thus, fewer IL-2 producing cells upon secondary challenge. Under 
this view, one would expect the effector subsets to be also negatively influenced 
during the secondary immune response. We noticed a trend for lower IFN-γ and 
TNF-α positive cells in the LN and spleen of aR3-treated mice, which was, however, 
not statistically significant. We retrospectively considered that the advantage of the 
adoptive transfer system might actually smooth out the effects of anti-VEGFR3 
treatment in the establishment of immune responses; the abundance of antigen-
specific CD8+ T cells, being readily available in the LN and spleen following transfer, 
might actually decrease the sensitivity of our system. We turned to a non-adoptive 
transfer experimental setup, to evaluate the impact of blocking VEGFR3 signaling to 
the endogenous antigen-specific CD8+ T cell population (Fig. 4.8). We observed a 
lower frequency of the memory effector subset (TEM) upon subunit vaccination in the 
LN, as well as both in the LN and spleen following challenge immunization for the 
anti-VEGR3 – treated mice. More importantly, we also noted a decrease in the levels 
of cytolytic, IFN-γ and CD107a-expressing, effector cells in the spleen of anti-VEGR3 
– treated mice during the secondary immune response. Although these studies need 
to be repeated in order to confirm our observations, the data are consistent with our 
findings from the adoptive transfer setup while similar trends were observed when a 
bacterial pathogen was used for the challenge immunization. Most of the alterations 
in antigen-specific CD8+ T cell cellularity and phenotypic profile in response to aR3 
treatment were detected in the spleen; this is consistent with our current hypothesis 
for the generation of an early pool of antigen-specific CD8+ T cells. At the time points 
investigated in our studies, which are typically thought to model the peak rather than 
the early stages of the immune response, the antigen-experienced cells educated by 
LECs must have been reactivated by professional APCs giving rise to effector cells 
that exit the LN and head to the periphery. Also, corroborating evidence has recently 
emerged attributing more active roles to LECs in the generation of protective 
immunity. Tamburini et al. have recently demonstrated that vaccine-elicited antigen 
persistence in LN LECs was dependent on LEC proliferation and resulted in immune 
protection by circulating memory CD8+ T cells (16). Further investigation is required 
in order to conclude about the effect of limiting lymphangiogenesis on the generation 
of CD8+ T cell responses following immunization. Our studies indicate that the 
endogenous model appears more suitable to address the questions posed while the 
investigation should be extended to different time points upon vaccination. 
While blocking VEGFR3 might allow us to interpret the effect of LEC expansion 
following immunization and its contribution in the outcome of the immune response, it 
might also entail some side effects that could cloud the clarity of our observations. 
VEGFR3 is known to be expressed in activated macrophages (28) as well as other 
CD11b+ monocytic populations (29). Although, here, we have not detected any 
noticeable alteration in the CD11b+ subset in response to anti-VEGFR3 treatment, as 
well as to any other subset of the hematopoietic compartment, it is likely that our 
observations might have been indirectly affected by VEGFR3 blocking. Previous 
studies have demonstrated that blockade of VEGF-C/D dramatically reduces the 
infiltration of CD11b+/Gr-1+ macrophages in the dLN in the course of LPS-induced 
dermal acute inflammation while it downregulates lymph flow and inflammation 
resolution (7). Following infection or immunization, the afferent lymphatic vessels 
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expand to accommodate the increased migration of APCs (15) while HEVs increase 
in size and quantity to allow for the efficient circulation of naïve T cells (44). 
Alterations on those main routes for immune cell recruitment upon VEGFR3 
blockade will affect trafficking in and out of the LN and might influence our 
observations in terms of T cell cellularity at specific time lapses during the immune 
response. In a model of chronic inflammation in obliterative airway disease (OAD), 
inhibition of VEGFR3 signaling inhibited lymphangiogenesis and reduced infiltration 
of CD4+ T cells (45). Furthermore, the expression of VEGFR-3 on macrophages has 
been recently suggested to serve as a negative feedback mechanism to prevent 
excessive reaction following bacterial infection by regulating proinflammatory 
cytokine production (28). This suggests that ablation of VEGFR-3 ligand binding on 
macrophages might impact the microenvironment and thus, influence the phenotype 
and function of the elicited antigen-specific CD8+ T cells. Therefore, aside from 
limiting the extensive expansion of LECs, the usage of VEGFR3 might directly affect 
the function of immune cells as well as indirectly modify the kinetics of the elicited 
immune response. Those side effects should be taken into careful consideration 
when interpreting our findings with regard to LECs’ contribution in the initiation of 
adaptive immunity. 
In addition to abrogating inflammation-induced lymphangiogenesis in the course of 
an immune response, we also sought to specifically ablate LECs in order to assess 
their precise contribution in the development of immune responses. Lineage specific 
ablation has been a very useful means to investigate the role of FRCs in antiviral T 
cell responses and revealed an unprecedented function of FRCs in regulating B cell 
immunity (32). We generated the Prox1-DTR mouse model that allows for conditional 
LEC ablation in vivo (Fig. 4.9) by administration of diphtheria toxin. Systemic 
administration of DT in the Prox1-Cre+-DTR mice, as well as high dose of DT via 
intradermal injection, led to death 24h later while examination of the abdominal 
contents revealed intestinal hemorrhage and abnormal liver morphology (Fig. 4.10). 
There was no sign of systemic toxicity induced by DT per se, since the littermate 
control mice did not display any sign of disease. In a similar model, in which Cre 
recombinase is directed by the LYVE-1 promoter, administration of diphtheria toxin 
led to ablation of the intestinal lymphatic vessels and resulted in septic shock and 
death after 24h, due to dissemination of intestinal pathogens into the circulation (18). 
Taking into consideration that Prox1 is expressed by various cell types in different 
organs, including the lacteals and collecting vessels of the ileum and the liver (46), 
we sought to explore low-dose local administration of DT in order to achieve LEC 
ablation while preventing intestinal barrier distortion and subsequent death. 
Intradermal administration of DT in the ear skin resulted in successful deletion of 
lymphatic vessels in the ear (Fig. 4.11), which reappeared after two weeks with the 
mice displaying normal phenotypes during this time period. We have not yet 
managed to optimize local DT administration in the footpads to induce effective 
deletion of LECs in the dLNs (Fig. 4.12). However, the inducible selective ablation of 
lymphatic vessels in the ear is a very useful tool for functional assays involving 
lymphatic drainage and could be harnessed for our purposes of studying the 
immunological role of LECs in future studies. Our plan would be to immunize the 
mice with our subunit vaccine, following LN LEC-specific ablation, and subsequently 
assess the frequency, phenotype and functional potential of the antigen-specific 
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CD8+ T cells at different time points, early after vaccination as well as after the 
establishment of memory. As an alternative to this approach, we are currently 
considering the generation of a LEC-specific MHC I conditional knockout, in which 
the function of MHC I antigen presentation in LECs would be abolished, or specific 
antigen targeting to LECs coupled with the elimination of professional APCs in the 
LN. 
Adding to this, it would be challenging to further investigate how the anatomical 
location of LECs might reflect potential alterations in their immunological role. It has 
been already reported that LECs in the skin display phenotypic and functional 
differences compared to LECs in the LN (34, 47). In the context of endogenous self-
antigen presentation, Cohen et al. have shown that LN resident LECs display greater 
tolerogenic potential compared to LECs from peripheral tissues (48), as identified by 
the variability in PD-L1 expression as well as the levels of the tissue-restricted 
tyrosinase antigen. Variations have also been detected among the different 
anatomical subsets of LECs in the LN. Therefore, the microenvironment might 
actively control the diverse immunomodulatory aspects of LECs. This also introduces 
the possibility of diverse dedicated LEC subsets, which display plasticity and shape 
their immunological function depending on localization. Other than the diversity of 
environmental factors with respect to location, the anatomical positioning is also 
coupled to differential interactions with immune cells. Thus, location might actively 
influence the impact of immunological modulation by LECs.  
Taken together, we explored two different approaches aiming to illuminate the 
physiological role of antigen-presentation by LN LECs and its impact in the 
establishment of adaptive immunity following inflammatory antigenic challenge. Our 
studies were focused on a setting of acute inflammation, with direct LN hyperplasia 
following immunization and resolution of the response later on. We have 
demonstrated that LN LECs can actively scavenge exogenous antigen in an 
inflammatory setting integrating signals from their microenvironment and we have 
some first evidence about how limiting LN LEC proliferation in the course of subunit 
vaccine immunization might affect the immunological outcome of the elicited 
response. However, our findings might be altered in the setting of a chronic 
inflammatory disease; it is well established that LEC expansion might have different 
functional consequences with respect to the site and time frame during inflammation. 
The developed Prox1-Cre-DTR mouse model provides an additional tool in 
determining the direct role of LECs in the generation of immunity and the 
establishment of immunological memory. Integrating the knowledge acquired here in 
the implementation and design of our ensuing studies will allow us to fully address 
the questions raised with potentially valuable implications for the design of future 
vaccines. 
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Chapter 5    
Conclusions, implications and future 
directions 
Throughout this thesis, we explored the immunological role of lymphatic endothelial 
cells (LECs) with regard to their direct involvement in the induction of immunity and 
tolerance. We focused on the presentation of exogenous antigens on MHC I by LECs 
and investigated the immunological outcome of their subsequent interactions with 
CD8+ T cells. Our findings reveal previously unknown roles of LECs in CD8+ T cell 
immunity and highlight the diverse aspects of LECs’ contribution in 
immunomodulation. 
5.1 Deciphering the physiological significance of antigen 
presentation by LECs and reconciling their seemingly 
contradictory functions 
When we sought to investigate the immunological role of LECs, the dominant 
perspective and emerging evidence strongly implicated LECs in the impairment of 
immune responses. First, various LEC-driven inhibitory mechanisms, mostly indirect, 
were demonstrated to abrogate the induction of effector CD8+ T cells under steady 
state or inflammatory conditions. The endogenous expression of peripheral tissue-
restricted antigens (PTAs) in LECs and more importantly, their presentation to CD8+ 
T cells for the induction of deletional tolerance (1) was reported around the same 
time, to establish LECs as mediators of peripheral tolerance. Subsequently, the 
ability of LECs to cross-present tumor-derived antigen, resulting in suppression of 
anti-tumor CD8+ T cell responses, was revealed, opening new questions about a 
similar role for LECs during homeostasis.  
Different pieces of evidence support the concept of LECs as complementary 
gatekeepers of peripheral tolerance via the presentation of exogenous antigens. 
Their anatomical position renders LECs as very suitable candidates for 
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immunological sampling. The lymph, which constantly drains from the periphery to 
the lymph nodes (LNs), contains peptides and proteins, derived from tissue 
homeostatic turn-over (2, 3). We hypothesized that LECs, being the first to encounter 
those antigens upon their arrival in the LN, might be able to capture and cross-
present them to subsequently tolerize self-reactive CD8+ T cells. Medullary and 
cortical LECs come to close contact with naïve T cells as they enter and exit the LN 
lumen, while subcapsular sinus LECs might intimately interact with naïve T cells 
reaching the LN via afferent lymphatics. Thus, we speculated that LECs might mimic 
the function of immature DCs under non-inflammatory conditions and, similarly to 
other non-hematopoietic antigen presenting cells (APCs), safeguard the 
uninterrupted preservation of peripheral tolerance. 
Our findings were in agreement with our hypothesis; LEC-educated CD8+ T cells 
proliferated, bearing features of an activated state, but displayed early-generation 
apoptosis and failed to produce effector cytokines. This indicates that antigen 
presentation by LECs under steady state conditions might assist peripheral tolerance 
against draining peripheral self-antigens. In agreement with the earlier studies, our 
observations reaffirm the concept of LECs’ implication in the regulation of immunity, 
this time via the cross-presentation of exogenous antigens.  
Supplementation of the LEC- CD8+ T cell cocultures with exogenous IL-2 did not 
reverse the dysfunctionally activated phenotypes, indicating that LEC-educated CD8+ 
T cells are not merely exhausted. Motivated by relevant findings with liver sinusoidal 
endothelial cells (LSECs), showing that initially “tolerized” CD8+ T cells, primed by 
cross-presenting LSECs, were reactivated under viral challenge (4), we asked 
whether LEC-educated CD8+ T cells could exit the non-responsive state. In depth 
investigation of the functionality of LEC-educated CD8+ T cells demonstrated that the 
cells can survive in an inactive state with the ability to escape and become functional 
upon antigenic inflammatory challenge. More specifically, the antigen-specific CD8+ T 
cells, educated by LECs under steady state conditions, displayed phenotypic and 
functional memory-like features and gave rise to cytotoxic effector cells following 
secondary antigen encounter. Importantly, in the setting of a bacterial infection, LEC-
educated CD8+ T cells participated in host’s protection and further preserved a 
secondary-memory persistent population. Our data point to an additional role of 
antigen-presentation by LECs; that of a potential safety mechanism which might 
complement immune responses when required. These unexpected findings do not 
contradict our earlier observations for the contribution of LECs in the maintenance of 
peripheral tolerance. The reactivated cells only gave rise to cytotoxic effectors when 
stimulated under inflammatory conditions and failed to do so in the presence of 
immunosuppressive molecules. Our studies indicate that the requirements for the 
functional reactivation of LEC-educated CD8+ T cells are similar to the ones for naïve 
cells, preventing the possibility of harmful responses and the induction of 
autoimmunity. Additional mechanistic studies are needed in order to better 
characterize, qualitatively and quantitatively, the reactivation threshold in LEC-
educated compared to conventional antigen-experienced or naïve CD8+ T cells. 
Furthermore, we still cannot predict what would be the outcome of CD8+ T cell 
education against self-antigens, which might also drain to the LN during inflammation 
and how tolerance would be maintained in this setting. 
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While our studies have been mainly focused on CD8+ T cell education by LECs 
under steady state conditions, an evident question is whether LECs alter their 
behavior during inflammation, induced by pathogen infection or immunization. We 
demonstrated that LN LECs can also take up exogenous antigen under inflammatory 
conditions in vivo. Their phenotypic profile, in terms of immunological marker 
expression, was altered suggesting that LECs are prone to sense inflammatory 
triggers. We observed higher levels of per cell expression of MHC class I, however, 
we did not observe any significant alterations on the phenotypic profile of LEC-
educated CD8+ T cells in response to inflammatory or danger signals. 
In light of our findings, we suggest a model in which LECs can constantly sample 
peripheral antigens present in the lymph, both in the steady-state as well as during 
inflammation. Due to their advantageous location in the LN, LECs might actually be 
the first to do so, and they are not expected to discriminate with regard to the origin 
of the antigen. Following antigen uptake, LECs may interact with naïve CD8+ T cells 
patrolling the LN in search of their cognate antigen. This interaction would lead to the 
generation of antigen-experienced CD8+ T cells that would either be apoptotic and 
die, or survive but remain inactive. In case of homeostasis, presentation of harmless 
self-antigens would result in the generation of a small pool of antigen-experienced 
CD8+ T cells, which could not display effector function and would contract over time. 
In contrast, in case of infection, these cells would be reactivated by professional 
APCs that have encountered the antigen in the presence of danger signals.  
Although further investigation is required to undoubtedly establish the observed 
double function of antigen-presentation by LECs, it is tempting to speculate on the 
different roles that it might serve and the different gaps it might fill in the big picture of 
adaptive immunity. First, it might prevent the induction of autoimmunity without 
completely eliminating T cell receptor (TCR)-specific CD8+ T cells from the T cell 
repertoire. This safety mechanism might be very important in case of systemic 
antigen dissemination before the onset of innate immunity. Several pathogens, such 
as poxviruses, Hepatitis A and C, and Salmonella, have been shown to deploy 
mechanisms to overcome innate immunity (5). Antigen presentation by immature 
DCs under non-inflammatory conditions is known to induce tolerance and therefore, 
LECs’ function might rescue pathogen-specific cells from deletion. Secondly, the 
generation of antigen-experienced CD8+ T cells may supplement and enhance the 
magnitude of immune responses. The fast drainage of foreign antigen from the 
periphery, following infection, may lead to the early development of antigen-
experienced CD8+ T cells by LECs, which can in turn be amplified once the migrating 
DCs bearing the antigen reach the LN. Additionally, the unique differentiation state of 
LEC-educated CD8+ T cells suggests that LECs might also contribute to the 
development of immunological memory and therefore, contribute to protection in 
future pathogen infection. The observed persistence of a secondary memory-like 
subset in LEC-educated CD8+ T cells following pathogenic challenge further supports 
this notion. Moreover, it is intriguing to think that LECs may be able to sense and 
integrate signals, such as cytokines and chemokines, in their microenvironment, 
which in turn, would allow them to direct their diverse functions. 
LECs’ contribution to the induction of both immunity and tolerance might also help 
explain the seemingly contradictory roles of lymphangiogenesis in different settings. 
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On one hand, lymphangiogenesis has been reported to favor suppression of efficient 
anti-tumor immune responses and promote tumor growth, whereas in the setting of 
chronic inflammatory disorders, lymphangiogenesis has been linked with 
deterioration of the disease (6, 7). Through the scope of our findings, these 
observations can be reevaluated; Antigen presentation by LECs in the tumor-draining 
LN (-dLN) or in the tumor stroma would result in the induction of inactive CD8+ T cells 
with non-immediate effector function, as it has been previously reported (8). The 
possibility that those LEC-educated CD8+ T cells would be reactivated in the 
immunosuppressive microenvironment of the tumor is very low. Thus, in the context 
of a tumor, education by LECs would not lead to effective anti-tumor responses but 
rather be exploited by the tumor to facilitate its progression. In contrast, in a 
microenvironment rich in inflammatory cytokines and danger signals, as the one 
usually observed in the setting of chronic inflammation or following transplants, LEC-
educated cells would be more prone to reactivation, generating cytotoxic effectors 
and thus, result in disease aggravation or transplant rejection.  
Although our understanding for the immunological role of LECs has grown and we 
can now better evaluate their implication in the regulation of immune responses, 
there is still more work to do in order to illuminate the relative significance of their 
contribution. Earlier reports have underlined the importance of antigen presentation 
by non-hematopoietic stromal cells in CD8+ T cell expansion using chimeric mice and 
several infection models (9-11). Those studies suggest that the relevance of antigen 
presentation by non-hematopoietic stromal cells may be pathogen-dependent as well 
associated to the kinetics of the immune response. In order to interpret the impact of 
LEC-education in the generation of immunity, we employed a subunit vaccine model 
that triggers remarkable expansion of the lymph node coupled to increased LEC 
proliferation and combined it to treatment with a vascular endothelial growth factor 
receptor 3 (VEGFR3) blocking antibody. We speculated that by inhibiting 
lymphangiogenesis and therefore, limiting the number of LECs, we could determine 
how LEC-education might affect the outcome of immune responses. Treatment with 
anti-VEGFR3 only partially restricted LEC proliferation in the lymph node and 
therefore, slightly influenced the expansion capacity, phenotype and functional 
potential of antigen-specific CD8+ T cells following primary immunization as well as 
secondary antigenic challenge. Further studies and the development of more 
elaborate models are required in order to precisely determine the relative importance 
of LEC versus professional APC antigen presentation. 
5.2 Acknowledging the limitations towards the development 
of more sophisticated tools to study the immunological role 
of LECs 
While our studies have revealed previously unknown functions of LECs, there is still 
a long way before we truly understand the relative physiological significance of their 
contributions in the establishment of adaptive immunity. In the absence of a suitable 
in vivo model to study uptake, processing and presentation of exogenous antigens in 
LECs, we have employed an in vitro coculture system using mainly sorted LN LECs 
from primary cultures and TCR-transgenic CD8+ T cells. The use of cultured LECs 
cannot exclude the possibility of alterations in their gene expression profile, as it has 
119
been previously observed (12). While keeping this limitation in mind, this 2D system 
allowed us to study the pathways implicated in antigen trafficking and processing in 
LECs, to evaluate their phenotypic profile in the presence of T cells, as well as to 
determine the mechanisms implicated in LEC-CD8+ T cells interactions under 
different conditions. Furthermore, the established cocultures provided us with 
satisfying numbers of LEC-educated CD8+ T cells with a reproducible phenotype for 
subsequent in vivo transfer to further investigate their function in the mouse.  
Whenever possible, we have exploited approaches in our means to study directly the 
role of antigen presentation by LECs in vivo. We have generated β2m-/- BM chimeric 
mice in order to confirm the in vitro observed antigen-specific CD8+ T cell 
proliferation under steady state-conditions. While this approach enabled us to 
discriminate between the contribution of hematopoietic versus non-hematopoietic 
APCs in antigen presentation and subsequent T cell education, it has its own 
limitations; it requires extensive attention in order to eliminate the effect of 
radioresistant APCs and more importantly, it does not allow us to distinguish the 
contribution of LECs among the other lymph node stromal cell (LNSC) subsets. An 
alternative approach to address this issue would be to combine the use of chimeric 
mice together with a LEC-targeting platform for the delivery of the antigen or 
similarly, modified antigen formulations allowing for specific LEC targeting. The 
mannose receptor is almost exclusively expressed in LECs, among LNSCs ((13) and 
the Immunological Genome Project Consortium), and thus, this might be an 
interesting element to exploit. We are currently planning to perform such experiments 
using mannose-targeting formulations that have been developed in our laboratory. 
Along the same lines, instead of the chimeric mice, we also consider the use of the 
CD11c-DTR mice, allowing for deletion of CD11c+ professional APCs (14, 15), 
coupled to treatment with clodronate-containing liposomes (16) or with the 
(macrophage-targeting) anti-CSF-1R antibody (17, 18) in order to ablate both 
dendritic cells and macrophages. Another option for the study of LEC-induced CD8+ 
T cell response in vivo would be the generation of LEC-specific H-2kd transgenic 
mice. Such an approach has been previously engaged to evaluate the induction of 
the CD8+ T cell response by different APCs in vivo (19). It would involve the 
expression of H-2kd under the Lyve-1 or the Prox-1 promoter to generate transgenic 
mice that express H-2kd only on LECs. Immunization with a peptide or a pathogen 
expressing an immunodominant H-2kd-restricted CD8+ T cell epitope would then 
allow us to characterize the induction of the CD8+ T cell response by LECs in vivo. 
The expression of Lyve-1 and Prox-1 by other cell types, such as macrophages or 
hepatocytes, respectively, should be taken into consideration (20, 21). 
To assess the precise contribution of LECs in the development of immune 
responses, we generated the Prox1-DTR mouse model that allows for conditional 
LEC ablation in vivo. Lineage specific ablation has been previously employed to 
investigate the role of other LNSCs subsets in adaptive immunity (22, 23) leading to 
revolutionary findings. While we achieved selective ablation of lymphatic vessels in 
the ear, the Prox1-DTR mouse model displayed several complications; the most 
important being that systemic administration of diphtheria toxin (DT) resulted in death 
due to Prox-1 expression in other cell types in several organs, similar to the 
previously developed Lyve-1 – driven DTR model for LEC ablation (21). We are 
currently trying to optimize the conditions for local deletion of LECs in the LN, while 
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keeping in mind that LEC ablation is very likely to trigger significant alterations in the 
architecture of the LN, which might add another layer of complexity in the 
interpretation of the observed immunological effects. Under this view, a mouse model 
that would allow knocking-out specifically the antigen-presentation machinery in 
LECs would be a more useful tool to investigate their immunological role. We are 
currently considering the generation of a LEC-specific MHC-I conditional knockout 
model by crossing the Prox1-CreERT2 mice with the β2m-flox mice, which can be 
performed in two steps (24). This would allow us to precisely evaluate the 
contribution of antigen presentation to CD8+ T cells by LECs in adaptive immunity. 
Although developing tools to target LECs is not trivial, it would facilitate not only the 
in vivo investigation of their immunological function but also, their therapeutic 
exploitation. The few approaches that have been explored involve ligands that bind 
to molecules expressed on LECs, such as hyaluronic acid (25), which can bind to 
Lyve-1 on LECs, and the LyP-1 peptide, which can bind to p32 protein on tumor 
associated lymphatics and tumors (26, 27). The LyP-1 peptide has been shown to 
contain motifs that can bind to neuropilin-2 (NRP-2) on the target cells, while NRP-2–
blocking antibodies have recently been shown to reduce tumor lymphangiogenesis 
(28, 29). Therefore, this is another potential interesting target. Although these 
approaches present different limitations, combining those with the poly(propylene 
sulfide) (PPS) nanoparticle (NP) platform that has been widely used in our laboratory 
for efficient targeted delivery to the LN, might result in the development of a valuable 
tool for studying LECs in vivo. Our laboratory has been actively investigating these 
different options. Furthermore, a wide range of receptors, such as scavenging, Fc or 
complement receptors, are expressed on LECs (13, 30) which have not been 
explored yet as potential targets for LEC-specific engagement.  
Another approach to bridge the current gap between in vivo and in vitro studies 
would be to take advantage of the emerging systems that try to recapitulate different 
aspects of the physiological microenvironment and architecture of the LN. It is widely 
established that the way the cells are cultured, the biochemical and biophysical 
interactions with their neighboring cells, as well as fluid flow can greatly influence 
their function (7, 31, 32). Although these systems are not technically simple to 
develop and still bear the limitation of using primary sorted cells, they can incorporate 
some of the missing physiological aspects. Our laboratory has been actively working 
on the development of such a 3D system (33), which can, at least partly, mimic the 
physiological conditions of mechanical tension and flow, as well as the relevant cell-
cell interactions in the context of the LN. We are currently investigating whether by 
using this system we can replicate our findings derived from the conventional 2D 
coculture setup. 
5.3 Exploiting the immunomodulatory function of LECs for 
therapeutic applications 
Although many questions remain to be answered, our growing perception of the 
complex immunological role of LECs already prompts us to speculate on whether 
and how we could exploit their function to modulate immune responses with a 
therapeutic benefit. Given the diverse impact of LECs in adaptive immunity, as 
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presented here, different therapeutic interventions could potentially benefit from their 
immunomodulatory function. 
Considering that LECs can generate antigen-experienced CD8+ T cells with a non-
terminally differentiated status, which display central memory-like phenotypic and 
functional characteristics, suggests that they could be usefully integrated in the 
design of vaccination strategies. It is already well established that the route of 
administration, as well as the delivery method of the vaccine significantly impact the 
magnitude of the elicited immune response.  Preferential administration via the 
intradermal route would allow for antigen uptake by LECs, while antigen modification 
or a specialized LEC-targeting delivery platform could be employed to specifically 
deliver the antigen to LECs. Antigen presentation by LECs could induce an early pool 
of antigen-specific T cells with memory-like features while preventing the induction of 
short-lived effector cells with reduced memory potential, as previously observed in 
cases of strong inflammatory challenge (34-36). Such a strategy, coupled to a fine-
tuned boost immunization might constitute an alternative with beneficial effects in the 
magnitude and quality of the vaccine-elicited response, providing the required long-
lived immunological memory. The design of such vaccines might be more beneficial 
against pathogens that target lymphoid tissues and harness them for replication, 
such as HIV or hepatitis (37), or in case of viruses that are known to induce T cell 
exhaustion (38). Furthermore, this alternative might be worth investigating in case of 
viruses such as vaccinia virus (VV) or vesicular stomatitis virus (VSV), which infect 
both hematopoietic and non-hematopoietic cells, and for which LECs have been 
reported to act as antigen reservoirs (9, 39). 
Improved knowledge on LECs immunological function could also aid the 
development of better strategies for tumor immunotherapy. The direct LEC-driven 
immunosuppression in the setting of a VEGF-C overexpressing tumor has already 
been demonstrated and discussed here (8). Different strategies could be employed 
in order to alter the observed harmful impact of antigen presentation by LECs. Here, 
we revisit new and previously proposed approaches with respect to LECs’ 
immunomodulatory function. First, the blockade of lymphangiogenesis, which has 
already been suggested as a therapeutic strategy to eliminate metastasis and tumor 
progression (6, 40) can be utilized to also limit the scavenging of tumor antigen by 
LECs and subsequent dysfunctional activation of tumor specific CD8+ T cells. 
Alternatively, considering that LEC-educated CD8+ T cells can generate cytotoxic 
effector cells following reactivation under immunogenic conditions, reversing the 
immunosuppressive microenvironment of tumors might aid in tumor eradication. The 
targeted delivery of danger signals, as used in adjuvant immunotherapy, and 
proinflammatory cytokines in the tumor stroma or in the tumor-dLN could be 
beneficial, since they would turn the dysfunctional LEC-educated anti-tumor CD8+ T 
cells into CTLs. However, we should bear in mind that LECs themselves are known 
to produce diverse regulatory molecules implicated in immune suppression, such as 
TGF-β and IL-10 (30, 41). Switching LEC signaling mechanisms during interaction 
with CD8+ T cells could be another alternative. Having shown that LEC-CD8+ T cell 
interactions are primarily governed by the PD-L1 signaling axis, combination 
therapies of blocking antibodies, which have already being explored for tumor 
immunotherapy in the clinics (42), might now be re-visited coupled to LEC-targeting 
or tumor-dLN - targeting platforms. Our laboratory currently explores such strategies. 
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In the context of chronic inflammation, such as rheumatoid arthritis, inflammatory 
bowel disease and psoriasis, lymphatic remodeling is known to detrimentally 
influence disease resolution (43). Similarly, lymphangiogenesis and increased 
lymphatic density in the grafted tissue has been associated with poor graft survival 
and rejection. Other than a route of trafficking for APCs and soluble antigen to the 
LN, along with the enhanced flow of lymph, for the activation of T cells and 
subsequent immune rejection of the graft, LECs might also directly participate in the 
induced immune response toward the graft. The use of lymphangiogenic inhibitors, 
as previously suggested, would be beneficial in these cases by limiting the extent of 
harmful undesired immune responses. 
Although the relative contribution of antigen presentation by LECs in the contexts 
here discussed has not yet been determined, the therapeutic concept emerging from 
our studies is that targeting LECs to exploit their immunomodulatory function in 
combination with other approaches might improve immunotherapeutic strategies and 
minimize harmful side-effects. 
 
 
In recent years, the contribution of the lymphatic endothelium in the regulation of 
immune responses has been gaining appreciation. In this thesis, we established 
LECs as bona fide APCs and revealed their contribution in the maintenance of 
peripheral tolerance during homeostasis. We unveiled a previously unanticipated role 
for LN LECs in the modulation of CD8+ T cell responses, including their participation 
in anti-infectious immunity and the establishment of immunological memory. We 
developed different tools in order to evaluate the relative significance of LECs’ 
immunological functions and gained valuable insight for their active involvement in 
the development of adaptive immunity. Collectively, this thesis illuminates the 
multifaceted immunological role of LECs and further promotes them as major players 
in several physiological and pathological events, challenging the traditional 
perception of lymphatics. Hopefully, our findings will be translated into therapeutic 
advances by exploiting the immunomodulatory features of LECs to enhance the 
efficacy of future vaccines and immunotherapeutic strategies. 
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